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Chapter 1 
General introduction 

General introduction 
1.1 BACKGROUND 
Despite the availability of modern sanitation, public health measures, 
antibiotics, and vaccines, children still suffer worldwide a sizeable number 
of infectious diseases before reaching adulthood. Most of these infections 
are self-limiting. However, the two syndromes studied in this dissertation: 
bacterial meningitis and septicemia are life-threatening entities in a young 
child. Early recognition and initiation of adequate treatment are major 
determinants for a good outcome. The most common causative pathogens 
of childhood bacterial sepsis and meningitis are Neisseria meningitidis, 
Streptococcus pneullloniae and Haelllophillls injluenzae. N. lIIeningitidis is 
also the major cause of fulminant septic shock in previously healthy 
children. During the 1970's and early 1980's research on sepsis or bacterial 
meningitis was frequently directed to the development of antimicrobial 
regimens that achieve high bactericidal titers in cerebrospinal fluid in an 
attempt to accelerate bacteriological cure and thereby improve outcome. 
However, despite the availability of excellent antibiotics and highly 
qualified intensive care treatment, morbidity and mOltality did not 
appreciately change. More recently research on sepsis and meningitis has 
focused on selected aspects of the host inflammatory response [1-12]. These 
studies were mainly performed in animal experimental models, and have 
led to the development of novel therapeutic regimens, which may in the 
future improve outcome of disease [13-15]. The major scientific 
achievement, however, has been the development of a new generation of 
conjugate vaccines against N. meningitidis, H. injlllenzae and S. 
pnellllloniae. Global implementation of the use of these vaccines will 
hopefully lead to eradication of these bacterial diseases in the future. 
1.2 HISTORICAL PERSPECTIVE 
The earliest documentation of patients with meningitis can be found in 
the writings of Hippocrates. It took however many centuries, before the 
Englishman T. Willis in 1684 described a clinical picture similar to 
meningococcal disease [16]. The first description of the clinical and 
pathological features of bacterial meningitis was only recorded in the early 
19th century. Epidemic cerebrospinal meningitis was first described by 
Gaspard Vieusseux of Geneva in 1806 [17]. Vieusseux observed that many 
of his patients had purple spots on the skin and marked engorgement of the 
brain at autopsy. Most victims were infants and children. He noted that the 
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patients complained of violent headache, stiffness of the spine and 
convulsions. Elisha Nmih of Goshem, Connecticut, observed a similar 
epidemic in 1807 which he described in a monograph published in 1811, 
the first published book on this disease [18]. The puzzling late discovery of 
meningitis as a clinical entity did not delay a futiher rapid development of 
knowledge on its etiology. 
The sporadic nature of outbreaks and the apparent absence of 
transmission of infection by victims led many nineteenth-century writers to 
believe that the disease was not contagious and was somehow linked to 
climatic or envirorunental conditions such as crowding. However by about 
1860, it was widely assumed that some SOli of poison or agent was 
involved in the pathogenesis of meningitis. In 1887 an Australian 
pathologist, Anton Weichselbaum, described the meningococcus under the 
name Diplococcus intracellularis meningitidis [19]. This was followed by 
the first in vivo diagnosis of meningitis by lumbar puncture performed by 
Quincke in 1891 and the first identification of the pathogen in a living 
patient by Heubner in 1896 [20, 21]. Heubner found typical "biscuit 
shaped" diplococci in pus cells. By 1910 it was recognized that the 
meningococcus was responsible for epidemics of meningitis and that other 
bacteria could cause sporadic cases. 
H injluenzae was initially identified in 1892, when Pfeiffer described 
a pleomorphic gram-negative rod and erroneously identified it as the 
causative agent of influenza [22, 23]. After 1918, when this microorganism 
was only infi·equently isolated from the lungs of patients who died during 
an influenza pandemic, it was reduced to the role of secondary invader. The 
organism was given its name "Haemophilus" by Winslow et al. in 1920 
[24]. Prior to that time, H injlllenzae became recognized as the major 
pathogen responsible for bacteremia and meningitis in children. In 1931, 
Pittman first reported the presence of encapsulated and unencapsulated 
forms of H injluenzae [25]. Encapsulated forms were classified into six 
serological types. Invasive disease was subsequently documented to be 
mainly caused by type b organisms. 
Pasteur and Sternberg, working independently in 1880 and 1881 
demonstrated pneumococci in human saliva as roughly lancet-shaped pairs 
of coccoid bacteria [26-29]. Previous repOlis had already identified similar 
bacteria [30, 31]. However, Pasteur and Sternberg were the first to 
demonstrate the pathogenic potential of this microorganism. By 1886 the 
bacterium was referred to as Pneumococcus because of its ability to cause 
pneumonia [32]. Later in that same decade, the pneumococcus was clearly 
demonstrated to be a major cause of meningitis [33] and otitis media [34]. 
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In the pre-antibiotic era, bacterial meningitis was a deadly disease in 
most cases (90%). Immunotherapy by direct installation of immune serum 
supplemented with complement was the first effective therapeutic 
intervention in bacterial meningitis resulting in a reduction of the mortality 
rate to 25% [35-38]. Immunotherapy remained in use until the introduction 
of sulfonamides and penicillins the \930's. Since then bacterial meningitis 
and meningococcal sepsis have become curable disease entities with 
variable mortality rates dependent on the individual pathogen and patient 
characteristics (neonates, immunosuppressed patients, neurosurgical 
patients, skull trauma, elderly patients). 
1.3 PATHOGENESIS 
The pathogenesis of bacterial meningitis and meningococcal disease 
have major similarities. N. meningitidis, H inf/uenzae and S. pnel/moniae 
are organisms, which colonize the nasopharynx and spread between 
individuals by the inhalation of droplets [39]. Virulent strains need to 
overcome the ban'ier of the nasopharyngeal mucosa in order to become 
invasive. Favorable circumstances for infection may be provided by 
climatic conditions (especially a low absolute humidity) as well as by 
predisposing viral respiratory infections [40, 41]. 
Advances during the last decade in molecular microbiology and 
immunology have increased our understanding of the pathogenesis of 
bacterial meningitis and septic shock. We now know that the host 
inflammatory response to infection contributes substantially to the clinical 
evolution of bacterial meningitis and septic shock [2, 42]. Infections begin 
when microorganisms circumvent 01' penetrate host barriers such as skin 01' 
mucosa. Depending on the infecting agent's virulence and the extent of the 
host response, microbial invasion of the bloodstream and/or the 
cerebrospinal fluid compmiment may occur. It is not yet completely 
understood why infection in some patients results in ovetwhelming 
septicemia, whereas in others meningitis develops in conjunction with 
bacteremia. We propose that genetic variability in the host response may 
playa role in this process as suggested by the data presented in chapter 10. 
Changes in the central nervous system occurring during bacterial 
meningitis include metabolic alterations, an elevated intracranial pressure, 
and a decrease in the cerebral blood flow. The mechanisms leading to these 
changes involve bacterial cell-wall components and host factors such as 
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cytokines, arachidonic acid metabolites, platelet activating factor, 
complement, granulocytes, and reactive oxygen intermediates [43]. 
In septicemia, toxic bacterial products present in the circulation 
activate systemic host defenses, including plasma factors (complement and 
clotting cascades) and cellular components (neutrophils, monocytes, 
macrophages, and endothelial cells). Activated cells in tum produce 
potentially toxic host mediators (cytokines such as tumor necrosis factor-a, 
and interleukin-l, kinins, eicosinoids, platelet activating factor, and nitric 
oxide) that augment the inflammatory response. This escalating immune 
response, in conceit with microbial toxins, may lead to shock, multiple 
organ failure, and death [44]. 
The outcome of both sepsis and meningitis is clearly dependent on 
many factors including the virulence of the microorganism, the presence of 
an adequate immune response, and the extent of the host inflammatory 
response. 
1.4 AIMS OF THE STUDY 
In this thesis we studied selected aspects of the clinical outcome and 
inflammatory host response of children with bacterial meningitis and 
meningococcal septic shock. Specific aims of our studies were as follows: 
1. Analysis of the clinical outcome of the most serious forms of disease: 
pneumococcal meningitis and meningococcal sepsis. 
2. Development of a new prognostic scoring system in patients with septic 
shock and purpura. 
3. Determination of the presence of clonality in pneumococcal strains fi'om 
children with meningitis. 
4. Study of the role and balance between proinflammatory and 
antiinflammatory mediators in the cerebrospinal fluid compallment of 
children with bacterial meningitis. 
5. Evaluation of the role of nitric oxide in the pathophysiology of bacterial 
meningitis. 
6. Evaluation of the role of proinflammatory and antiinflammatory 
mediators, and the extent of abnormalities in coagulation and fibrinolysis 
in patients with meningococcal septic shock. 
7. Evaluation of the presence of age-related differences in coagulation 
abnormalities in patients with septic shock and purpura. 
8. Effect of a polymorphism in the promoter of the plasminogen activator 
inhibitor-gene on outcome of patients with meningococcal septic shock. 
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1.5 OUTLINES OF THE THESIS 
Part I (chapters 2 to 7) contains several studies on the 
pathophysiological, microbiological and clinical aspects of bacterial 
meningitis in children. Chapter 2 briefly reviews novel developments in 
the pathophysiology and therapy of bacterial meningitis. Chapter 3 
evaluates the outcome in a large group of children with pneumococcal 
meningitis diagnosed between 1970 and 1994. In chapter 4, we 
investigated whether clonal relatedness could be observed in pneumococcal 
isolates of these children. The next three chapters contain studies on the 
involvement of several mediators in the pathophysiology of bacterial 
meningitis. Chapter 5 describes the role and balance between 
proinflammatory and antiinflammatory mediators in the cerebrospinal fluid 
compaliment of children with bacterial meningitis. The possible role of 
interleukin-12, a novel cytokine with proinflammatory effects, is described 
in chapter 6. In chapter 7, we describe the role of nitric oxide in the 
pathophysiology of bacterial meningitis. 
Part II (chapters 8 to 13), contains the results of studies in patients 
with meningococcal septic shock. Chapter 8 reviews the epidemiology, 
microbiology, pathophysiology, clinical features and prevention of 
meningococcal sepsis. In chapter 9, we describe the outcome of patients 
with meningococcal septic shock. Futihermore, we repOli the development 
a new prognostic score that predicts death or survival. In chapter 10 selUm 
levels of proinflammatory cytokines, counterinflammatory compounds and 
plasma levels of hemostatic parameters in patients with meningococcal 
septic shock were measured. Subsequently, the association between these 
levels and clinical characteristics, such as duration of petechiae were 
studied. In chapter 11 the involvement of interleukin-12 in the host 
defence during septic shock is investigated. In chapter 12, we studied the 
influence of age on motiality and on severity of clotting abnormalities in 
children with meningococcal sepsis. In chapter 13 the influence of 
plasminogen activator inhibitor-gene promoter polymOlphism on the 
outcome of patients with meningococcal septic shock is analyzed. Chapter 
14 discusses the significance of the presented data and their mutual 
interrelationship in the context of the literature. Recommendations for 
future research are given. Finally, the results of this dissertation are 
summarized in English as well as in Dutch. 
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PART I 
BACTERIAL MENINGITIS 

Chapter 2 
Bacterial Meningitis: 
Mechanisms of Disease and Therapy 
R.F. Komelisse, R. de Groot, H.J. Neijens 
Department of Pediatrics, Division of Infectious Diseases and Immunology, 
Sophia Children's Hospital/Erasmus University, Rotterdam, The Netherlands 
European Journal of Pediatrics 1995; 154: 85-96 

Bacterial Meningitis 
2.1 ABSTRACT 
Bacterial meningitis continues to be a serious infectious disease with a 
high morbidity and mOitality in young children. Early recognition and 
initiation of adequate treatment are the major determinants for a good 
outcome. Recent advances in our understanding of the host inflammatory 
response by cytokines may result in the use of new therapeutic strategies. 
Such modulation of the inflammatory response may reduce the incidence of 
sequelae and death. The use of steroids as adjunctive therapy in children 
with bacterial meningitis probably has beneficial effects although the 
available data are still controversial. Additionally, studies in experimental 
meningitis models indicate that non-steroidal anti-inflammatory dmgs and 
monoclonal antibodies against bacterial products, cytokines and CD 18 on 
leukocytes reduce the extent of the meningeal inflammation. Human studies 
to evaluate the efficacy of these immune modulators are expected to statt 
soon. However, prevention of bacterial meningitis by conjugate vaccines 
against Streptococcus pneumoniae and Neisseria meningitidis will be the 
most promising development in the next decade. 
2.2 INTRODUCTION 
Despite continuing improvements in therapy bacterial meningitis is still 
associated with fatality rates of 3%-6% and the development of severe 
sequelae in approximately 16% of cases [1-6]. Prevention of meningitis by 
the use of novel conjugate vaccines against Streptococcus pnelllnoniae and 
Neisseria meningitidis will be a point of major interest in the next decade. 
Recent research has contributed to our understanding of the 
pathophysiology of bacterial meningitis. This has resulted in new 
therapeutic approaches. The use of anti-inflammatory drugs in combination 
with antibiotics in bacterial meningitis has become a topic of major interest. 
This review focusses on the nature of the inflammatory response to 
infection in the cerebrospinal fluid (CSF) and the pathophysiological 
alterations induced by bacterial meningitis. Finally, recent advances in 
treatment will be discussed. 
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2.3 EPIDEMIOLOGY 
Bacterial meningitis is mainly a disease of young children. During the 
neonatal period gram-negative enteric bacilli (Escherichia coli and 
Klebsiella species), group B streptococci, and Listeria monocytogenes are 
the most common pathogens. These organisms are mainly acquired at 
delivery. The three major causative organisms in infants above 3 months of 
age are N. meningitidis, Haemophillis injlllenzae and S. pneulI1oniae. They 
account for more than 90% of bacterial meningitis in children between 3 
months and 10 years. The incidence and relative fi'equencies of these 
bacteria differ markedly depending on genetic factors, the geographic area, 
and the recent introduction of efficacious conjugate vaccines against H. 
injluenzae type b in many countries. 
Epidemiological studies have identified several risk factors for 
bacterial meningitis. Age is the most impOitant risk factor. Boys are 
affected more frequently than girls. Several studies have repOlted the 
presence of racial differences in the incidence of bacterial meningitis. Black 
and Hispanic populations are at 2-4 times greater risk than Caucasians [7-
10]. Socioeconomic rather than racially determined factors are responsible 
for this increased risk [8]. The native NOith American population also has a 
high incidence of bacterial meningitis. For example, rates of over 
200/100,000 per year in the overall population have been described among 
Canadian Inuits [11]. Another host factor which increases the risk of 
pneumococcal sepsis and meningitis is splenectomy. Patients with 
deficiencies in the terminal components of complement (C5-9) also have an 
increased risk of meningococcal meningitis. Children in day care centres 
have an increased risk of acquiring invasive bacterial disease in comparison 
with children in home care. 
2.4 DIAGNOSIS OF BACTERIAL MENINGITIS 
Nonspecific clinical findings predominate in the newborn and in young 
infants. These include abnormal temperature, somnolence, il1'itability, and 
poor feeding. The presence of a bulging fontanelle is a relatively 
characteristic sign in this age group but not present early in the disease. 
More characteristic findings are often seen in children and adults and 
include alteration of the mental status, nuchal rigidity, and the signs of 
Kernig and Brudzinski. A lumbar puncture has to be performed if the 
slightest evidence suggests the presence of bacterial meningitis. Rapid 
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Figure 1. Schematic view of the biochemical changes in the cerebrospinal fluid (CSF) profile 
and detection of elevated cytokine levels during bacterial meningitis. The normal ranges (N) for 
white blood cells (WBe), protein, glucose and lactate in the CSF arc indicated by vertical bars. 
Rx marks the timcpoint of initiation of antibiotic therapy. The data were derived from the studies 
of Lebel ct al. [93] and Odio el al. [941. 
diagnosis and initiation of therapy are the major prognostic factors 
determining a favourable outcome, Initial management decisions are based 
largely on the Gram-stain and CSF characteristics (leukocytes, glucose, 
lactate and protein). The CSF parameters reflect the metabolic and 
structural alterations, such as increased blood brain barrier (BBB) 
permeability, which characterize the inflammatory response (Figure 1), 
Leukocytes 
A characteristic feature of bacterial meningitis is CSF leukocytosis, 
Before leukocytes reach the CSF a co-ordinated action takes place of 
adherence to vascular endothelium, and subsequent migration across the 
endothelial monolayer into the CSF compartment. This process is mediated 
by adhesion-promoting receptors and ligands located on leukocytes and 
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endothelium which are activated by exposure to lipopolysaccharide (LPS) 
and to cytokines: interleukin (IL)-I/3, tumor necrosis factor (TNF)-a and 
interferon-y [12-16). Bacterial replication or lysis in the CSF compaltment 
induces endothelial cells to produce IL-8. IL-8 is a potent chemoattractant 
[17). The initial reversible adherence of leukocytes to endothelial cells is 
mediated by three lectin-like carbohydrate-binding molecules called 
selectins (granule membrane protein-140 [CD62P), endothelial cell adhesion 
molecule-I [CD62E), leukocyte adhesion molecule-I [CD62L)). Each 
selectin recognises specific carbohydrate sequences on either leukocytes or 
endothelial cells. Leukocytes are first observed to 1'011 along endothelial 
cells adjacent to the extravascular site of inflammation. Studies indicate that 
selectins are involved in the leukocyte rolling. Strong adhesion is mediated 
by leukocyte integrins that bind to counter receptors on endothelium. The 
integrin family of adhesion receptors consists of heterodimeric 
glycoproteins with an a and /3 subunit. They can be classified on the basis 
of their /3 subunit, e.g. /32 integrins (CDllaJCD18a and CDllb/CDI8) and 
/37 integrins (CD49d//37) [18). The early selectin-adhesion decreases with 
continued cytokine stimulation by cleavage of the selectin from the cell 
surface or inhibition of its binding. At the same time /32 and /37 integrin-
mediated adherence of the neutrophils to intercellular adhesion molecules 
(CD54 and CDI02) and vascular cell adhesion molecules (CDI06) on 
endothelial cells is induced. Subsequently leukocytes traverse the cerebral 
capillary endothelium by diapedesis [19). 
Glucose and lactate 
The changes in glucose and lactate levels are not only induced by 
living bacteria and leukocytes. The anaerobic brain metabolism in bacterial 
meningitis contributes to the development of increased CSF lactate 
concentration and hypoglycon-hachia [20). It seems likely that local changes 
in the brain as a result of ischaemia or mediated by humoral factors, induce 
an increased production of lactate. Another explanation for the development 
of hypoglycorrhachia was demonstrated in experimental canine meningitis. 
In these animals low CSF glucose reflected the inhibition of can'ier-
mediated transpOlt across the BBB [21, 22). The increased use of glucose 
by the brain and the abnormal glucose transpOlt across the BBB may 
fillthel' contribute to hypoglycorrhachia [23). 
Protein 
The elevated concentration of protein in CSF during bacterial 
meningitis is caused by an increased permeability of the BBB. A uniform 
response consisting of an early and sustained increase in formation of 
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pinocytotic vesicles and a progressive increase in the separation of tight 
junctions between endothelial cells is observed during the course of experi-
mental meningitis [24]. The cytokine-endothelium-leukocyte interaction is 
probably responsible for the dislUption of the barrier by opening 
intercellular junctions and thereby permitting the passage of setum proteins 
into the subaracbnoidal space. 
2.5 PATHOGENESIS OF INFECTION 
The three most common microorganisms in bacterial meningitis have 
several propelties that promote adherence, colonization and invasion of the 
mucous membranes of the nasopharynx. Mucosal attachment is mediated by 
microbial vimlence factors such as pili and nonpilar adhesins. Several host 
defence mechanisms must be evaded before attachment may occur. The 
bacteria have to inactivate secretory IgA and escape from the ciliary 
clearance mechanisms of the nasopharyngeal mucosa. The three major 
pathogens all secrete a protease capable of cleaving human IgAl. 
ImpOltantiy, IgAI is the dominant immunoglobulin class in the 
nasopharyngeal mucosa, which is the site of adherence and invasion by 
these bacteria [25, 26]. 
Invasion across the nasophatyngeal mucosa takes place by an endo-
cytotic process (N. meningitidis) or through the intercellular route by separ-
ations in the apical tight junctions of columnar epithelial cells (H 
injluenzae) [27, 28]. Once the mucosal barrier is crossed, bacteria must 
overcome additional host defences to survive in the bloodstream and to 
invade the meninges. The most impOltant vitulence factor in this respect is 
encapsulation. The polysaccharide capsule inhibits neutrophil phagocytosis 
and prevents classical complement pathway bactericidal activity thus 
enhancing intravascular bacterial survival and replication. 
2.6 PATHOPHYSIOLOGY OF THE INFLAMMATORY RESPONSE 
Since CSF defences against infection are very limited, bacteria can 
proliferate rapidly. Host defence (humoral factors and phagocytes) must be 
recmited from selUm, a process that develops parallel to BBB dislUption 
and alteration of the cerebral metabolism. These abnormalities all arise as 
part of an inflammatory response mediated by cytokines. 
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Cell-wall components 
Experimental evidence has accumulated that cell-wall components are 
responsible for triggering the inflammatory response in the subarachnoid 
space. These are mainly peptidoglycan-teichoic acid in gram-positive micro-
organisms and LPS molecules (endotoxins) in gram-negative bacteria. Both 
are potent inducers of inflammation. Intracisternal inoculation of any of 
these components into the CSF compartment of animals induces meningeal 
inflammation [29-32]. Observations in animals with experimental 
pneumococcal as well as H influenzae meningitis indicate that initiation of 
antibiotic therapy results in a more pronounced increase in inflammatory 
indices and cytokine levels in the CSF [33-35]. Additional evidence 
indicates that LPS does not act alone during gram-negative bacillary 
meningitis [36]. These bacteria also contain similar amounts of 
peptidoglycan [37]. LPS is not present in the CSF in sufficiently high 
concentrations to directly injure the cerebrovascular endothelium. In 
contrast, clinically relevant concentrations of LPS (1-10 ng/ml) are able to 
induce CSF leukocytosis and are potent at priming leukocytes for the 
production of inflammatory mediators. Peptidoglycan is only a weak 
inducer of inflammatory mediators. However, peptidoglycan can cause 
cellular separation of endothelia at concentrations 100-fold less than 
required for LPS and may be responsible for the induction of BBB 
permeability in gram-negative meningitis [38]. 
Two studies in infants with gram-negative meningitis have 
demonstrated increased endotoxin concentrations in CSF and ventricular 
fluid when intrathecal or intraventricular antibiotic therapy was given in 
addition to parenteral antibiotics. These increased endotoxin concentrations 
have been associated with an augmented meningeal inflammation and with 
a rise in adverse outcome in infants with coliform meningitis treated with 
intraventricular gentamicin [39-42]. 
Cytokincs 
The host responds with the release of cytokines upon recognition of 
the presence of bacterial products in the subarachnoidal space. TNF -u and 
IL-IB appear to playa pivotal role in triggering the cascade of meningeal 
inflammation [43]. 11-6, another cytokine found in CSF from patients with 
bacterial meningitis, has also been implicated in the pathogenesis of this 
infection. Although production of these inflammatory cytokines has been 
linked to the development of central nervous system injury,· the precise 
mechanism has not been elucidated. It has been suggested that cytokines 
are produced by glial cells and brain capillary endothelial cells [44]. 
Experimental studies have indicated that intracisternal inoculation of 
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endotoxin is followed by detection of TNF-o. and IL-lfi activity. 
Subsequently, leukocytosis and changes in protein, glucose and lactate 
concentrations are observed within hours. Combined injection of TNF-o. 
and IL-J /3 into the CSF has a synergistic effect [35]. Administration of 
dexamethasone or polymyxin B before or together with H. ilif!uenzae type 
b (Hib) Iipo-oligosaccharide, inhibits CSF TNF-o. and decreases the 
meningeal inflammatory response [33, 43, 45, 46]. TNF-o. and IL-l/3 can 
also be detected in initial CSF samples of children with bacterial meningitis 
[48]. The presence of IL-l/3 is associated with CSF inflammatory abnormal-
ities, an increased TNF-o. concentration, and an adverse outcome [49]. 
Some reports describe an association between indices of inflammation or 
the clinical course and TNF-o., IL-l/3 and IL-6 levels. Infants with culture-
proven viral meningitis or with non-infected CSF have low or non-
detectable IL-lfi and TNF-o. levels [50-55]. 
Arachidonic acid metabolites 
Arachidonic acid metabolites play an important role as mediators 
and/or modulators of inflammation. These products may be involved in 
many of the pathological processes in meningitis. They are released after 
stimulation with bacterial and immunological antigens by a variety of cells, 
including neutrophils, platelets, and vascular endothelial cells. TNF -a and 
IL-lfi induce phospholipase A2 activity thereby triggering the production of 
these proinflammatory substances [56]. 
Previous studies have demonstrated a significant increase in 
prostaglandin E2 (PGE2) (cyclo-ogygenase products) but not leukotriene B, 
(lipo-oxgygenase product) concentration in CSF during pneumococcal 
meningitis in rabbits [57]. Intracisternally administered PGE2 did not induce 
detectable CSF leukocytosis, but caused a dose-related increase in protein 
content [58]. PGE2 and PGI2 are elevated in the CSF of infants and children 
with bacterial meningitis. The concentration of PGE2 correlates significantly 
with protein, TNF-o., and IL-J/3 concentrations in the initial CSF sample 
[59]. 
Platelet activating factor 
CSF platelet activating factor (P AF) concentrations are significantly 
higher in children with H. inj/uenzae meningitis than in afebrile and febrile 
control subjects without meningitis. The concentrations correlate strongly 
with concomitant bacterial counts and with both LPS and TNF-o. 
concentrations in admission CSF samples. LPS and a variety of cytokines, 
such as TNF -a and IL-l/3, are potent inducers of P AF by poly-
morphonuclear leukocytes (PMNL), macrophages/monocytes, endothelial 
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cells and neuronal cells [60-62]. PAF recruits and activates PMNL and 
monocytes at the site of inflammation and induces the release of other 
inflammatory mediators. P AF in high concentrations is toxic to neuronal 
cells. P AF acts synergistically with LPS and TNF -a in the development of 
microvascular tissue damage [63, 64]. 
Leukocytes 
Several hours after meningeal infection an intense influx of leukocytes 
occurs. Cytokines stimulate the function of neutrophils and provoke 
degranulation superoxide production and increased adherence to the 
endothelium. It has been demonstrated that products of leukocytes, such as 
polyunsaturated fatty acids and oxygen-free radicals can induce brain 
edema, increased lactate production, and energy depletion in cOltical brain 
slices of rats [65, 66]. However, not all studies demonstrate adverse effects 
of leukocytes. When the effects of experimental pneumococcal meningitis 
were compared between normal and neutropenic rabbits similar changes of 
brain water content (brain edema), intracranial pressure, and CSF 
concentration of lactate and protein were observed [67]. 
2.7 THERAPY 
Antimicrobial therapy 
The combination of ampicillin and chloramphenicol has been known 
for many years as an effective empirical therapy of bacterial meningitis. 
Ampicillin resistant 13-lactamase producing H. influenzae has become a 
major problem in many European countries and the United States of 
America. A recent collaborative European study shows a mean rate of 
resistance of 10% for all palticipating countries [68]. In addition, sporadic 
cases of chloramphenicol-resistant H. influenzae have been documented. 
Combined resistance to chloramphenicol and betalactams is increasing [69-
74]. N. meningitidis resistant to 13-lactam antibiotics is also increasingly 
encountered. Spain has been a major source for penicillin-resistant N. 
meningitidis [75]. Infections caused by resistant pathogens lead to higher 
rates of morbidity and mOltality than infections caused by susceptible 
pathogens. 
A consensus among expelts about the choice of initial empiric therapy 
of childhood meningitis is still lacking. Third generation cephalosporins 
have become important antibiotics for the treatment of presumed bacterial 
meningitis in infants and children [76-79]. Among these cephalosporins, 
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cefotaxime, ceftriaxone, and ceftazidime have been studied extensively [80-
82]. All three agents are extremely active against H injluenzae (including 
Il-Iactamase producing strains), N. meningitidis and S. pneulIloniae. 
However, cephalosporins are inactive against Listeria monocytogenes, 
Streptococcus faecalis and methicillin-resistant staphylococci. Empiric 
therapy of bacterial meningitis in children up to 3 months of age should 
include ampicillin for activity against L. monocytogenes and enterococci. 
Once the etiological agent has been identified and its susceptibility 
determined, therapy can be altered to a single drug or a combination of 
drugs active in vitro. The duration of therapy is dependent on the clinical 
response of the patients. Seven days is generally considered adequate for 
meningococcal infections and 10 days for H inf/uenzae and pneumococcal 
meningitis [83]. Despite the availability of active antibiotics against the 
common meningeal pathogens, the outcome of meningitis has not changed 
over the last decades. Therefore investigators have been focusing on novel 
approaches to diminish neurological sequelae of meningitis. 
Fluid restriction 
It is generally recommended that children with bacterial meningitis 
receive less than maintenance fluid to treat or prevent the syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH) [84, 85]. However, 
a recent study in infants with bacterial meningitis shows that elevated levels 
of antidiuretic hormone may also be explained as an appropriate response to 
intravascular volume depletion rather than as the result of hypothalamic-
pituitary axis dysfunction [86]. The loss of cerebrovascular autoregulation 
in bacterial meningitis may be compensated by secretion of antidiuretic 
hormone to maintain adequate cerebral blood flow. The cerebral blood flow 
during bacterial meningitis depends on the cerebral perfusion pressure 
which is the difference between the mean atlerial blood pressure and the 
intracranial pressure. Two studies in rabbits with experimental meningitis 
compared fluid restriction with a normal fluid regimen. Fluid restriction 
resulted in reduced mean atlerial blood pressure, significantly decreased 
cerebral blood flow and increased anaerobic glycolysis of the brain. The 
fluid regimen, however, did not have a major effect on the degree of brain 
edema [20, 87]. Since cerebral blood flow is often reduced in bacterial 
meningitis, fluid restriction may even worsen the neurological outcome. 
Clinical trials to evaluate the effect of fluid regimen on outcome have not 
been performed. Current recommendations in children with bacterial 
meningitis may have to be revised in view of these new experimental data. 
Fluid restriction should possibly only be limited to those patients with 
meningitis who fulfil the diagnostic criteria for SIADH. 
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Adjunctive therapy 
The improvements in our understanding of the pathophysiology of 
bacterial meningitis may lead to the development of novel therapeutic 
approaches. Modulation of the inflammatory cascade may reduce the 
incidence of sequelae and death in patients with bacterial meningitis. 
Interventions will be directed against harmfi.tl bacterial products (e.g. 
monoclonal antibodies, polymyxin B), cytokines (e.g. monoclonal 
antibodies, steroids), leukocytes (e.g. monoclonal antibodies, pentoxi-
phylline, radical scavengers) or some consequences of the disease, e.g. 
brain edema, increased intracranial pressure or alterations of the cerebral 
blood flow (Table I). 
Table 1. Adjunctive anti-inflammatory agents 
in the trcatment of bacterial meningitis 
- Corticosteriods 
- Monoclonal antibodies 
• Anti-endotoxin 
• Anti-IL-IB; anti-TNF-a 
• Anti-eDlS 
- Cyclo-oxygenase inhibitors 
- PentoxifylIinc 
- Radical scavengers 
• Superoxide dismutase (SOD) 
• Catalase 
Corticosteroids. In vitro 
studies indicate that pretreatment 
of cultured cells with dexame-
thasone suppresses the synthesis 
and release of cytokines induced 
by bacterial products [88-90). The 
inflammatory response in the CSF 
of rabbits after intracisternal 
inoculation of bacterial products 
such as endotoxin or live H. 
injlllenzae may be blocked by 
dexamethasone. However, this is 
only effective when dexametha-
sone is initiated before or at the same time as the antibiotic [33, 45, 46). 
TNF-a. and IL-IB levels in the CSF are reduced concomitantly with 
concentrations of POE, [59). Dexamethasone also decreases brain water 
content, intracranial pressure, and CSF lactate in animals with S. 
pnellll10niae or H. iliflllenzae meningitis [47, 91, 92). 
Clinical studies to evaluate the efficacy of dexamethasone in bacterial 
meningitis have yielded controversial results (Table 2). Lebel et al. [93) 
demonstrated that conventional antibiotic therapy (cefuroxim or ceftriaxone) 
plus dexamethasone resulted in improved outcome in the treatment group in 
comparison with a placebo-treated group. Children treated with 
dexamethasone had a significantly lower incidence of sensorineural 
deafness (15% vs 3.3%) and of other neurological sequelae 12 months later 
[33). The study of Odio et aI., in which dexamethasone administration was 
started before the initiation of cefotaxime therapy failed to find a significant 
reduction in hearing impairment in the steroid treated group. However, an 
overall reduction in the incidence of neurological complications (including 
hearing loss) was seen in the treatment group in comparison with a placebo 
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Table 2. Oven,jew of sequelae ill recent placebo/dexamethasone therapy studies in children 
treated for bacterial meningitis. 
Antibiotic 
No (%) of children with audiological (A), 
Study 
therapy 
neurological (N) 01' combined (e) sequelae p 
SEQ Placebo Dexamethasone 
Lebel et al. [93J Cefuroxim A 16/38 (42) 9/43 (21) < .05 
N 3/34 ( 9) 1/38 ( 3) NS 
C NA NA NA 
Lebel et al. [93] Ceftriaxone A 14/46 (30) 7/49 (14) NS 
N 6/41 (15) 2/43 ( 5) NS 
C NA NA NA 
Odio et al. [94] Cefotaximc A 7/44 (16) 3/50 ( 6) NS 
N 15/48 (31) 5/51 (10) .008 
C 18/48 (38) 7/51 (14) .007 
King et al. [95] Not uniform A 4/51(9) 5/48 (I I) NS 
N 3/51 (7) 3/48 ( 6) NS 
C NA NA NA 
Wald et al. [96] Ceftriaxone A NA NA NA 
N NA NA NA 
C 10174 (14) 6/68 ( 9) NS 
Schaad et al. [97] Ceftriaxonc A 8/55 (15) 3/60 ( 5) NS 
N 5/55 ( 9) 3/60 ( 5) NS 
C 9/55 (16) 3/60 ( 5) NS 
Schaad et al. [97] Ceftriaxone C 28/175 (16) 12/177 ( 7) .007 
(meta·analysis) 
Abbreviations: SEQ, sequelae; NA, not available; NS, not significant. 
group (14% vs 38%) [94]. The majority of cases of meningitis in these two 
studies were due to H injluenzae while N. lIIeningitidis and S. pnellllloniae 
wiII become more important in the coming years due to the introduction of 
Haemophilus conjugate vaccines. In a study from Egypt mOltality was 
reduced in patients (children and adults) with pneumococcal meningitis by 
using dexamethasone. This cOlticosteroid also protected against hearing loss 
in this group of patients [98]. These three studies showed a significant 
reduction in neurological sequelae with dexamethasone, but benefits were 
statistically significant only when the sequelae were unusually common as 
result of suboptimal therapy (cefuroxim), suppOltive, and diagnostic 
management (in developing countries). The results of these studies could 
not be confirmed in more recent trials, which detected no significant 
difference between steroid-treated patients and control subjects [95-97]. 
However, a meta-analysis of sequelae in ceftriaxone-treated bacterial 
meningitis in children indicated that dexamethasone as adjuvans therapy is 
superior to placebo [97]. The American Academy of Pediatrics advises to 
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use dexamethasone in patients with proven or strongly suspected bacterial 
meningitis. However, the Canadian Pediatric Society has not yet decided to 
recommend routine use of dexamethasone therapy [99, 100]. 
FU1thennore, the use of corticosteroids is associated with potential side-
effects suppOlting the need for more information to assess the risks or 
benefits [101]. In the repOlt by Lebel et al. [93], 2% of the patients had 
gastro-intestinal bleeding. None of the patients receiving placebo had this 
complication. At present, the fi'equency and severity of this complication of 
dexamethasone are unknown. Other studies indicate that glucocorticoids 
potentiate ischaemic injury to neurons. Since decreased cerebral blood flow 
appears to be one of the pathophysiological features of bacterial meningitis, 
it is impOltant to know whether dexamethasone has beneficial effects on 
hearing but worsens cerebral cOltical function [102]. These impOltant 
questions concerning the place of cOlticosteroids should be addressed 
further in carefully conducted clinical trials in homogeneous populations. 
Monoclonal antibodies against endotoxin. Inhibition of the effects of 
endotoxin may have beneficial effects on gram-negative bacterial 
meningitis, since the toxic moiety of endotoxins (lipid A) can be 
neutralized by polymyxin B or by monoclonal antibodies to lipid A [103-
106]. Indeed, cures of bacterial meningitis were achieved in the pre-
antibiotic era by direct installation of immune selUm supplemented with 
complement [107-110]. Direct CSF inoculation was needed for this therapy. 
Experimental studies in rats demonstrate that intravenous administration of 
an IgG monoclonal antibody results in low CSF levels (" 5.5%) [111]. 
Intracistemal inoculation of an IgM monoclonal antibody or polymyxin B 
directed against the lipid A moiety of E. coli LPS reduced the cefotaxim-
induced increase in CSF LPS concentration and brain water content. The 
monoclonal antibody was clearly more effective in reducing brain water 
content although no differences were observed in the capacity to neutralize 
endotoxin [34]. 
Monoclonal antibodies against cytokines. Intracisternal administration 
of TNF -ex and IL-l J3 in rabbits induces a brisk inflammatory response, 
which may be blocked by antibodies against the cytokines. Moreover, 
simultaneous intracistemal administration of anti-TNF -ex polyclonal 
antibody with Hib lipooligosaccharides neutralizes CSF TNF -ex activity and 
is associated with substantial attenuation of the meningeal inflammatory 
changes [46]. 
Monoclonal antibodies against CD18. Agents that attenuate the 
augmented granulocyte-endothelial interaction followed by leukocyte influx 
into CSF could be beneficial in preventing brain damage. Monoclonal 
antibodies against the CD 18 family of adhesion-promoting receptors on 
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leukocytes have been studied. Animals recelvmg intravenous mAb IB4 
(CD IS antibody) before intracisternal inoculation with living bacteria (s. 
pneulIloniae, H. influenzae, N. lIIeningitidis), endotoxin or cell-wall demon-
strate a dramatic reduction in CSF leukocyte density and protein 
concentration. Cerebral edema was absent in mAb-treated animals [112, 
113]. 
Inhibition of prostaglandins. Non-steroidal anti-inflammatory agents 
inhibit the cyclo-oxygenase pathway and reduce meningeal inflammation in 
bacterial meningitis. Cyclo-oxygenase inhibitors (indomethacin, diclofenac, 
oxindanac) block the development of brain edema and decrease the number 
of leukocytes in comparison with non-treated animals. In addition, the 
influx of protein in the CSF compmtment is prevented by these inhibitors. 
Oxindanac has a stronger activity than other cyclo-oxygenase inhibitors 
(indomethacin, diclofenac). A study in rabbits with experimental meningitis 
demonstrated a dramatically decreased mortality by the use of a 
combination of ampicillin plus oxindanac in comparison with treatment 
with ampicillin alone or ampicillin plus dexamethasone or indomethacin. 
Trials of selected nonsteroidal anti-inflammatory agents hold much promise 
[35, 57, 5S, 114, 115]. 
PentoxifYlline. Recent studies suggest that pentoxifylline, a xanthine-
derived phosphodiesterase inhibitor, can inhibit the inflammatory process. 
Pentoxifylline can reverse or counteract many of the effects of endotoxin 
and endotoxin-induced cytokines on leukocyte !tmction (116]. Studies in 
rabbits with experimental meningitis indicate that continuous intravenous 
infusion of pentoxifylline compared with saline significantly reduces CSF 
concentrations of leukocytes, protein, and lactate [117]. Pentoxifylline also 
reduces the release of cytokines from primary murine microglial cell 
cultures. When added concomitantly with LPS, pentoxifylline blocked the 
release of TNF -0; and IL-I B but not IL-6, while dexamethasone inhibited 
the release of TNF -0; and IL-6. Pentoxifylline, but not dexamethasone, 
inhibited TNF-o; release from microglia previously stimulated with LPS 
[liS]. 
Radical scavengers: sllperoxide disllllltase and catalase. Reactive 
oxygen species in experimental meningitis are capable of inducing 
vasodilation of cerebral atterioles, increased BBB permeability, increased 
lactate production and brain edema. Pfister et al. studied the effects of two 
radical scavengers in experimental meningitis. Superoxide dismutase 
completely blocked the increase of regional blood flow, intracranial 
pressure, and brain water content during the early phase of experimental 
pneumococcal meningitis. Catalase, another radical scavenger, only pmtly 
attenuated the increase of regional cerebral blood flow, intracranial pressure 
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and brain water content. These results suggest that the increase of regional 
cerebral blood flow, brain water content, and intracranial pressure is mainly 
caused by superoxide or its products [119, 120]. 
2.8 VACCINATION 
Recently, conjugate vaccines against H. injluenzae type b (Hib) have 
been developed. These vaccines, but not the previous non-conjugated ones, 
are immunogenic and effective during the age of the highest incidence of 
meningitis caused by Hib. A very low rate of side-effects was noted [121-
128]. Hence, Hib vaccination has been introduced in childhood vaccination 
programmes in an increasing number of countries. Subsequently a 90% 
reduction in H. influenzae meningitis has been observed [123, 129]. 
However, a substantial number of children have bacterial meningitis caused 
by N. meningitidis and S. pneumoniae. Meningococcal disease is caused by 
several serogroups N. meningitidis; serogroup B is the most common cause 
in Europe, N011h-America and several countries in Latin America. A 
meningococcal non-conjugate tetravalent A, C, Y, and W135 poly-
saccharide vaccine is available and has been shown to be safe and 
immunogenic in adults, but not in young infants. The serogroup B 
polysaccharide, however, is poorly immunogenic in humans and has not 
been useful for development of a vaccine. Therefore, vaccines based on 
outer membrane proteins are currently being evaluated for their efficacy 
[130, 131]. Recent field trials with such vaccines have demonstrated only 
pattial protection against group B infection [132, 133]. Several 
pneumococcal conjugate vaccines combining the most relevant serotypes 
coupled to different protein antigens are already available [134]. 
The final aim would be a combined conjugate vaccine, including 
adequate immunogenic stlUctures of Hib, meningococci and pneumococci to 
provide a protective antibody response at an early age. 
2.9 CONCLUSIONS 
Brain damage in patients with bacterial meningitis results fi'om the 
combined deleterious effects of the micro-organisms and its products and of 
the host inflammatory response. A number of pathophysiological alterations 
have been demonstrated in animal models. These include brain edema, 
elevation of intracranial pressure, changes in CSF outflow resistance, 
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mOlphological changes of the BBB, and changes in cerebral blood flow. In 
addition, mediators of pathophysiological changes have been identified, 
including cytokines, cyclo-oxygenase metabolites, and P AF. Several 
adjunctive therapeutic interventions have been developed to modulate the 
damaging host response to invading micro-organisms. The new treatment 
strategies are directed against bacterial products, cytokines, and white blood 
cells. Most of these adjunctive therapies have only shown advantageous 
effects when administered before or simultaneously with the induction of 
experimental meningitis. However, pentoxifylline has been shown to 
attenuate the infiammatOlY process by reducing the release of cytokines in a 
model previously exposed to endotoxin. The use of corticosteroids as 
adjunctive treatment in human studies shows the presence of a possible 
beneficial effect. Nevertheless, routine use of steroids in children with 
bacterial meningitis is still a subject of intense debate, because recent 
studies did not demonstrate a significant difference in the percentage of 
neurological or audiological sequelae. Although improvement of treatment 
strategies has given encouraging results, prevention of bacterial meningitis 
by development and introduction of a combined conjugate vaccine against 
the three common causative pathogens will be the major challenge of the 
next decade. 
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Pneumococcal Meningitis 
3.1 ABSTRACT 
We studied the outcome of pneumococcal meningitis in 83 children 
admitted to a refetTal hospital whose meningitis was diagnosed between 
1970 and 1994. The median age of the children was 8 months (range, 3 
days to 12.3 years). The most fi'equently isolated capsular serotypes and/or 
serogroups of Streptococcus pnellmoniae were 6, 14, 18, 19, and 23. 
Twenty-nine children (35%) were refetTed by other hospitals. A m0l1ality 
rate of 17% (primary referrals, 7%; secondary referrals, 35%) was 
observed. At discharge, 25 survivors (36%) had sequelae: hearing loss (?; 
30 dB) in 19% and neurological sequelae in 25%. During admission, the 
presence of coma, respiratory distress, shock, a cerebrospinal fluid (CSF) 
protein level of?; 2.5 gIL, a peripheral white blood cell count of < 5xl09/L, 
and a setum sodium level of < 135 mmollL were associated with m0l1ality. 
Sequelae were associated with the presence of coma and a CSF glucose 
level of < 0.6 mmollL. We conclude that the m0l1ality rate of 
pneumococcal meningitis is lower among children than among adults. 
Children often die of neurological sequelae while adults fi'equently die of 
cardiorespiratory failure due to underlying diseases. For children, coma, 
respiratory distress, and shock during admission were clinical findings with 
the strongest predictive value for sequelae or death. 
3.2 INTRODUCTION 
Streptococcus pneull10niae is a fi'equent cause of pneumonia, otitis 
media, and bacteremia and the third most common pathogen of meningitis 
in infants and children. The recent introduction of the Haemophilus 
injluenzae type b vaccine in many countries increases the relative 
importance of S. pneull10niae as a major cause of acute bacterial meningitis 
in children. Epidemiologic studies in the Netherlands have estimated that 
the annual incidence of pneumococcal meningitis is - 1.5 cases per 100,000 
population [1, 2]. The incidence of pneumococcal meningitis in children 
younger than 5 years of age is substantially higher (7 cases per 100,000 
population) [3, 4]. 
Despite continuing improvements in antibiotic and supportive therapy, 
pneumococcal meningitis is still associated with a high m0l1ality rate and 
substantial morbidity. The mortality rate among children ranges between 
4% and 16% [4-9]. The mortality rate among adults is substantially higher. 
Among the elderly older than 70 years of age, the m0l1ality rate may be > 
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50% [6, 10-13]. Neurological sequelae, including hearing impairment, 
hydrocephalus, convulsions, and mental retardation, have been described in 
29%-56% of children with pneumococcal meningitis [4, 7, 14-16]. In 
follow-up studies of pneumococcal meningitis [17, 18], the rate of 
sensorineural hearing impairment has ranged from 21 % to 50%. The 
incidence of sequelae in adults at discharge in some studies was as high as 
72% [11]. 
The purpose of the present study was to evaluate the epidemiology and 
outcome of pneumococcal meningitis in children admitted to the Sophia 
Children's HospitallUniversity Hospital Rotterdam (Rotterdam, The 
Netherlands) between 1970 and 1994. The outcome for children was 
compared with the outcome for adult patients with pneumococcal 
meningitis in other studies. In addition, the prognostic significance of 
several clinical features and laboratory parameters was evaluated. 
3.3 PATIENTS AND METHODS 
Patients with pneumococcal meningitis who were admitted to our 
hospital were identified retrospectively by discharge diagnosis from I 
January 1970 to 30 April 1994. The medical records of all patients 
younger than 18 years of age were abstracted with use of a standard form. 
Pneumococcal meningitis was defined as a bacterial culture of CSF positive 
for S. pnellllloniae, the presence of gram-positive cocci in CSF, or a blood 
culture positive for S. pnellllloniae in combination with clinical evidence of 
meningitis and a CSF WBC count of > 10 mm3• Patients who received 
antibiotic therapy before transfer to our institution were also included in the 
study. In addition, two patients with a clinical history of recurrent 
pneumococcal meningitis were included in the study; however, only their 
first episodes were examined. Medical records from our hospital as well as 
those from referring hospitals were analyzed for demographic parameters, 
clinical features, laboratory data, antibiotic therapy, complications, and 
outcome. Clinical and laboratory data on the day of admission to the first 
hospital were used for statistical analysis. In some medical records, 
laboratOlY data were missing or not detelmined, but this never occurred for 
> 13 patients for a given characteristic. 
Bacteriologic methods 
Microorganisms were identified according to standard procedures [19]. 
Pneumococcal isolates from blood andlor CSF were sent for serotyping to 
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the Netherlands Reference Laboratory for Bacterial Meningitis (Amsterdam) 
and to the World Health Organization's Collaborating Centre for Reference 
and Research on Pneumococci (Copenhagen). The available isolates were 
serotyped by the capsular swelling (quellung reaction) procedure with use 
of type-specific antisera obtained from the Statens Seruminstitut 
(Copenhagen). Since the Netherlands Reference Laboratory for Bacterial 
Meningitis stalted to collect S. pneullloniae strains fi'om CSF and/or blood 
in 1975, serotyping was not performed on strains isolated before that year. 
Susceptibility to penicillin G was determined by the disk diffusion test with 
use of oxacillin disks according to the methods of the National Committee 
for Clinical Laboratory Standards [20]. 
Definitions 
Fever was defined as a temperature of> 38.0° C. Consciousness levels 
during admission were graded as alelt or irritable, somnolent or lethargic, 
and comatose. Shock was defined as a systolic blood pressure that was < 2 
SDs of the age-related mean value or severely decreased peripheral 
perfusion during physical examination. Respiratory distress was defined as 
a condition that required mechanical ventilation because of one or more 
episodes of apnea or respiratory failure. Nonsurvivors included patients who 
died during the acute phase of infection as well as during the follow-up 
period as a result of sequelae of meningitis. Patients were examined at 
discharge to detect neurological sequelae. Spasticity or paresis was defined 
as hypeltonia, slight of incomplete paralysis, or paralysis of one or more 
limbs. Seizures were defined as a convulsive disorder of any type that was 
present after hospitalization. Hearing impairment was established by 
audiometric measurements: pure tone audiogram or brain stem auditory 
evoked potentials (BAEP). Assessment of hearing in young children with 
BAEP was available fi'om 1981 onward. A hearing loss of 2 30 dB that 
was determined by an audiologist as a probable sensorineural loss was 
defined as hearing impairment. Severe deafuess was diagnosed when a 
bilateral hearing impairment of > 70 dB was present [17]. The scoring 
sytem of Herson and Todd was used to assess the clinical severity of 
pneumococcal meningitis [21]. Patients were divided in different groups for 
statistical analyses. Survivors were compared with nonsurvivors. In 
addition, a comparison was made between survivors with and without 
sequelae and between children younger and older than 2 years of age. The 
referred patients were compared with the patients who were primarily 
admitted to our hospital. 
51 
Chapter 3 
Statistical analysis 
Results are expressed as means ± SD unless othelwise noted. 
Differences between groups of variables were tested with the Student's t-
test or the Mann-Whitney test. Differences in frequencies of various 
findings between groups were analyzed by the Fisher's exact test. An exact 
trend test was used to analyze a difference between groups of categorical 
variables with three ordered categories (e.g., levels of consciousness). Two-
tailed P values < .05 were considered statistically significant. The relative 
risk and the 95% confidence interval for the presenting signs and initial 
laboratory measurements relation to mOltality and morbidity were also 
determined. A significance level of .0 I was used for the prognostic 
indicators because of multiple post hoc hypothesis testing (Bonferroni 
procedure). The data processing was performed with SPSS-PC+ version 4.0 
(SPSS, Chicago). 
3.4 RESULTS 
Patients 
A total of 83 children were included in the study. The diagnoses of 
pneumococcal meningitis was confirmed by a positive CSF culture in 78 
cases. The remaining five children had a blood culture positive for S. 
pnellllloniae and an elevated CSF WBC count. Seventy-six percent (53 of 
70) of the available blood cultures were positive for S. pnellllloniae, and 
94% of the gram-stains revealed gram-positive diplococci. 
Serotypes of S. pnellllloniae 
A total of 55 strains were available for typing. The strains isolated 
fi'Om the 28 remaining patients were missing for a variety of reasons. 
Eleven of these 28 isolates were not available because they were cultured 
before 1975. Seventeen strains were not sent to the reference laboratory. 
The most prevalent serotypes and/or serogroups in descending order of 
fi'equency were 19, 14, 18, 6, and 4, which together accounted for 62% of 
all cases of pneumococcal meningitis diagnosed between 1975 and 1994 
(Table 1). 
Baseline characteristics 
The median age of all patients was 8 months (range, 3 days to 12.3 
years). Fifty-four percent of the patients were younger than 1 year of age. 
Only 22% of the patients were older than 4 years of age. The male-to-
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female ratio was 2.1. Approximately one-third (29 of 83) of all patients 
were referred from another hospital, usually for intensive care treatment 
because of respiratory distress or mental status that required careful 
monitoring. The average duration of preceding general symptoms of illness 
before initiation of intravenous antibiotic therapy was 2.5 ± 2.7 days (range, 
< 12 hours to 14 days). In foul' patients, the disease developed during 
hospitalization. 
During admission, 41 of the 83 patients had the classical triad of signs 
of fever, nuchal rigidity, and change in mental status. The other 42 children 
had a least one of these signs. Fever was the only presenting sign in six 
patients. Neck stiffness was present in 67% of patients during initial 
examination. Most patients had abnormal mental status at the time of 
presentation: 34% were alert or irritable, 54% were somnolent or lethargic, 
and 12% were comatose. Seizures OCCUlTed in 30% of the patients prior to 
or within 24 hours after admission to the first institution. A high propOltion 
(34%) of children needed respiratory SUppOlt. Thhteen patients (16%) were 
in shock on arrival at the hospital. Eleven patients died during the acute 
phase of meningitis. Three patients died later as a consequence of 
neurological sequelae. Twenty-five survivors (36%) had one or more 
sequelae at discharge £i'OIn the hospital. The outcome of pneumococcal 
meningitis did not improve during the study period. The mOltality and 
morbidity rates remained similar between 1970 and 1994. 
Serotype and/o)" serogroup 
I 9119A11 9F 
14 
181l8e 
6/6A 
4 
3 
7F 
8 
Others 
Predisposing factol's 
No (%) 
10 (18) 
9 (17) 
6 (II) 
5 (9) 
4 (7) 
3 (5) 
3 (5) 
3 (5) 
12 (23) 
Table 1. Capsular serotypes 
andlor serogroups of 55 strains 
isolated from children with 
pneumococcal meningitis. 
Twelve patients had an underlying disorder: malignancies (/1 = 4), 
hydrocephalus (/1 = 3), asplenia (/1 = I), AIDS (/1 = 1), X-linked 
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hypogammaglobulinemia (n = I), short bowel syndrome (n = I), and type 
III glycogenosis (n = I). Three patients had one or more previous episodes 
of bacterial meningitis. Predisposing conditions directly related to the 
episode of pneumococcal meningitis were infections (33 patients) or prior 
head injury andlor surgelY (8 patients). The most common associated 
infection was otitis media (23 patients). Other infections, including 
pneumonia, sinusitis, mastoiditis, or a combination of these infections, were 
present in 10 patients. The possible portal of entry remained unknown for 
51 % of all patients. 
Treatment 
The antibiotics most frequently used at the time of admission were a 
combination of penicillin and chloramphenicol (39 patients), a combination 
of cefotaxime and amoxicillin (26 patients), and penicillin alone (4 
patients). For the remaining 14 children, most of whom were admitted 
before 1975, other initial antibiotic regimens were prescribed. All isolates 
were susceptible to penicillin. Antibiotic therapy was changed to penicillin 
monotherapy after the results of susceptibility testing became available. 
Survivors vs. nonsurvivors 
The clinical features of and laboratOlY data for survivors and 
nonsurvivors at the time of admission are summarized in Tables 2 and 3, 
respectively. The overall mOliality rate was 17%. The clinical conditions 
(level of consciousness, hemodynamic condition, and respiratOlY status) of 
the nonsUlvivors were worse than those of the sUlvivors. The Herson and 
Todd severity scores were higher for the nonsUlvivors, but the difference 
was not significant. Most of the deaths were a result of complications of the 
CNS. Three patients probably died as a consequence of fulminant septic 
shock. The peripheral WBC counts and the serum sodium levels in the 
nonsurvivors were significantly lower than those in the sUlvivors. The CSF 
protein concentrations were higher in the nonsurvivors (P = .012). There 
was a significant difference in mOliality between patients refel1'ed fi'om 
another hospital and patients who were primarily admitted to our hospital 
(10 [34%] of 29 vs. 4 [7%] of 54, respectively; P = .017). A comparison of 
the refel1'ed patients and the children who were primarily admitted to our 
hospital revealed that the level of consciousness (8 [28%] of 29 vs. 2 [4%] 
of 54, respectively; P = .003), the hemodynamic status (8 [28%] of 29 vs. 5 
[9%] of 54, respectively; P = .054), and the respiratory condition (20 [69%] 
of 29 vs. 8 [15%] of 54, respectively; P <.001) during admission were 
worse in the referrals. 
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Table 2. Clinical features at the time of admission of 83 patients with pneumococcal meningitis. 
Outcome of all episodes Sequelae in survivors 
Feature Nonfatal Fatal Absent Present 
(n ~ 69) (n ~ 14) P (n ~ 44) (n ~ 25) P 
Age (months)' 28 ± 37 39 ± 41 .54 27 ± 36 30 ± 38 .79 
Male 46 (67) 10 (71) 1.00 29 (66) 17 (68) 1.00 
Duration of symptoms (days)"' 2.6 ± 2.8 1.8 ± 1.5 .48 2.4 ± 2.7 2.9 ± 3.1 .44 
Clinical score *t 2.7 ± 1.7 4.1 ± 2.9 .063 2.3 ± 1.6 3.3 ± 1.7 .032 
Level of consciousness 
Alert or irritable 25 (36) 3 (21) 18 (41) 7 (28) 
Somnolent or lethargic 39 (57) 6 (43) .024 24 (55) 15 (60) .22 
Comatose 5 (7) 5 (36) 2 (5) 3 (12) 
Neck stiffness 46 (67) 6 (43) .49 31 (70) 15 (60) .43 
Seizures 19 (28) 5 (36) ,33 12 (27) 7 (28) 1.00 
Vomiting 13 (19) 2 (14) 1.00 12 (27) I (4) .023 
Shock 5 (7) 8 (57) <.001 o ( .. ) 5 (20) .005 
Respiratory distress 15 (22) 13 (93) <.001 10 (23) 5 (20) 1.00 ~ 
'" ~OTE: Data are number (%) of patients with feature unless otherwise specified, ~ Mean ± SD. 
"j'Herson and Todd severity score [21}, " c 
" 
" 
" 
-~ 
:;:. 
o<i 
V> I~ V> 
v. 
Table 3. Laboratory parameters at the time of admission for 83 patients with pneumococcal meningitis. Q 0\ 
{l 
Outcome of all episodes Sequelae in survivors ~ 
Analysis, parameter Nonfatal Fatal p Absent Present p 
..., 
(n = 69) (n = 14) (n = 44) (n = 25) 
Hematologic 
Hb level (mmollL) 6.7 ± l.l 6.7 ± 1.0 .96 6.7 ± l.l 6.6 ± 0.9 .96 
Peripheral WEC count (1 O'IL) 19.8± Il.l 11.2 ± 12.8 .001 22.3 ± 11.7 15.7 ± 8.8 .021 
Platelet count (IO'IL) 383 ± 206 233 ± 138 .079 431 ±221 296 ± 147 .053 
Serum chemistIy 
Sodium level (mmollL) 135±5 129 ± 7 .002 135±3 134 ± 7 .77 
Potassium level (mmollL) 4.3 ± 0.7 4.2 ± 0.8 .71 4.4 ± 0.7 4.0 ± 0.7 .11 
Glucose level (mmollL) 7.4±3.1 7.7 ± 4.0 .47 7.8 ± 2.9 6.5 ± 3.4 .10 
pH 7.39 ± 0.09 7.31 ± 0.19 .21 7.40 ± 0.08 7.36 ± 0.10 .17 
pca, (!<pa) 4.7 ± 1.0 5.0 ± 1.7 .61 4.7 ± 0.8 4.6 ± 1.5 .60 
BE (mmollL) -2.5 ± 4.0 -5.8 ± 8.0 .35 -1.9 ± 3.7 -4.0 ± 4.3 .06 
CSF 
WEC count (/mm') Median 1530 525 .14 1770 800 .02 
Range 6-34,000 29-30,000 6-40,000 15-35,000 
Protein level (gIL) Median 1.4 3.9 .012 1.4 1.4 .89 
Range 0.1-8.0 0.5-25.0 0.1-8.0 0.1-8.0 
Glucose (mmollL) Median 0.9 0.5 .27 2.7 0.5 .005 
Range <0.2-6.8 <0.2-4.1 <0.2-6.8 <0.2-4.3 
CSF Iserum glucose ratio Median 0.26 0.07 .21 0.34 0.09 .11 
Range 0-1.09 0-0.55 0-1.09 0-0.88 
NOTE: Data are means ± SD unless othef'Nise specified. Abbreviations: WBC, white blood cell; eSF, cerebrospinal fluid; 
Hb, Hemoglobin; BE, base excess. 
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Neurological and audiological sequelae 
The clinical features of and the laboratory findings for the survivors 
with and without sequelae are shown in Tables 2 and 3, respectively. 
Twenty-five survivors (36%) had one or more neurological sequelae at 
discharge. Sensorineural hearing loss was diagnosed for 13 survivors (19%). 
A severe bilateral hearing loss was detected in six children. Audiological 
examination of four patients revealed a unilateral sensorineural hearing loss 
of > 80 dB. Other neurological sequelae were present in 17 survivors 
(25%): seizures (n = 7), paresis or spasticity (n = 7), and cranial nerve 
abnormalities (n = 5). Two patients had hydrocephalus. Forty-four patients 
recovered without any sequelae. 
Clinical features and CSF characteristics according to age 
The clinical features of and laboratory data for patients older and 
younger than 2 years of age at the time of admission are depicted in Table 
4. The presence of neck stiflliess was significantly different between the 
two groups, whereas CSF characteristics were similar. The m011ality rate 
was higher among the children older than 2 years of age, but this difference 
was not significant (8 [25%] of 32 vs. 6 [12%] of 51, respectively; P = 
.14). The occurrence of sequelae was similar in both age groups. 
Prognostic indicators 
A number of clinical findings and laboratory measurements were 
associated with a poor outcome (Table 5). Quantitative variables were 
dichotomized. The cutoff values for quantitative prognostic variables were 
based either on the results of previous studies or on the value for which the 
highest relative risk could be calculated. The relative risk for m011ality and 
morbidity and the 95% confidence interval for the prognostic indicators 
were calculated. The presence of an underlying disorder and predisposing 
conditions were not associated with sequelae or death. A difference in CSF 
glucose concentration between survivors and nonsurvivors was not 
observed. A limited number of parameters were associated with the 
development of sequelae in survivors: shock during admission (RR = 3.2; 
95% CI = 2.2-4.6; P = .005), a CSF WBC count of < 1000/mm3 (RR = 1.6; 
95% CI = 1.0-2.7; P = .031), and a CSF glucose level of < 0.6 mmollL 
(RR = 2.9; 95% CI = 1.4-6.0; P = .004). 
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Table 4. Clinical features and CSF characteristics at the time of admission according to age 
of 83 patients ,vith pneumococcal meningitis. 
Patients younger than Patients older than 
Feature or characteristic 2 years of age 2 years of age P 
(1/ ~ 51) (1/ ~ 32) 
Age (months)* 6 ± 5 67 ± 36 <.001 
Sex No. (%) of males 33 (65) 23 (72) 
No. (%) of females 18 (35) 9 (28) .63 
Duration of symptoms (days)* 2.5 ± 2.7 2.4 ± 2.6 .68 
No. (%) with indicated level of 
consciousness 
Alert or irritable 9 (37) 9 (28) 
Somnolent or lethargic 29 (57) 16 (50) .11 
Comatose 3 (6) 7 (22) 
No. (%) with neck stiffness 24 (47) 28 (88) <.001 
No. (%) with seizures 18 (35) 6 (19) .14 
No. (%) with shock 8 (16) 5 (16) 1.00 
No. (%) with respiratory distress 15 (29) 13 (41) .34 
CSF characteristic 
WSC count (/nuD3) 
Median 1170 1530 .098 
Range 6-34,000 92-32,000 
Protein level (giL) 
Median 1.4 1.7 .60 
Range 0.1-25.0 0.1-12.5 
Glucose level (111Il1olfL) 
Median 0.5 2.2 .27 
Range <0.2 - 6.8 <0.2 - 5.0 
CSF/senlill glucose ratio 
Median 0.13 0.34 .68 
Range 0-1.09 0-0.90 
*Mean ± SD. Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell. 
3.5 DISCUSSION 
S. pneullloniae is a common pathogen of childhood meningitis. Groups 
at high risk for pneumococcal meningitis are the very young (younger than 
5 years old) and the elderly (65 years of age of older) [2, 22]. The outcome 
for patients with pneumococcal meningitis is less satisfactory than that for 
patients with bacterial meningitis caused by other microorganisms. Reviews 
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on pneumococcal meningitis have predominantly included cases in adult 
patients or a combination of cases in pediatric and adult patients [4, 6, 11, 
13, 23-28]. We evaluated 83 cases of pneumococcal meningitis in children 
admitted to Sophia Children's HospitallUniversity Hospital Rotterdam 
between 1970 and 1994. We compared our data with those fi'om other 
studies. 
Most (54%) of the patients were younger than 1 year of age. A 
predominance of male patients was seen, as has been rep0/1ed by other 
researchers [6, 26]. Recent studies of pneumococcal disease in children in 
N0/1h America and western Europe demonstrated that cel1ain serotypes 
and/or serogroups (6, 14, 18, 19 and 23) are responsible for most cases of 
bacteremia and meningitis [2, 3, 8, 29-33]. The distribution of serotype 
and/or serogroups of S. pnelllnoniae in the present study is remarkably 
similar. 
Despite the progress in medical treatment, the outcome of 
pneumococcal meningitis in the present study remained similar in the 
period between 1970 and 1994. The overall mortality rate among the 
patients was 17%. Because of the substantial number of patients referred by 
other hospitals, this rate is relatively high in comparison with rates rep0/1ed 
in previous studies [4-6, 9, 14, 34]. The m0/1ality rates of pneumococcal 
meningitis in children who were either primarily admitted or referred to our 
hospital were 7% and 34%, respectively (P = .017). The higher m0/1ality 
rate among the secondary referrals was expected since this group of patients 
had significantly worse levels of consciousness and worse hemodynamic 
and respiratory conditions during admission. Bohr et al. [6] also rep0/1ed a 
significant difference in m0/1ality rates between patients (all ages) referred 
by other hospitals and patients primarily admitted to their hospital (27% vs. 
9%, respectively; P < .05). The m0/1ality rate among adult patients with 
pneumococcal meningitis is higher than that among children. A recent 
retrospective study of pneumococcal meningitis in Dutch adults rep0/1ed a 
mortality rate of 33% [11], which was higher than our rate (P = .06). The 
fatal outcome of pneumococcal meningitis in adults, most of whom are 
elderly, is frequently due to the development of cardiorespiratory failure 
caused by underlying disorders. In contrast, children often die as a result of 
neurological complications. It is interesting that pneumococcal meningitis in 
adults was more fi'equently associated with pneumonia (range, 16%-39%) 
[11, 24-26, 35, 36]. This finding is in contrast with our observation that 
only three (4%) of 83 children had pneumonia. The presence of underlying 
disorders and predisposing conditions in the patients in the current study 
was not associated with a bad outcome. Age-specific differences in 
outcome were also not observed. However, neck stiffhess was seen 
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Table 5. MOl'tality rate of pneumococcal meningitis according to presenting signs and 
initial laboratory measurements. 
Sign or measurement 
Level of consciousness 
Comatose 
NOllcomatose 
Respiratory distress 
Yes 
No 
Shock 
Yes 
No 
Peripheral WBC (lO'/L) 
< 5.0 
:> 5.0 
Serum sodium (mmoIlL) 
< 135 
:> 135 
CSF WBe (hum') 
< 1,000 
:> 1,000 
eSF glucose (mmollL) 
< 0.6 
:> 0.6 
eSF proteiu (gIL) 
:> 2.5 
< 2.5 
No. of cases No. (%) of 
tested nonsurvivors 
10 
73 
28 
55 
13 
70 
8 
72 
37 
34 
31 
45 
34 
39 
25 
48 
5 (50) 
9 (12) 
13 (46) 
I (2) 
8 (62) 
6 (9) 
5 (63) 
8 (II) 
12 (32) 
I (3) 
8 (26) 
4 (9) 
6 (18) 
4 (10) 
8 (32) 
2 (4) 
RR (95% CI) p 
4.1 (1.7-9.7) .01 
25.5 (3.5-185.4) <.001 
7.2 (3.0-17.3) <.001 
5.6 (2.4-13.1) .002 
11.0 (1.5-80.4) .002 
2.9 (1.0-8.8) .06 
1.7 (0.5-5.6) .50 
7.7 (1.8-33.5) .002 
Abbreviations: CI, confidence interval; RR, relative risk; WBC, white blood cells; eSF, 
cerebrospinal fluid. 
significantly more often in patients older than 2 years of age. This 
observation is in agreement with the finding that nonspecific symptoms 
predominantly occur in newborns and young infants [37). 
We observed that one or more sequelae were present at discharge in 
36% of the survivors. It is interesting that the rate of sequelae was not 
significantly higher among the refel1'ed patients. The incidence of 
neurological sequelae has ranged between 25% and 56% in several reports 
[4, 7, 14-16). Many of the neurological abnormalities observed in the 
survivors will probably resolve within I year [38). A hearing impairment, 
which is usually permanent, was observed in 19% of the patients. In a 
recent review [18) the incidence of permanent sensorineural hearing 
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impairment after pneumococcal meningitis was 32% (range, 21%-50%). We 
may have underestimated the percentage of patients with hearing loss since 
an audiological assessment was performed in only 52% of all survivors. 
Assessment of hearing was performed in 74% of the patients with 
pneumococcal meningitis who were admitted since 1980, when the 
measurement of BAEP became available. The percentage of children with 
hearing impairment in that period remained similar (21%). 
Several clinical findings were associated with a high mortality rate 
among children in the present study. An altered level of consciousness at 
the time of admission was associated with an increased rate of mortality. 
This association was highly significant in patients who were comatose. The 
presence of shock was a bad prognostic indicator for mOttality and 
morbidity. The mOttality rate was also significantly increased among 
patients who needed mtificial ventilation. These findings were also repOtted 
previously [6, 24, 26, 39]. 
Various investigators have evaluated the prognostic impOltance of 
laboratory parameters in fatal cases of pneumococcal meningitis and in 
cases in survivors with sequelae. An unfavorable outcome has previously 
been associated with a decreased CSF WBC count [24, 25, 35], a low CSF 
glucose level (e.g., < 0.6 mmol/L) [14, 24, 27, 39], a high CSF protein 
concentration (e.g., > 1.5 gIL) [II, 24, 25, 27, 28, 40, 41], high CSF levels 
of lactate or fibrin-degradation products, high CSF bacterial counts, or high 
CSF bacterial antigen titers [25, 35, 42]. However, other investigators could 
not confirm these associations [6, 36]. In the present study, the following 
laboratory measurements were associated with a poor outcome: a decreased 
CSF glucose level « 0.6 mmol/L), an elevated CSF protein level (;:>: 2.5 
gIL), a decreased peripheral WBC count « 5 x I 091L), and a low serum 
sodium level « 135 mmollL). Patients with a low CSF WBC count « 
1,000/mm3) tended to have worse outcomes. These data were similar to the 
data in most other studies, although the cutoff values of the variables were 
slightly different. Bolu' et al. [6] observed that pleocytosis was not 
associated with significant differences in mortality rates; however, an 
increased rate of sequelae was found among children with high CSF WBC 
counts (> 5,000/mm3). In the present study, the CSF glucose level was 
significantly decreased only in the survivors with sequelae, while in other 
repOlts higher mortality rates were also observed [14, 24, 27]. We conclude 
that the mortality rate of pneumococcal meningitis is lower among children 
than among adults. Children often die of neurological sequelae, whereas 
adults frequently die of cardiorespiratory failure due to underlying diseases. 
For children, coma, respiratory distress, and shock at the time of admission 
were clinical findings with the strongest predictive value for a bad outcome. 
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4.1 ABSTRACT 
The molecular epidemiological characteristics of pneumococcal 
meningitis in children were studied. Pneumococcal isolates were 
characterized by serotyping and two genotyping methods, BOX 
fingerprinting and restriction Jiagment end labeling, to evaluate whether 
clonal strains were present within the serotypes or serogroups. During a 17-
year period, 68 children admitted to the Sophia Children's Hospital were 
diagnosed with meningitis due to Streptococcus pneullloniae. Pneumococcal 
isolates fi'om 44 patients were still available for analysis. All strains were 
susceptible to penicillin. Serotypes/serogroups 14, 19, 6, and 8 represented 
56% of all isolates. The results of the molecular typing methods 
demonstrate the absence of clonal relatedness between isolates from 
patients with pneumococcal meningitis. 
4.2 INTRODUCTION 
Streptococcus pneullloniae remains a major cause of morbidity and 
mOitality and is the third most common microorganism worldwide in 
children with bacterial meningitis. Pneumococci can be divided into 84 
serotypes on the basis of differences in stlUcture and antigenicity of 
capsular polysaccharides [1]. A continuing survey of capsular types of S. 
pneulIloniae from cerebrospinal fluid (CSF) or blood remains necessary to 
determine if the CUll'ent and future multivalent (conjugate) polysaccharide 
vaccines still contain the predominant serotypes. Serotyping is a useful 
technique to study the epidemiological relatedness of S. pneulIloniae 
isolated during outbreaks [2]. However, capsular serotyping does not give 
an accurate estimation of genetic relatedness between isolates [3, 4]. 
Several new phenotypic and genotypic methods have been developed and 
applied to study relationships among isolates from clinical outbreaks, 
mainly with dlUg-resistant S. pneu/lloniae. These techniques include 
penicillin-binding protein profile analysis, multilocus enzyme 
electrophoresis, DNA fingerprinting by pulsed-field gel electrophoresis, 
polymerase chain reaction (PCR) fingerprinting, and ribotyping [4-8]. 
Application of these techniques has revealed that penicillin-resistant clones 
from a limited number of serotypes (6B, 19A, 23F) are responsible for the 
rapid worldwide dissemination of antibiotic-resistant pneumococci. 
Recently, our group reported that BOX fingerprinting and restriction 
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fragment end labeling (RFEL) are very suitable molecular tecbniques for 
typing pneumococcal strains [9]. 
We previously reviewed our clinical experience with pneumococcal 
meningitis in children [10]. Forty-four of 68 pneumococcal isolates taken 
between 1975 and 1992 were still available for further analysis. The aim of 
the cun'ent study was to investigate by RFEL and BOX fingerprinting 
whether clonal isolates were present within the different serotypes/ 
serogroups. 
4.3 MATERIALS AND METHODS 
Identification of pneumococcal strains 
We surveyed the medical records of children < 18 years of age 
admitted to the Sophia Children's HospitallUniversity Hospital Rotterdam, 
The Netherlands between 1975 and 1992 and diagnosed with pneumococcal 
meningitis. Meningitis was defined by the isolation of S. pnell/1loniae from 
CSF or blood in combination with clinical evidence of meningitis and a 
CSF white blood cell count> 10 cells/mmJ • Only one isolate per disease 
episode was analyzed. Sixty-eight children were diagnosed with 
pneumococcal meningitis. Forty-four strains were available for serotyping 
and genotyping. 
Bacteriological methods 
Pneumococcal isolates Jiom blood and/or CSF were sent for 
identification to the Netherlands Reference Laboratory for Bacterial 
Meningitis (University of AmsterdamlNational Institute of Public Health 
and the Environment) and to the WHO Collaborating Center for Reference 
and Research on Pneumococci (Copenhagen, Denmark). Microorganisms 
were identified according to standard procedures. All strains were serotyped 
by the capsular swelling procedure (quellung reaction) using type-specific 
antisera obtained from the Statens SelUminstitut, Copenhagen. Susceptibility 
to penicillin G was determined by the disk diffusion method using oxacillin 
disks according to the National Committee for Clinical Laboratory 
Standards [11]. 
DNA isolation, restriction endonuclease digestion, and DNA probes 
Bacterial cultures were grown in Todd-Hewitt broth containing 0.5% 
yeast extract at 37°C to an optical density of 0.5 at 560 nm. Bacterial cells 
from 5 ml cultures were harvested by centrifugation and genomic DNA was 
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extracted by the cetyl-trimethyl-ammoniumbromide (CTAB) method [12]. 
The restriction enzymes Pvull and EcoR! were used to digest the CT AB-
purified chromosomal DNA samples [13]. The oligonucleotides BR-A 
(5'ATACTCTTCGAAAATCTCTTCAAAC) and BR-C (5'TATACTCAAT-
GAAAATCAAAGAGCA) were derived from the BOX repeat sequence of 
S. pneumoniae [14]. The oligonucleotide primer pair BR-AlBR-C was used 
in PCR to generate the 151 base pair (bp) BOX repeat probe. Amplification 
of the DNA probe by PCR was performed as previously described [15]. 
The PCR-amplified probe was labeled by the enhanced chemiluminescence 
gene detection system (Amersham International, Bucks, UK) according to 
the manufacturer's recommendations. 
Restriction fragment end labeling 
Restriction ii'agment end labeling was performed as described by Van 
Steenbergen et al. [16], and modified by Hermans et al. [9]. Briefly, 
purified pneumococcal DNA was digested by EcoR!. DNA restriction 
fi'agments were labeled at 72°C with [a_32p] dATP using Taq DNA 
polymerase. The radio-labeled fragments were denatured and separated 
electrophoretically on a 6% polyactylamide sequencing gel containing 8 M 
urea. Subsequently the gel was transferred onto filter paper, vacuumdried, 
and exposed for variable lengths of time at room temperature to 
radiographic films (Fuji RX film; Fuji Medical Systems, The Netherlands). 
BOX fingerprinting 
Molecular analysis of the pneumococcal isolates was also performed 
by BOX fingetprinting [9]. By this method, purified chromosomal DNA of 
S. pnelll1loniae strains was digested with .!'YllII. Internal markers were added 
to the digested DNA samples as described previously [12]. The restriction 
fi'agments were separated electrophoretic ally on a 0.8% agarose gel, 
denatured, and transferred onto a nylon membrane (Hybond N+; Amersham 
International) by vacuum blotting (VacuGene; Pharmacia LKB 
Biotechnology, Sweden). Hybridization analysis was performed using the 
lSI bp BOX repeat probe. Hybridization and detection was cat1'ied out by 
the chemiluminescence gene detection system as recommended by the 
manufacturer (Amersham). 
Computer-Assisted analysis of DNA fingerprints 
The fingetprints displayed by RFEL were analyzed using the Windows 
version of the Gelcompar software, version 3.10 (Applied Maths, Belgium) 
after imaging of the autoradiograms with a scanner (HP Scanjet IIcxIT; 
Hewlett Packard, USA) at 190 dots per inch. Fingerprint patterns were 
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Table 1. Capsular serotypes of pneumococci isolated from cerebrospinal fluid during the 
period 1975·1992. 
Ol'der of Serotype No. (%) Cumulative No. (%) frequency 
14 9 (20) 9 (20) 
2 19119A119F 6 (14) IS (34) 
3 616A 5 (I I) 20 (45) 
4 18118C 5 (I I) 25 (56) 
5 4 4 (9) 29 (65) 
6 7F 3 (7) 32 (72) 
7 8 3 (7) 35 (79) 
8 3 2 (5) 37 (84) 
9 1/2113B115B/23/27/33F 7 (16) 44 (100) 
normalized using pneumococcus-specific bands that were present in the 
fingerprints of all strains. Comparison of the fingerprints displayed by 
RFEL was performed by unweighted pair group method using arithmetic 
averages (UPGMA) [17], and using the Jaccard similarity coefficient 
applied to peaks [18]. 
The BOX fingerprints were analyzed according to the software 
manufacturer's instmctions. The mobilities of the DNA fragments 
hybridizing with the DNA probe were compared with a set of intemal 
molecular weight markers by superimposing autoradiograms containing the 
DNA fingerprints and autoradiograms containing the intemal markers of 
known molecular size [12]. This procedure enabled us to normalize the 
position of each of the hybridizing fi'agments, irrespective of autoradiogram 
and/or gel distortions. Comparison of the BOX fingerprints was performed 
using the Pearson correlation coefficient. 
4.4 RESULTS 
Susceptibility testing and serotyping of the pnenmococcal strains 
Susceptibility testing was performed using the 44 available isolates. All 
isolates were susceptible to penicillin. The isolates were also characterized 
by serotyping. Serotype distribution is depicted in Table 1. S. pneumoniae 
belonging to the eight most common groups comprised 84% of all 
infections. The most prevalent serogl'Oups were 14, 19, 6, and 18, 
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accounting for 56% of all cases. Geographical or temporal clustering of 
serotypes could not be demonstrated. 
Molecular analysis of the pneumococcal strains 
The collection of pneumococcal isolates were analyzed by RFEL. The 
fingerprint patterns of 43 isolates were suitable for computerized analysis. 
Fingerprints were all different from each other (Figure 1). However, one 
pair of fingerprints (891308 serotype 19F and 910105 serotype 14) was 
more than 95% identical, but these isolates were less than 70% identical in 
the analysis by BOX fingerprinting. BOX fingerprinting resulted in 44 
distinct fingerprint patterns (Figure 2) using a cut-off value of 95% 
similarity (data not shown). These data demonstrate the enormous genetic 
heterogeneity of the pneumococcal meningitis isolates. 
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Figure 2. Molecular epidemiological analysis of 44 Streptococcus pneumoniae strains by BOX 
fingerprinting. The lane numbers correspond with the following strains: lane 1, strain 760774; 
lane 2, 840380; lane 3, 820149; lane 4, 780993; lane 5, 851190; lane 6, 891744; lane 7, 871165; 
lane 8, 830904; lane 9, 790228; lane 10, 910833; lane II, 790590; lane 12, 840580; lane 13, 
850531; lane 14,890279; lane 15, 841312; lane 16,910798; lane 17,800876; lane 18,871694; 
lane 19, 801407; lane 20, 891630; lane 21, 880547; lane 22, 891829; lane 23, 820492; lane 24, 
911320; lane 25,892465; lane 26,800129; lane 27,892468; lane 28, 911085; lane 29, 790431; 
lane 30,840018; lane 31, 921168; lane 32, 860227; lane 33,780215; lane 34,750339; lane 35, 
830466; lane 36, 870741; lane 37, 890992; lane 38, 760772; lane 39, 810721; lane 40, 840929; 
lane 41, 891308; lane 42, 750051; lane 43, 910105; and lane 44, 780966. Numbers at left 
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4.5 DISCUSSION 
S. pneumoniae is a major pathogen in meningitis in children and 
adults. The aim of the present study was to identify the molecular 
epidemiological characteristics of pneumococcal meningitis in children. We 
questioned whether clonal types would be present within the limited 
number of serotypes/serogroups. 
Serotype distribution of S. pneumoniae varies with age, geographic 
area, time, and site of infection [19]. Pneumococcal types 6, 7F, 14, ISC, 
19F, and 23F have previously been reported to be responsible for the large 
majority of pneumococcal infections in children [19]. The distribution of 
serotypes in our study was similar, with a limited number of serotypes (14, 
19, 6, and IS) accounting for 56% of all isolates. However, clustering 
observed by serotyping was not confirmed by the two genotypic methods, 
RFEL and BOX fingerprinting. Since the strains were sampled over a 
l7-year period, the epidemiological relatedness of these strains is unlikely, 
and subsequently, the high degree of genetic diversity is not surprising. 
Furthermore, genetic diversity has been demonstrated to be higher in 
dlUg-susceptible pneumococci compared with dtug-resistant isolates [20]. 
The dtug-susceptible phenotype of the strains used in this study might 
therefore also contribute to the observed high degree of genetic diversity 
within this group. 
Analysis by RFEL and BOX fingerprinting of ten multiply resistant 
serotype 23F S. pneumoniae strains isolated from different locations during 
a five-year period in the USA [7] displayed identical fingerprints 
(unpublished observations). These data SUppOlt the power of these two 
methods to analyze clonality among pneumococci presumably over decades. 
Therefore, these techniques may allow the investigation of long-term 
epidemiological issues, such as global spread or global persistence of 
celtain pneumococcal sel'Otypes. 
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Antiinflammatory Mediators in Bacterial Menigitis 
5.1 ABSTRACT 
The antiinflammatory mediators interleukin (IL )-10 and soluble tumor 
necrosis factor (TNF) receptors p55 (sTNFR-55) and sTNFR-75 in 
cerebrospinal fluid (CSF) fi'om 37 children with bacterial meningitis were 
studied. CSF concentrations of IL-I 0, sTNFR-55, and sTNFR-75 and of the 
proinflammatory cytokines TNF -a, IL-6, and IL-8 were markedly elevated 
and were, with the exception of the sTNFRs, significantly higher in CSF 
than in selUm. CSF concentrations of sTNFR-55 and sTNFR-75 were only 
associated positively with IL-IO levels. CSF glucose levels con'elated 
highly with levels of IL-lO, sTNFR-55, and sTNFR-75 and weakly with 
TNF -a and IL-6. Cytokine levels in CSF decreased rapidly, while sTNFR 
levels remained elevated for at least 24 hours. 
5.2 INTRODUCTION 
Proinflammatory cytokines (tumor necrosis factor-a [TNF-a], 
interleukin [IL]-6, IL-8) are released within the cerebrospinal fluid (CSF) 
compartment of patients with bacterial meningitis upon recognition of 
bacterial products. The production of proinflammatoty cytokines and the 
extent of the inflammatory response are pattly controlled by 
antiinflammatoty compounds, such as IL-IO, and naturally occun'ing 
antagonists of TNF-a, including soluble extracellular domains of the 55-
and 75-kDa membrane-bound TNF receptors (sTNFR-55 and sTNFR-75). 
IL-IO is produced by monocytes/macrophages, the Th2 subset of T 
helper lymphocytes, and B lymphocytes and suppresses the synthesis of 
proinflammatory cytokines by T cells [I], polymorphonuclear leukocytes 
[2], and monocytes/macrophages [3]. IL-IO protects against TNF-mediated 
lethality in murine models of endotoxemia [4]. CSF levels of IL-IO are 
significantly increased in patients with bacterial meningitis, suggesting a 
role for IL-IO in the control of the inflammatoty response in the CSF 
compaltment [5]. 
The biologic activity of TNF-a is also neutralized by sTNFR-55 and 
sTNFR-75 [6]. Release of sTNFR-55 and sTNFR-75 may provide a 
mechanism for modulation of excessive TNF -a activity in response to 
injury or infection. sTNFRs are shed from the cell surface of 
polymorphonuclear cells and monocytes in response to many of the same 
inflammatoty stimuli that are known to induce TNF-a [7]. Of interest, IL-
10 induces in vitro an increased release of sTNFRs from monocytes .[8, 9]. 
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To investigate the role of antiinflammatory compounds (IL-IO, 
sTNFR-55, sTNFR-75) and their relation to proinflammatory cytokines 
(TNF-a, IL-6, IL-8) in children with bacterial meningitis, selUm and CSF 
levels of these mediators were measured in 37 patients. The kinetics of 
these mediators in the CSF compartment and the association between 
mediators and CSF characteristics were also studied. 
5.3 METHODS 
Patients and controls 
Patients between the ages of 3 months and 18 years diagnosed with 
bacterial meningitis between August 1992 and September 1994 were 
included. The patients were admitted to the Depatiments of Pediatrics of 
Sophia Children's Hospital, Zuiderziekenhuis, Reinier de Graaf Gasthuis, or 
Juliana Children's Hospital. Bacterial meningitis was defined as the 
presence of a positive bacterial culture fi·otn CSF or a positive blood culture 
in combination with clinical evidence of meningitis and a CSF white blood 
cell (WBe) count> lOx 1061L. Patients with prior antibiotic treatment were 
excluded. 
Initial CSF and selUm samples were collected in most patients. A 
subset of patients had a second lumbar puncture done in a randomized 
fashion at 6, 12, or 24 h after initiation of antibiotic treatment. These 
patients were treated with intravenous ceftazidime (150 mg/kg/day in three 
doses). The remaining patients were treated with ceftazidime or cefotaxime, 
but a second lumbar puncture was not done., 
Paired control samples of selUm and CSF were obtained from pediatric 
cancer patients who were in remission. The lumbar punctures in these 
children were done as pati of diagnostic protocols. 
Laboratory studies 
CSF samples from patients and controls were examined for WBC 
count and levels of glucose and protein. Samples of blood and CSF were 
cultured before antibiotic treatment and were processed according to 
standard procedures. Antibiotic susceptibility was determined by disk 
diffusion method. CSF and setum samples were stored at -70°C until used 
for different assays. 
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SelUm and CSF levels of TNF-a, IL-6, IL-8, IL-IO, sTNFR-55, and 
sTNFR-75 were assayed with ELISA kits (Medgenix, FleUlus, Belgium), 
according to the manufacturer's instructions, with the following detection 
limits (lowest positive standard): TNF-a, 15 pg/mL; IL-6, 30 pg/mL; IL-8, 
7 pg/mL; IL-10, 11 pg/mL; sTNFR-55, 0.4 ng/mL; and sTNFR-75, 1.0 
ng/mL. 
Statistical analysis 
Differences between groups in continuous variables were tested for 
significance with the Mann-Whitney test. Pearson's (I') and Spearman's (l~) 
con'elation coefficients were used to evaluate the relation between variables. 
A regression analysis for repeated measurements evaluated the change in 
concentration of the mediators with time. P :S.05 (two-tailed) was 
considered significant. 
5.4 RESULTS 
Patients and controls 
The mean age of the 37 patients was 3.3 years (range, 0.3-13.0). There 
were 17 boys and 20 girls. The causative pathogens were Haemophilus 
injluenzae (n = 16) Neisseria meningitidis (n = 14), Streptococcus 
pneumoniae (n = 6), and Fusobacterium necrophorum (n = 1). Twenty-one 
patients had a second lumbar puncture at 6 (n = 8), 12 (n = 4), or 24 h (n = 
9) after initiation of antibiotics. All strains were susceptible to ceftazidime 
and cefotaxime. 
Control subjects were 10 patients who were in remission from acute 
lymphatic leukemia. All CSF samples from the controls were sterile and 
had normal CSF characteristics. Chemotherapy had been discontinued for at 
least 3 months. The children in the control group were 2.7-16.5 years old. 
Proinflammatory cytokines (TNF-o<, IL-6, IL-8) 
Median CSF concentrations of TNF-a, IL-6, and IL-8 during the acute 
phase of bacterial meningitis were 555, 89,590, and 2604 pg/mL, 
respectively. These levels were significantly (P < .001) elevated compared 
with those of control subjects (Figure 1). Levels of TNF -a, IL-6, and IL-8 
correlated with each other by significantly positive (P < .001) cOll'elation 
coefficients between .57 and .77. 
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IL-IO in initial serum and CSF samples 
IL-I0 was detected in 33 of 35 initial CSF samples fi'om patients with 
bacterial meningitis (Figure 1). CSF lL-10 levels were below the detection 
limit (11 pglmL) in all control subjects. The median CSF concentration of 
L-lO in patients was 701 pglmL (range, <11-4000), which was significantly 
higher than in the control population (P < .001). CSF levels of IL-lO 
cOl1'elated positively with TNF-o: (I' = .71, P < .001), IL-6 (I' = .60, P < 
.001), sTNFR-55 (I' = .53, P = .003), and sTNFR-75 (I' = .61, P < .001) but 
not with IL-8 (I' = .28, P = .10). Selum levels of IL-lO in 22 patients were 
also significantly elevated (median, 78 pglmL; range, <11-20,000) in 
comparison with levels in the control subjects (median, <11 pglmL; ,P < 
.001). 
Figure 1. Cerebrospinal fluid COIl-
centrations of proinflammatory 
cytokines tumor necrosis factor-a 
(TNF-a, n ~ 35), interleukin (IL)-6 (/I 
~ 35), and IL-S (II ~ 35) and 
antiinflammatory compounds IL-lO (11 
~ 35), soluble TNF receptor p55 
(sTNFR-55, II ~ 31), and sTNFR-75 (II 
= 31) during acute phase of bacterial 
meningitis ce) and in control subjects 
(0). Horizontal bars = medians in 
patients; dashed lines = detection limits 
of each mediator. 
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sTNFR-55 and sTNFR-75 in initial serum and CSF samples 
CSF concentrations of both sTNFRs were measured in 31 patients 
(Figure I). The median CSF level of sTNFR-55 was 3.6 nglmL (range, 1.1-
25.0) versus 0.6 nglmL (range, <0.4-0.9) in control subjects (P < .001). 
Median CSF sTNFR-75 concentrations were 13.0 nglmL «1.0-140.4) in 
patients and below the detection limit in control subjects (P < .001). 
A positive correlation was observed between sTNFR-55 and sTNFR-75 
levels (r = .88, P < .001). CSF levels of sTNFR-55 and sTNFR-75 
correlated significantly with IL-IO concentrations (r = .53, P = .003, and r 
= .61, P < .001, respectively) but not with TNF-a, IL-6 or IL-8 levels. 
Median selUm levels of the sTNFRs were significantly higher in patients (n 
= 23) than in control subjects (sTNFR-55, 6.0 nglmL [range, 2.3-18.3] vs. 
1.5 nglmL [range, 1.2-2.1], P < .001; sTNFR-75, 19.7 nglmL [range, 5.3-
126.0] vs. 4.1 nglmL [range, 3.7-4.4], P < .001). 
TNF -or, IL-6, IL-8, IL-IO, sTNFR-55, and sTNFR-75 in initial paired 
serum-CSF samples 
The median concentrations of TNF -a, IL-6, IL-8, and IL-IO were 
significantly higher in initial CSF specimens than in selUm. In contrast, 
median concentrations of both sTNFRs were similar in the 23 available 
pairs of selUm and CSF samples on admission (sTNFR-55, 6.0 nglmL 
[range, 2.3-18.3] vs. 3.7 ng/ML [range 1.1-25.0], P = .43; sTNFR-75, 19.7 
nglmL [range, 5.3-126.0] vs. 13.0 nglmL [range, < 1.0-140.4], P = .88). 
Correlation between CSF inflammatory parameters and levels of TNF-
or, IL-6, IL-8, IL-IO, sTNFR-55, and sTNFR-75 
CSF glucose concentrations were highly con-elated with levels of IL-I 0 (r, 
= -.87, P < .001), sTNFR-55 (r, = -.81, P < .001), and sTNFR-75 (r, = -.85, 
P < .001), whereas cOIl'elations with TNF-a and IL-6 were relatively low. 
In contrast, IL-8 concentrations were not significantly associated with CSF 
glucose concentrations. The CSF concentrations of the mediators were, with 
the exception of IL-8, significantly correlated with the WBC count. CSF 
levels of protein were significantly associated with concentrations of TNF-a 
(r, = .54, P = .002), IL-6 (r, = .52, P = .002), IL-8 (r, = .48, P = .006), IL-
10 (r, = .53, P = .002), and sTNFR-75 (I~ = .37, P = .05) but not with 
sTNFR-55. 
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Figure 2. Kinetics of tumor necrosis factor a (TNF-a, 11 = 20) and antiinflammatory compounds 
interleukin (lL)·IO (1/ ~ 20), soluble TNF receptor p55 (sTNFR·55, 1/ ~ 19), and sTNFR·75 (1/ ~ 
19) in cerebrospinal fluid compartments of patients with bacterial meningitis. Dashed lines = 
detection limits of some mediators. 
Kinetics of TNF-(I', IL-6, IL-8, IL-I0, sTNFR-55, and sTNFR-75 
CSF levels of TNF-a, IL-6, IL-8, and IL-IO declined 46% (95% 
confidence interval [CI], 39%-57%; P < .001), 52% (95% CI, 39%-63%; P 
< .001), 58% (95% CI, 45%-67%; P < .001), and 50% (95% CI, 35%-61%; 
P < .001) per 6 h, respectively. However, levels of the sTNFRs did not 
significantly decrease but remained markedly elevated, at least during the 
initial 24 h of treatment (Figure 2). 
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5.5 DISCUSSION 
In the present study, proinflammatory cytokines (TNF-o:, IL-6, IL-8) 
and antiinflammatory mediators (IL-IO, sTNFR-55, sTNFR-75) were 
markedly elevated in serum and CSF of children with bacterial meningitis. 
The concentrations of the proinflammatory cytokines were significantly 
higher in CSF, suggesting a compartmentalized release in the subarachnoid 
space of patients with bacterial meningitis. This has been also rep01ted by 
others [10]. 
Antiinflammatory compounds IL-IO, sTNFR-55, and sTNF-75 down-
regulate the host response. Administration of recombinant IL-IO effectively 
inhibits systemic LPS-induced synthesis of proinflammatory cytokines. In 
addition, IL-IO suppresses the synthesis of nitric oxide and reactive oxygen 
intermediates, which are involved in the pathophysiology of bacterial 
meningitis [II]. In agreement with Lehmann et al. [5], we observed 
significantly elevated levels of IL-IO in CSF of children with bacterial 
meningitis. IL-IO is mainly produced in the CSF compartment, since CSF 
levels are significantly higher than serum levels [5]. Endogenous IL-J 0 
production in the CSF compartment may thus play an important role as a 
natural regulatory and antiinflammatory cytokine. 
We observed significantly elevated levels of sTNFR-55 and sTNFR-75 
in CSF and serum of patients with bacterial meningitis, as rep01ted by 
others [12]. TNF-o: induces release of sTNFR-55 and sTNFR-75 from 
neutrophils in suspension in a time- and dose-dependent manner [13]. The 
shedding of these receptors and the resultant acute decrease of TNFRs on 
the cell surface may serve to transiently desensitize cells, thereby providing 
a mechanism for inhibition of TNF-o: activity. This process may have 
implications in vivo, since soluble receptors may inhibit TNF -0: bioactivity 
by binding to the molecule and preventing ligand binding to the cellular 
TNFRs. Of interest, levels of sTNFRs in this study were exclusively 
associated with concentrations of IL-I 0 but not with concentrations of TNF-
0:, IL-6, or IL-8. This is in agreement with the recent observation that IL-J 0 
induces an increase in the synthesis and cell-surface turnover of sTNFRs 
from monocytes [8, 9]. IL-JO thus may suppress TNF activity in the CSF 
compattment by an inhibition of TNF-o: secretion, stimulation of the release 
of sTNFRs, and down-regulation of the expression of surface TNFRs [8, 9]. 
In our study, serum and CSF levels of sTNFR-55 and sTNFR-75 were 
similar. The relatively low CSF levels of sTNFRs may be pattly explained 
by a release of sTNFRs from polymorphonuclear leukocytes before entry of 
these cells into the CSF compartment. Alternatively, shedding of sTNFRs in 
the CSF compartment may be lower because of the IO-fold lower WBC 
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count in CSF than in peripheral blood in these patients. The significantly 
higher stimulus by TNF-a and IL-IO for release of sTNFRs in the CSF 
compartment apparently does not compensate for this inequality. 
CSF inflammatory characteristics were significantly associated with the 
levels of inflammatory mediators. CSF glucose levels correlated strongly 
with levels of IL-IO, sTNFR-55, and sTNF-75 and weakly with levels of 
TNF-a. . 
The CSF levels of TNF-a, IL-6, IL-8, and IL-IO decreased rapidly. 
This feature is similar to that observed in consecutive semm samples of 
experimental models of bacteremia or endotoxemia and in patients with 
sepsis [14]. The elevated levels of sTNFR-55 and sTNFR-75 in the present 
study persisted for a remarkably long time (at least 24 h), as is observed in 
bacteremia [15]. This may be due to slow clearance fi'om the CSF 
compattment or to continuing release. 
We conclude that IL-IO, sTNFR-55, and sTNFR-75 were released 
along with proinflammatory cytokines in the CSF compartment of patients 
with bacterial meningitis. IL-IO may have been pattly responsible for the 
release of sTNFRs in the CSF compatiment. CSF levels of TNF -a, IL-6, 
IL-8, and IL-IO rapidly decreased, while CSF levels of the sTNFRs 
remained elevated. 
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Interleukin-12 and intelferon-r in bacterial meningitis 
6.1 ABSTRACT 
To assess the role of interleukin (IL)-12 and interferon (IFN)-y in 
children with bacterial meningitis, bioactive IL-12 (P70) and the inactive 
IL-12 subunit p40 as wll as IFN-y were measured in seJum and 
cerebrospinal fluid (CSF) fi'om 35 children with bacterial meningitis and 10 
control subjects. The production of IFN-y is induced by IL-12 with TNF-a 
as a costimulator and inhibited by IL-IO. CSF concentrations of IL-12 p40 
as well as those of IFN-y were markedly elevated whereas IL-12 p70 was 
hardly detectable. Detectable CSF levels of IFN-y correlated positively with 
IL-12 p40 (r = .40, P = .02) and TNF-a (r = .46, P = .04), but not with IL-
6, IL-8 or IL-IO. In contrast to CSF levels of TNF-a, IL-12, and IL-IO, the 
IFN-y levels were significantly higher in patients with pneumococcal 
meningitis than in children with meningitis by Haemophilus influenzae and 
Neisseria meningitidis, which presumably was due to a high CSF TNF-a / 
IL-IO ratio in the former. We suggest that IFN-y production induced by IL-
12 and TNF-a may contribute to the natural immunity against 
microorganisms in the CSF compartment during the acute phase of bacterial 
meningitis. 
6.2 INTRODUCTION 
Proinflammatory cytokines (tumor necrosis factor [TNF]-a, interleukin 
[IL ]-6, IL-8 and interferon [IFN]-y are involved in the pathophysiology of 
bacterial meningitis [I]. Recently, a novel cytokine with proinflammatOlY 
effects has been described [2-5]. This cytokine, IL-12, augments the host 
defence against bacteria, bacterial products, and parasites. Bioactive IL-12 
is a heterodimeric protein of 70 kDa (P70) which consists of 40 kDa (P40) 
and 35 kDa (P35) subunits linked by a disulfide bond [3]. IL-12 is 
predominantly produced by macrophages and monocytes, but also by B 
cells [6] and polymorphonuclear leukocytes [7]. It has been shown to 
enhance the cytolytic activity of a number of effector cells including T 
cells, natural killer (NK) cells, lymphokine activated killer cells, and 
macrophages. FUtihermore, IL-12 also increases the proliferation of 
activated NK and T cells and stimulates the production of cytokines, such 
as IFN-y, granulocyte-macrophage colony-stimulating factor, and TNF-a 
[8-10]. The release of IFN-y is costimulated by TNF-a and IL-lB, and 
inhibited by IL-IO [11, 12]. 
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It has been proposed that IL-12 is involved in the early development of 
an immune response against infectious agents. Production of IL-12 
contributes to the control of the host response against infections with 
intracellular organisms such as Listeria monocytogenes [13] Toxoplasma 
gondii [14] and Leishmania major [15]. IL-12 mediated protection may be 
invoked through its ability to stimulate IFN-y, which inhibits the parasite 
[16]. Furthermore, IL-12 is also a key cytokine modulating the endotoxin-
induced infiammatory process in mice [17]. Metzger et al. have suggested 
that IL-12 augments the natural immune response due to innate or 
infiammatory components of the host defense system prior to the 
development of the humoral or cellular immune response [18]. This initial 
response may be impOltant in bacterial meningitis since CSF defense 
mechanisms against infection are limited. 
We questioned whether IL-12 is involved in the early phase of the 
infiammatOlY response in the CSF of children with bacterial meningitis. To 
this purpose the presence of IL-12 and its relation to other proinfiammatory 
(TNF-a, IL-6, IL-8, IFN-y) as well as anti-inflammatory (IL-IO) cytokines 
were studied in semm and CSF of 35 children with bacterial meningitis. 
6.3 METHODS 
Patients and controls 
Patients between the age of 3 months and 18 years who were 
diagnosed with bacterial meningitis between August 1992 and September 
1994 were eligible for inclusion. The patients were admitted to the 
Depmtments of Pediatrics of the Sophia Children's Hospital and 
Zuiderziekenhuis both in Rotterdam, Reinier de Graaf Gasthuis in Delft and 
Juliana Children's Hospital in The Hague. Bacterial meningitis was defined 
as the presence of a positive bacterial culture fi'om CSF or the presence of 
a positive blood culture in combination with clinical evidence of meningitis 
and a CSF white blood cell (WBC) count above IOx106/L. Patients with 
prior antibiotic treatment were excluded. Paired control samples of semm 
and CSF were obtained from 10 pediatric cancer patients who were in 
remission. The lumbar punctures in these children were done for diagnostic 
reasons. CSF samples from patients and controls were examined for WBC 
count and levels of glucose and protein. 
The Medical Ethics Committee of each of the palticipating centers 
approved the study protocol. Written informed consent was obtained fi'om 
the parents or the child's legal representatives. 
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Collection of samples 
Samples of blood and CSF were obtained on admission prior to the 
initiation of antibiotic treatment. Blood was collected into sterilized 
siliconized vacutainer glass tubes (Becton Dickinson, Meylan Cedex, 
France) and allowed to clot at room temperature. CSF samples were 
collected into pyrogen-fi'ee polystyrene tubes (FalconR, Becton Dickinson, 
Franklin Lakes, NJ). The samples were centrifuged at 2800 g at 4 °C for 10 
minutes. The supernatants were stored at -70°C until used for different 
assays. Samples were never thawed and refi'ozen before assay. 
Laboratory studies 
Cultures of blood and CSF were processed according to standard 
procedures [19]. The CSF WBC count, glucose and protein concentration 
were determined by routine laboratory procedures in each of the 
participating hospitals. 
IL- /2 p40: IL-12 p40 antigen was measured with an ELISA as 
described [20]. Results were related to a dose-response curve of 
recombinant IL-12 p40 and expressed as pglmL. The lower limit of 
sensitivity was 50 pglmL. 
IL-/2 p70: IL-12 p70 antigen was measured using an ELISA with 
mAb 20C2, which preferentially reacts with IL-12 p70, and mAb C8.6 
which reacts with IL-12 p40 and p70 antigens equally well [6]. 
Concentrations of p40 antigen up to 20 ng pel' ml were not detected by this 
ELISA. Observations in septic baboons showed a good conelation (1' = .87) 
between results obtained with this ELISA and a bioassay for IL-12 [21]. 
Recombinant human IL-12 p70 was used as a standard. The lower limit of 
sensitivity of this assay was 2.5 pglmL. 
IFN--y: IFN-y was measured using an ELISA obtained from the 
Depal1ment of Immune Reagents, Central Laboratory of the Netherlands 
Red Cross Blood Transfusion Service according to manufacturer's 
instructions. The lower limit of sensitivity of this assay was 10 pglmL. 
TNF-(Y., IL-6, IL-8 and JL-J 0: Serum and CSF levels of TNF -ex, IL-6, 
IL-8 and IL-I0 were measured with ELISA kits (Medgenix, Fleurus, 
Belgium) according to the manufacturer's instructions with the following 
detection limit (lowest positive standard): TNF-ex, 15 pglmL; IL-6, 30 
pglmL; IL-8, 7 pglmL; IL-lO, 11 pglmL. 
Statistical analysis 
Differences between groups in continuous variables were tested for 
significance with the Mann-Whitney test. Differences in frequencies of 
findings between groups were analyzed by the Fisher's Exact test. Pahwise 
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Table 1. Clinical and laboratory charactclistics of 35 children 
with bacterial meningitis and 10 control subjects. 
Age (years) 
Sex (No.) 
male 
female 
Micro-organisms (No.) 
H il1jluel1zae 
N. menillgilidis 
S. pneumoniae 
Others 
Cerebrospinal fluid 
WBC count (hum') 
glucose (mmollL) 
protein (giL) 
Patien ts 
(II = 35) 
1.8 
(OJ-13.0) 
15 
20 
15 
\3 
6 
I 
3330 
(15-34,000) 
1.7 
«0.1-5.3) 
1.5 
(0.2-8.0) 
Controls 
(II = 10) 
9.9 
(4.1-17.9) 
5 
5 
I 
(0·2) 
3.0 
(2.7-3.5) 
0.3 
(0.3-0.6) 
Except as indicated, data are expressed as median (range). 
Abbreviations: WBC, white blood cell. 
comparisons regarding the percentage of CSF levels above the detection 
limit were assessed with McNemar's test. The Spearman correlation 
coefficient (1') was used to evaluate the relation between specific variables. 
Two-tailed P values ~ .05 were considered significant. 
6.4 RESULTS 
Patients and controls 
The clinical and laboratory characteristics of patients and control 
subjects are shown in Table I. Thhty-five patients with a proven bacterial 
meningitis were enrolled. CSF samples fi'om the controls were sterile and 
showed normal characteristics. Chemotherapy had been discontinued in all 
of the control subjects for at least 3 months. None of the control subjects 
undetwent craniospinal irradiation or bone marrow transplantation. The 
controls were still in remission at the next follow up visit. The median age 
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(range) of the children in the control group was significantly higher than 
that of the patients (9.1 yrs [4.1-17.9] versus 1.8 yrs [0.3-13.0], P < .001). 
IL-12 and IFN-y in serum and CSF samples on admission 
The biologically active form ofIL-12 p70 was detected in CSF in 2 of 
the 35 (6%) patients on admission while the subunit p40 of IL-12 was 
detectable in 28 of the 35 (80%) patients with bacterial meningitis. CSF 
levels of IL-12 p40 and p70 were below the detection limit in all 10 control 
sUbjects. The percentage of detectable CSF levels of IL-12 p40 in the 
patients was significantly higher in comparison with those of control 
subjects (P < .001). In contrast, CSF levels of IL-12 p70 were not different 
between patients and control subjects. 
CSF levels of IFN-y were above the detection limit in 20 of the 35 
(57%) patients with bacterial meningitis whereas none of the control 
subjects had detectable IFN-y levels (P < .001). 
Pathogen-dependent differences in CSF levels of cytokines 
The pathogen-dependent CSF levels of TNF-a, IL-12, IFN-y IL-IO 
and the ratio between TNF -a and IL-lO are shown in Table 2. Children 
with meningitis by Haemophilus injluenzae or Streptococcus pneull10niae 
had comparably high CSF levels of IL-12 p40 (median 503 pglmL vs. 509, 
P = .50). CSF levels of IL-12 p40 were lowest in patients with 
meningococcal meningitis (median 86 pglmL). Detectable CSF levels of 
IFN-y were observed significantly more fi'equently in patients with 
pneumococcal meningitis in comparison with those in children with 
meningitis due to H. injluenzae and N. lI1eningitidis. Pathogen-dependent 
differences in CSF levels of TNF -a and IL-l0 were not observed. The CSF 
ratio of TNF -a I IL-l0 was significantly higher in patients with 
pneumococcal meningitis in comparison with that in children with 
meningitis by H. injluenzae and N. meningifidis. Comparison between the 
ratio of TNF -a I IL-lO of H. injluenzae against the other two pathogens 
and the ratio of TNF-a I IL-IO of N. meningitidis against the other two 
pathogens did not yield signficant results. 
Serum versus CSF levels of IL-12 and IFN-y on admission 
Paired samples of CSF and serum were available in 20 patients with 
bacterial meningitis. The median (range) serum levels of IL-12 p40 were 
comparable to those of control subjects (165 pglmL [72-1042] vs. 109 [59-
299], P = .52). The proportion of detectable serum levels of IL-12 p70 and 
IFN-y was also comparable between patients and control subjects (IL-12 
p70: 2 of 20 [10%] vs. 0 of lO [0%], P = .54; IFN-y: 6 of 20 [30%] vs. 1 
of lO [10%], P = .37) 
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Figure 1. Serum and CSF concentrations of IL-12 p40 and IFN-y 011 admission in 20 patients 
with bacterial meningitis. Horizontal broken line d~notes detection limit. 
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Table 2. CSF levels of TNF-a, IL-12, IFN-y, JL-I0 and the ratio between TNF-a and 11..-10 
in patient with pneumococcal meningitis and those with meningitis to H. iujluellzae and N. 
mellillgilidis. 
H. illjluenzue and S. pllelllJlOlliae 
N. llleuillgitidis P 
(n ~ 28) (n ~ 6) 
TNF -r:< (pglmL) 414 2324 .OS* 
«15 - 10600) (355 - 4631) 
IL-12 p70 (%) 2 (7) 0(0) 1.0 t 
IL-12 p40 (pglmL) 358 509 .55' 
«50 - 11936) «50 - 5390) 
IFN-y (%) 13 (46) 6 (IOO) .02t 
IL-lO (pglmL) 654 736 .98' 
«10 - 4000) (109 - 1694) 
Ratio TNF-aIlL-IO 0.9 2.1 .04' 
(0.2 - 117.5) (1.5 - 30.3) 
Data are expressed as median (range) or as number of cases above treshold (%). *MRnn-Whitney 
test, tFisher Exact test. Abbreviations: CSF, cerebrospinal fluid; TNF-a, tumor necrosis factor-a; 
IFN-y. interferon-y; IL, interleukin. 
Detectable concentrations of IL-12 p40 in eSF on admission occUl1'ed 
more often than in corresponding selUm samples (P = .03, McNemar test), 
whereas those of IL-12 p70 and IFN-y in selUm and eSF were not 
significantly different (Figure I). 
Correlation between IL-l2 and IFN-y, TNF-cr, IL-6, IL-8, IL-lO and 
other characteristics in CSF on admission 
eSF levels of IL-12 p40 on admission con'elated with those of TNF-u 
(r = .49, P = .004), IL-6 (r = .42, P = .02) and IL-IO (r = .61, P < .001) 
and detectable eSF levels of IFN-y (r = .51, P = .02), but not with those of 
IL-8 (r = .18, P = .16). Interestingly, detectable eSF concentrations of IFN-
y on admission correlated only significantly with eSF levels of IL-12 p40 
(r = .51, P = .02) and TNF-u (r = .48, P = .04) as shown in Figure 2. eSF 
WEe count, glucose and protein concentration were significantly correlated 
with eSF levels oflL-12 p40 (r = .40 and P = .02, r = -.69 and P < .001, r 
= .35 and P = .05 respectively). In contrast, eSF levels of IFN-y were not 
associated with any of these eSF characteristics. 
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6.5 DISCUSSION 
IL-12 is produced by phagocytic cells in response to infection and 
stimulates adaptive immunity by selectively inducing the Thl cytokine 
pattem (IL-2 and IFN-y) [22, 23]. FUlihennore, it induces production of 
IFN-y and TNF-u and activates the cytotoxic activity of NK-cells [8-10]. 
IFN-y in tum enhances the function of macrophages and 
polymorphonuclear leukocytes by stimulating non-specific defense 
mechanisms such as phagocytosis and secretion of reactive oxygen 
intermediates [24]. Together, these responses contribute to innate host 
defence systems against invading microorganisms and are usually effective 
in reducing the load of infection. Our findings suggest that such a host 
defense mechanism involving IL-12 and IFN -y is operating in the CSF 
compatiment of patients with bacterial meningitis. 
In the present study, CSF levels of IL-12 p40 in patients with bacterial 
meningitis were elevated while those of IL-12 p70 hardly detectable. This 
is in agreement with the observation that p40 is released in excess to the 
bioactive protein (P70) [4, 6]. Although CSF levels of IL-12 p70 were 
below the detection limit « 2.5 pglmL) in most patients, this not 
necessarily tules out the presence of IL-12, since biologic activity of IL-12 
such as enhancement of NK-cell cytotoxicity has been repOlied in the 
presence of concentrations below 1 pM [3, 25]. Furthermore, bioactive IL-
12 may have escaped detection by binding to specific receptors on cells. 
CSF levels of IFN-y were also elevated in our patients with bacterial 
meningitis as was previously observed by others [26-29]. The levels of IL-
12 p40 were significantly higher in the CSF compartment than in setum 
implicating intrathecal production. Our results do not allow conclusions 
regarding the cellular source of IL-12 in the CSF compatiment. 
We observed a significantly positive correlation between CSF levels of 
IL-12 p40 and IFN-y, TNF-u, IL-6, and IL-1O. In vitro studies suggest that 
these cyiokines may not be responsible for the secretion of IL-12 [6]. Thus, 
likely these cotl'elations reflected a common stimulus i.e. the 
microorganisms or their products. Experimental data indicate that IL-12 is 
required for IFN-y production. This is confirmed by the observation that 
IL-12 circulates in the setum before the appearance of IFN-y. FUlihermore, 
pretreatment with anti-IL-12 antibodies inhibits production of IFN-y in 
response to a challenge by endotoxin [17, 30]. IL-12 is not the only 
cyiokine needed to induce the release of IFN-y. In the SCID model of 
listeriosis, TNF -u is an important cofactor for IFN-y production by NK 
cells in vivo [31] and in vitro [31, 32]. However, TNF-u by itself is unable 
to induce IFN-y production. Neutralization of TNF-u with monoclonal 
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antibodies inbibits in vitro IFN-y production in NK -cell and inhibits in vivo 
macrophage activation, resulting in increased systemic bacterial spread [31]. 
Futihermore, the release of IFN-y is inbibited by IL-IO which prevents 
production of IL-12 and of the costimulatory cytokines IL-lll and TNF-a 
by accessOlY cells [11]. These data together explain that CSF levels oflFN-
y in our patients were only associated with IL-12 and a possible co-
stimulator TNF-a. Thus, both IL-12 and TNF-a were probably responsible 
for the production of IFN-y in the subarachnoid space of patients with 
bacterial meningitis. 
Interestingly, patients with pneumococcal meningitis had significantly 
higher CSF levels of IFN-y in comparison with those with meningitis due 
to H. influenzae and N. meningitidis as was previously observed by others 
[27]. This observation can not be explained by an increased IL-12 
production since CSF levels of IL-12 were not markedly higher in patients 
with pneumococcal meningitis. However, the high CSF ratio between the 
costimulator TNF-a and IL-IO, which inhibits IL-12 induced IFN-y 
production, in the patients with pneumococcal meningitis in comparison to 
those with meningitis due to other pathogens, may provide an explanation 
for the higher CSF levels of IFN-y in patients with pneumococcal 
meningitis. 
We conclude that the production of IFN-y in the CSF compartment of 
patients with bacterial meningitis is at least patily induced by IL-12 with 
TNF-a as a costimulator. We suggest that IL-12 induced IFN-y release may 
contribute to the local host defense in the subarachnoid space against 
bacterial meningitis. 
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Nitric Oxide in Bacterial Meningitis 
7.1 ABSTRACT 
To investigate the role of nitric oxide (NO) in bacterial meningitis, 
concentrations in selUm, cerebrospinal fluid (CSF), or both of the precursor 
(L-arginine) and degradation products of NO (nitrate, nitrite) and tumor 
necrosis factor (TNF)-a were measured in 35 patients and 30 controls. CSF 
nitrate levels were significantly elevated, mainly due to increased blood-
brain batTier permeability, and are therefore not a good parameter for 
gauging endogenous NO production in the CSF compatiment. CSF 
NO/nitrite levels were significantly elevated in patients. NO/nitrite levels 
decreased over time (26%/6 h; P < .001). CSF levels of NO/nitrite 
cot1'elated with those of TNF-a (I' = .55; P = .001) and glucose (I' = -.43; P 
= .02). CSF levels of L-arginine were lower in patients than in controls (P 
< .001). Dexamethasone did not exett a significant effect on NO 
metabolism. In conclusion, enhanced NO production may contribute to 
anaerobic glycolysis and neurologic damage in bacterial meningitis. 
7.2 INTRODUCTION 
Changes in the central nervous system of patients with bacterial 
meningitis include metabolic alterations, elevated intracranial pressure, and 
a decrease in cerebral blood flow. The mechanisms leading to these 
changes involve bacterial components [1-3] and host factors such as 
cytokines, arachidonic acid metabolites [4, 5], platelet-activating factor [6-
8], complement [9], granulocytes, and reactive oxygen intermediates [10, 
11]. The proinflammatOty cytokines tumor necrosis factor (TNF)-a and 
interleukin (IL )-1/3 play a pivotal role in the induction of the cascade of 
meningeal inflammation [12-14]. However, the precise mechanisms 
responsible for the development of central nervous system injUty are not yet 
completely understood. 
Recently, nitric oxide (NO) has attracted attention as a potential 
neurotoxic factor [15]. NO is a shOtt-lived fi'ee radical produced by a 
variety of cell types and involved in physiologic processes such as smooth 
muscle relaxation, neuronal signaling, inhibition of platelet aggregation, and 
regulation of cell-mediated cytotoxicity [16-19]. NO production results from 
the conversion of L-arginine to L-cittulline by the enzyme NO synthase 
(NOS). At least two classes of NO synthase are known: a constitutive, 
calcium-dependent form present in the brain and endothelial cells under 
basal conditions, and an inducible, calcium-independent form (iNOS), 
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which is produced after stimulation with cytokines (TNF-a, IL-IJ3, 
interferon-y) and lipopolysaccharides. The iNOS isofonn generates large 
amounts of NO that may have harmful cytotoxic effects. NO ultimately 
decomposes to form the stable end products nitrate and nitrite. NO 
production is repressed by glucocorticoids, transforming growth factor 131, 
IL-4, IL-I0, and prostaglandin E2 [20-25]. Cytokines stimulate the 
expression of iNOS in microglia and astrocytes [26-28]. This implies a 
possible role for NO in the central nervous system host response. Berkowitz 
et al. [29] reported that NO contributes to pial arteriolar dilation and 
impaired autoregulation of cerebral blood flow during experimental 
Haemophi/us influenzae meningitis in rats. Recently, cerebrospinal fluid 
(CSF) levels of the degradation products of NO (nitrate and nitrite) were 
repotted to be elevated in experimental animals and patients with bacterial 
meningitis [30-34]. 
The aim of the present study was to investigate the role of NO in the 
pathophysiology of bacterial meningitis. To this purpose, serum and CSF 
levels of the precursor (L-arginine) and the end products of NO (nitrate and 
nitrite) were studied in children with bacterial meningitis and in control 
subjects. The relationships between NO precursor and end products, CSF 
inflammatory characteristics, and TNF-a were studied. In addition, the 
effect of dexamethasone on NO synthesis was evaluated. 
7.3 METHODS 
SUbjects 
Patients. Eligible patients were children between the age of 3 months 
and 18 years who were diagnosed with bacterial meningitis between August 
1992 and July 1994. Bacterial meningitis was defined as the presence of a 
positive bacterial culture £i'om CSF or the presence of a positive blood 
culture in combination with clinical evidence of meningitis and a CSF 
white blood cell (WBC) count > 10 x 1O'/L. Patients with a history of 
hypersensitivity to J3-lactam antibiotics, prior antibiotic treatment or a 
congenital or acquired abnormality of the central nervous system were 
excluded. 
Initial CSF and serum samples were collected from all patients. A 
subset of the patients was enrolled in a prospective double-blind placebo-
controlled trial to study the beneficial effects of dexamethasone as adjuvant 
therapy in children with bacterial meningitis. These children were treated 
with intravenous ceftazidime (150 mg/kg/day in three doses) for at least 7 
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days and were given either dexamethasone sodium phosphate (0.60 
mg/kg/day in four doses during 4 days) or placebo (NaCI 0.9%) in a 
double-blind manner. A second lumbar puncture was done in a randomized 
fashion at 6, 12 or 24 h after the initiation of the study medication and 
antibiotic treatment. The remaining patients were also treated with 
ceftazidime or other appropriate antibiotics. In these children, a second 
lumbar puncture was not done. 
Controls. Paired samples of serum and CSF were obtained from 
pediatric cancer patients who were in remission. Lumbar punctures were 
done as pall of diagnostic and therapeutic protocols. 
Laboratory Studies 
CSF samples obtained fi'om patients and controls were examined for 
WBC count and levels of glucose and protein. Cultures of blood and CSF 
were done before the initiation of antibiotic therapy according to standard 
procedures [35]. CSF and serum samples were stored at _700 C until used 
for different assays. 
Nitrate and nitrite concentrations. The concentrations of nitrate and 
nitrite, the stable degradation products of NO, were measured in paired 
samples of serum and CSF. Nitrite levels in CSF were determined by a 
colorimetric method [36]. The combined levels of nitrate and nitrite in CSF 
and in serum samples were determined by the same assay after enzymatic 
reduction of nitrate to nitrite using nitrate reductase (1 U/mL) from 
Aspergillus (Boehringer, Mannheim, Germany). The CSF nitrate 
concentration was calculated by subtracting the nitrite level from the 
combined level. Serum nitrite concentrations were not measured separately 
since they are negligible in comparison with concentrations of nitrate. The 
detection limit of the nitrite and nitrate assays was 0.2 ~lmollL. CSF 
samples contaminated with blood were not analyzed. 
TNF-Ci. CSF levels of TNF-o; were assayed with amplified-sensitivity 
ELISA kits (Medgenix, Fleurus, Belgium) according to the manufacturer's 
instructions. TNF -0; detected with these kits represented the total pool of 
immunoreactive protein, regardless of whether the cytokine was biologically 
active or inactive once complexed to soluble receptors or inhibitors. The 
detection limit for TNF-o; was 10 pg/mL. 
Determination of L-arginine and L-citrulline in CSF. The amino acid 
levels in CSF samples were analyzed after deproteinization with 5% 
sulfosalicylic acid. Measurements were made with an amino acid analyzer 
(LKB 4151 Alpha Plus; Phannacia, Cambridge, UK) by ion-exchange 
ciu·omatography. The amino acids were colored with ninhydrin reagent, and 
the optical density was measured at 440 and 570 nm [37]. 
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Statistical analysis 
Differences between groups in continuous variables were tested for 
significance with the Mann-Whitney U test. Differences in frequencies of 
findings between groups were analyzed by Fisher's exact test. The 
Pearson's (I') and Spearman (1',) cOll'elation coefficients were used to 
evaluate the relation between specific variables. Regression analysis for 
repeated measurements was used to evaluate the change in concentrations 
of NO degradation products over time [38]. Two-tailed P ~ 0.05 was 
considered significant. 
Table 1. Clinical and laboratory characteristics of patients with bacterial meningitis and 
control subjects. 
Patients 
Characteristic Study Medication Controls 
Dexamelhasone Placebo None (1/ = 30) 
(1/ = 11) (/I = 15) (1/ = 9) 
Agc (years) 1.6t 2.5t I.It 8.6 
(0.5-11.0) (0.3-13.0) (0.8- 7.7) (3.4-17.9) 
Sex (No.) 
Male 3 7 6 19 
Female 8 8 3 10 
Etiologic agcnt (No.) 
Haemophilus injluenzae 6 4 6 
Neisseria meniugitidis 2 8 2 
Streptococcus pneul1lo11iae 2 3 I 
Others 0 0 
Cerebrospinal fluid 
WBC/mm J 930t 3330t 3550t I 
(96-10500) (15-34000) (180- 8700) (0·5) 
Glucose. mmollL 1.8* 2.5 1.0* 3.0 
«0.1-4.6) (0.1-5.3) (0.1-3.6) (1.9-3.7) 
Protein, gIL I.2t l.4t 2.4t 0.4 
(0.8·3.8) (0.2-S.0) (0.7-3.6) (0.2·0.6) 
TNF-o:, pg/mL 555t 460t 914t <10 
(206- 9000) «10- 3560) (lS-10600) 
NOTE: Except as indicated, data are expressed as median (range). Abbreviations: WBC, white 
blood cells; TNF-a, tumor necrosis factor n. 
>I< p < .05, t p < .00 I vs. controls. 
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7.4 RESULTS 
Patients and controls 
Clinical and laboratory characteristics of patients and control subjects 
are shown in Table I. Forty-six consecutive patients were included. Thitty-
five had bacterial meningitis. A causative pathogen was not found in 7 
patients, whereas in 4 patients, meningitis was caused by enteroviruses. 
These II patients were excluded fi'om further analysis. 
The mean age of the 35 children was 3.2 years (range: 0.3-13.0). 
Sixteen patients were boys and 19 were girls. Twenty-six of the 35 patients 
with bacterial meningitis were enrolled in the placebo-controlled trial (11 
dexamethasone and 15 placebo recipients). A second lumbar puncture was 
done 6 h (n = 8), 12 h (n = 4) or 24 h (n = 9) after initiation of the study 
medication. A second CSF sample could not be obtained in 5 patients 
because no fluid was obtained (n = 2), the patient withdrew fi'om the study 
(n = 2), or the the patient was in critical condition (n = I). 
Control subjects included 26 patients who were in remission from 
acute lymphatic leukemia and 4 patients in remission from non-Hodgkin's 
lymphoma. All CSF samples fi'om the controls were sterile and showed 
normal CSF characteristics (Table 1). Chemotherapy had been discontinued 
in all controls for at least 3 months. None of the control subjects underwent 
craniospinal irradiation. The mean (± SD) duration of remission was 2.7 ± 
0.9 years. Children in the control group were significantly older than the 
patients. Age-related differences in NO degradation products were not 
observed (data not shown). 
Laboratory Studies 
Nitrate levels in sel'll/II and CSF. The median (range) serum and CSF 
levels of nitrate and the CSF -to-serum ratio of nitrate are shown in Table 2. 
The median CSF combined nitrate plus nitrite levels, nitrate levels, and 
CSF-to-serum ratios of nitrate were significantly higher in the patients. 
Serum nitrate levels were significantly lower in the patients. 
CSF and serum nitrate levels were positively correlated in patients (n = 
27; /' = .41; P = .03) and in control subjects (n = 29; /' = .63; P < .001). 
CSF nitrate levels in patients were 1.6 times higher (P = .01) than in 
controls at similar serum levels of nitrate as shown by analysis of 
covariance (Figure 1). 
CSF nitrite levels. Levels of nitrite in the initial CSF samples fi'om 
patients with bacterial meningitis were significantly elevated in comparison 
with those in control subjects (P = .05). The median (range) CSF nitrite 
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Table 2. Levels and ratios of nitrate and nitrite in initial cerebrospinal fluid and serum 
samples of patients with bacterial meningitis and control subjects. 
Patients Contl'Ois 
(II ~ 35) (II ~ 30) P 
CSF nitrate+nitritc (J.-l1l1oJlL) 9.3 4.5 <.001 
(3.4-39.6) (1.3-13.9) 
CSF nitrate (~l11ollL) 5.8 3.9 .04 
(0.5-36.3) (0.8-13.5) 
CSF nitrite (~l11ollL) 0.9 0.5 .05 
(0.2-29.7) (0.3- 1.4) 
serum nitrate (~tmoI/L) 22.3 30.6 .005 
(9.6-98.2) (16.5-136.3) 
ratio CSF nitrate / 
serum nitrate 0.23 0.11 <.001 
(0.02-0.51 ) (0.05-0.32) 
CSF L-arginine (~llloIlL) 12 22 
(4-34) (18-34) <.001 
NOTE. Data are expressed as median (range). Abbreviation: eSF, cerebrospinal fluid. 
levels in bacterial meningitis caused by H influenzae, Neisseria 
meningitidis and Streptococcus pneumoniae were markedly different: 3.8 
(0.2-29.7), 0.5 (0.2-3.7), and 1.2 (0.4-2.8) ~lmollL respectively. CSF nitrite 
levels in children with H influenzae meningitis were significantly elevated 
(P = .003) compared with those in control subjects. Serious neurologic 
sequelae occurred in 3 patients with H influenzae meningitis. The nitrite 
levels in these patients were above the normal range (2.7, 3.3, and 11.5 
IlmollL). 
Figure 2 depicts CSF nitrite levels before initiation of the study 
medication and 6, 12, and 24 h afterward. Linear regression analysis for 
repeated measurements indicated that the mean CSF levels of nitrite 
decreased in time (26% [95% confidence interval, 14%-36%]/6 h; P <. .001) 
in contrast with CSF nitrate and selUm nitrate levels. Differences between 
CSF nitrite levels in patients treated with dexamethasone or placebo were 
not observed. 
A higher proportion of patients with a CSF nitrite level greater than 
normal (> 1.2 ~unollL, mean + 2 SD of levels in control subjects) had 
neurologic or audiologic sequelae (or both), in contrast to the patients with 
normal levels (3115 [20%] vs. 0/20; P = .07). One of the 3 patients with 
sequelae received dexamethasone as adjuvant therapy. 
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Correlations between CSF nitrite, nitrate, and TNF-a levels and CSF 
characteristics 
Median CSF levels of TNF -u were significantly higher in patients with 
bacterial meningitis than in control subjects (Table 1). In addition, CSF 
TNF-u levels were positively correlated with CSF nitrite but not CSF 
nitrate levels (Figure 3). CSF nitrite levels correlated negatively with CSF 
glucose levels (Figure 4) but not with CSF WBC counts or CSF protein 
levels. 
L-arginine and L-citrnlline. 
L-arginine levels in CSF from patients with bacterial meningitis were 
significantly lower than in CSF from controls (Table 2). Differences in 
levels of L-citmlline in both groups were not observed. CSF nitrite levels in 
patients were not correlated with CSF levels of L-arginine or L-citmlline. 
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Figure 1. Relationship between cerebrospinal fluid (CSF) nitrate levels and serum nitrate levels 
in patients with bacterial meningitis and in control subjects. 
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Figure 2. Mean nitrite levels versus time (I) in cerebrospinal fluid (CSF) in patients with 
bacterial meningitis (log[CSF nitrite] ~ -0.025 - 0.021 x I; P < .001). Dashed lines show 95% 
confidence limits for mean CSF nitrite level. 
7.5 DISCUSSION 
NO is a shoti-lived free radical that can be produced in vitro by 
microglia and astrocytes after stimulation with cyiokines and 
lipopolysaccharides. We questioned whether NO is involved as a mediator 
in the pathophysiology of bacterial meningitis in children. Visser et al. (32) 
recently reported that patients with meningococcal meningitis have 
increased CSF levels of nitrite and nitrate. Milstien et al. [31) also 
measured elevated levels of nitrite/nitrate in 3 patients with bacterial and 4 
with viral meningitis. 
In the present study, CSF concentrations of nitrate, nitrite, and 
combined nitrate and nitrite were significantly elevated in children with 
bacterial meningitis compared with levels in control subjects. CSF levels of 
nitrate, nitrite, or both in the control group were similar to those observed 
in other studies [31, 32, 39). Serum nitrate levels were significantly higher 
than CSF nitrate levels in both patients and' controls. In addition, serum 
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nitrate levels were lower in patients, probably as a result of diminished 
food intake (exogenous nitrites and nitrates) during the acute phase of 
illness [40]. 
The increased CSF nitrate concentration and CSF -to-serum ratio of 
nitrate in patients SUppOlt the presence of an enhanced production of NO. 
However, the increased blood-brain barrier permeability in patients in the 
presence of relatively high serum nitrate levels may provide another 
explanation for the increased CSF nitrate levels. We demonstrated that CSF 
nitrate levels depend both on serum nitrate levels and on the presence of 
meningitis. Although the CSF nitrate levels were nearly two times higher in 
patients at similar serum levels, we were unable to distinguish whether this 
was cansed by an enhanced NO production in the CSF compattment or by 
an increase in blood-brain banier permeability. We therefore conclude that 
CSF nitrate levels are not a good parameter for gauging endogenous NO 
production in the CSF compaltment of patients with bacterial meningitis. 
CSF concentration of nitrite may provide a better parameter for 
gauging endogenous NO production in the CSF compartment. CSF is 
comparable to an oxygen-containing aqueous solution, a condition in which 
NO is oxidized primarily to nitrite with little or no formation of nitrate 
[41]. CSF nitrite levels were significantly higher in patients than in 
controls. Also, children with H. injluenzae meningitis had significantly 
elevated CSF nitrite levels. H. injluenzae is probably a stronger inducer of 
iNOS than is N. meningitidis or S. pneulfloniae. 
CSF nitrite levels in children with bacterial meningitis decreased over 
time (26%16 h; P < .001) in contrast to CSF nitrate levels. The increased 
NO production seems to attenuate during recovery. CSF concentrations of 
L-arginine, the precursor of NO, were decreased in patients (P < .001). 
Heiblim et al. [42] also found that the CSF levels of L-arginine were 
decreased in patients with bacterial meningitis in comparison with those 
with febrile seizures. This decrease may be explained by the oxidation of 
L-arginine to NO by NO synthase. 
CSF TNF-o: levels were elevated in patients with bacterial meningitis, 
as previously repOlted by others [4, 14]. We found a strong cOll'elation 
between CSF levels of TNF -0: and nitrite. These data demonstrate that 
TNF -0: may be involved in the induction of arginine-dependent NO 
production in the CSF compaltment of patients with bacterial meningitis. 
These observations SUppOlt the presence of an increased formation of 
NO/nitrite in the CSF compartment during the acute phase of bacterial 
meningitis. 
The finding that a higher proportion of patients with CSF nitrite above 
the nOlmal range had neurologic or audiologic sequelae (or both) in contrast 
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to the patients with normal levels suggests that NO may be responsible for 
neurologic damage in humans. 
The cellular site of NO/nitrite production in children with bacterial 
meningitis is unknown. NO/nitrite can be generated by a variety of cell 
types, including neutrophils, microglialmacrophages, endothelial cells, 
astrocytes, neurons, and vascular smooth muscle cells, and by bacteria. 
Animal studies indicate that it is unlikely that all eSF nitrite results from 
formation by living bacteria (H inj/llenzae, S. pnellll1oniae). Intracistemal 
inoculation of heat-killed bacteria induces an increase in eSF nitrite 
comparable to that observed with living bacteria [30, 34]. 
We did not observe a cOll'elation between eSF NO/nitrite levels and 
eSF WBe count or eSF protein levels. Therefore, WBe are probably not 
the major source of NO/nitrite. In contrast, eSF nitrite levels significantly 
con'elated with eSF glucose levels. NO may inhibit the mitochondrial 
respiration that enhances anaerobic glycolysis. This mechanism may 
contribute to the decreased glucose concentration in the eSF compaltment 
in patients with bacterial meningitis [43-45]. Altematively, low eSF 
glucose levels may also be explained by inhibition of cal1'ier-mediated 
transpOlt across the blood-brain barrier [46, 47]. 
We did not observe differences in eSF nitrite levels at different time 
points after initiation of study medication (dexamethasone or placebo), 
although dexamethasone has been shown to inhibit NO synthase in vitro. 
However, by the time meningitis is diagnosed, iNOS gene expression is 
probably already induced. The failure of dexamethasone to inhibit iNOS 
mRNA and NO production after induction may explain the ineffectiveness 
of glucocOlticoids in treatment [20]. The absence of a significant effect on 
NO/nitrite production in the eSF compattment may also have been due to 
the limited number of patients. 
Adjustments for multiple testing were not made. Nevertheless, these 
results present a coherent picture of the role of NO in bacterial meningitis 
in children and are unlikely to be the result of chance alone. 
We conclude that the increased eSF NO/nitrite levels, the decrease of 
eSF NO/nitrite over time, and the decreased eSF levels of L-arginine (the 
precursor of NO) indicate the presence of enhanced NO production in the 
eSF compartment in patients during the acute phase of bacterial meningitis. 
An effect of dexamethasone on NO metabolism was not observed. The 
increased production of NO may be partly responsible for the anaerobic 
glycolysis in the eSF compartment and the OCCUl1'ence of neurologic 
damage in children with bacterial meningitis. 
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Meningococcal Sepsis 
8.1 INTRODUCTION 
Meningococcal disease remains a major health problem in many 
countries. Clinical manifestations valY from self-limiting bacteremia to 
meningitis 01' fulminant sepsis. Meningococcal sepsis is characterized by a 
rapid onset of disease, fever, purpura and ultimately shock. Non-specific 
presenting symptoms such as a flu-like picture and a non-specific rash are 
commonly observed. The diagnosis of meningococcal disease becomes 
obvious when petechiae are present. The mortality rate of meningococcal 
sepsis or septic shock varies between 20% and 50% [1-7]. Despite 
improvements in management and therapy, the outcome of patients with 
fulminant meningococcemia has not significantly changed over the past 
three decades. The application of molecular biological and immunological 
methods in animal experimental and human models of meningococcal 
sepsis has contributed to our understanding of the pathophysiology and 
opened new alleys to prevent meningococcal sepsis. This review seeks to 
provide a comprehensive overview on recent developments in the major 
areas of research on meningococcal sepsis. 
8.2 EPIDEMIOLOGY 
Meningococcal disease is endemic in certain geographic areas. 
Epidemics are reported worldwide and are predominantly caused by a 
patticular meningococcal clone. In Europe most infections are due to 
meningococcal serogroup B, whereas infections in Afi'ica are mainly caused 
by serogroup A [8-12]. In Europe and NOllh America meningococcal 
diseases mostly occur during winteltime, while the epidemics of sub-
Saharan Afi'ica occur during the hot dry months. Group C disease may also 
cause outbreaks. The incidence of disease caused by serogroup C appears to 
increase in some areas (Italy, British Columbia) [13]. From the mid 1970s 
to early 1980s an increasing incidence of meningococcal disease was 
repOlled in several European countries. Before 1980 the incidence of 
meningococcal disease ranged between 0.7 and 2.0 cases per 100,000 
inhabitants. During the 1980s the incidence of meningococcal disease 
gradually increased to 3.5 per 100,000 inhabitants [14]. 
Meningococcal disease is predominantly seen in children with a peak 
incidence around 2 years of age. A second peak is noted among teenagers. 
Serogroup C and to a lesser extent serogroup A are relatively fi'equent 
among older patients [IS]. Riordan and colleagues reported a change in the 
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clinical presentation of meningococcal disease. The proportion of patients 
with sepsis increased from 7% in 1977-1985 to 36% in 1990-1993 [16). 
Our group recently showed that the mOltality rate in infants with 
meningococcal septic shock is higher than in older children [17) 
The phenotype and genotype of N. meningitidis varies constantly in 
time and areas as demonstrated by Scholten et al. [12). 
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Figure 1. Diagram of the structure of the meningococcal cell wall. Reproduced from Hart et al. 
[37] 
Table 1. Phenotypic classification system of Neisseria mellillgilidis. 
System 
serogroups 
serotypes 
subserotypes 
immunotypes 
Basis No. of groups or types 
CPS 
Class 2/3 OMP 
Class IOMP 
LPS 
12 
20 
10 
12 
Names 
A, B, C, X, Y, Z, 29E, W135, H, I, K, L 
1, 2a, 2b, 2c .................... 21· 
PI.I, P1.2, ..................... PI.I6' 
LI-LI2 
Abbreviations: CPS, capsular polysaccharides; OMP, outer membrane protein; LPS, lipo-
polysaccharides. 'Not all the numbers between 1 and 21 or Pl.I and Pl.16 are used. 
The complete classification of a meningococcal strain is, for example: B:15:P1.16:L3. A strain 
can express more than one subserotype or immullotype·specific epitope, e.g. P1.7, 16 or L3,7,9. 
(From Verlteul et a!. [21]) 
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8.3 MICROBIOLOGY 
Neisseria meningitidis, is a gram-negative diplococcus that structurally 
resembles other gram-negative bacteria. The microorganism is characterized 
by surface expression of different capsular polysaccharides, by the presence 
of class 2 or 3 outer membrane protein (OMP), by the class I outer 
membrane protein, and by lipopolysaccharides, as described in Table I and 
depicted in Figure I [I8]. The most important virulence factor to survive in 
the bloodstream is encapsulation [19]. The polysaccharide capsule inhibits 
neutrophil phagocytosis and prevents classical complement pathway 
bactericidal activity thus enhancing intravascular bacterial replication and 
survival. Lipopolysaccharides (LPS), also called endotoxins, are shed by 
meningococci paltly in the form of cell-wall blebs. Endotoxin from the 
outer membrane has been studied extensively for its toxic and antigenic 
propelties and biochemistry [20, 21]. The importance of endotoxin as a 
mediator of gram-negative sepsis was demonstrated by Brandzaeg et al. 
[22]. High levels of circulating lipopolysaccharide correlate with fatal 
outcome [22-24]. Endotoxin is a potent stimulator of both cellular and 
humoral immunity [25, 26]. The presence of higher-molecular-weight LPS 
or sialylation of cell membrane glycoconjugates cOlTelates with increased 
resistance to killing by antibody and complement [27, 28]. Phase variation 
involving antigens that are targets of bactericidal antibodies also effects the 
sensitivity of a strain to serum bactericidal activity [29]. During growth, 
meningococci oversynthesize their outer membrane relative to the 
remainder of the organism. This results in the formation of bleb-like 
structures on the outer membrane which can be secreted [30]. 'Blebbing' 
and the continuous release of endotoxin in high amounts are characteristic 
features of meningococci. Blebs bind antibodies that would otherwise attach 
to whole bacteria and play a crucial role in the pathogenesis of septic 
shock. 'Blebbing' is also observed in other gram-negative organisms but 
usually to a lesser extent [31]. Bacterial propelties that contribute to the 
pathogenicity of the organism include the presence of a capsule, pili or 
fimbriae [32], outer membrane proteins and IgA protease (Table 2) [26, 33, 
34]. Attachment to epithelial or endothelial cells is mediated by pili and 
non-pilar adhesins [19, 35]. In this way and by the production of soluble 
products inducing ciliostasis N. meningitidis is able to escape from the 
ciliary clearance mechanisms of the nasopharyngeal mucosa. Another 
mechanism for survival is inactivation of IgA by IgA protease. However, 
this enzyme probably plays a minor role [36]. 
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Table 2. Virulence factors of Neisseria meJlillgifif/is. 
. Secreted compounds 
- Surface structures 
JgA protease 
Blebs 
Pili 
Capsular polysaccharides 
Outer membrane proteins 
Regulatory iron proteins 
Lipopolysaccharides 
The major outer membrane proteins of meningococci have been 
divided into five classes (class I, 2, 3, 4 and 5) [37]. Meningococcal class I 
(PorA; serosubtype) and class 2 and 3 proteins (PorB; serotype) are pOl'ins, 
permitting the passage of ions across the cell membrane [38]. Gene 
sequencing has permitted the construction of topology models [39]. 
Whereas the transmembrane parts of these proteins are highly conserved, 
the strain-variable domains, which play a crucial role in the host immune 
response, are located at the tips of various surface loops in these models. 
The surface-exposed loops are the longest (and therefore the most exposed) 
in class 1 protein. This may explain why antibodies against this protein are 
pa11icularly effective in bactericidal assays [39]. Class 4 aMP (Rrop) 
reveals homology with Escherichia coli OmpA [28]. The exact function of 
this protein is unknown, but some evidence for pore-forming properties has 
been obtained. Class 5 aMP's, Opa and Opc are so-called heat modifiable 
proteins. Opa and Opc proteins are thought to be imp0l1ant in bacterial 
adhesion and invasion in host cells [34]. 
8.4 COLONIZATION AND INVASION 
N. meningitidis may colonize the human nasopharynx. Transmission 
takes place by small droplets and is facilitated by crowding and lower 
socioeconomic status [40, 41]. The can'iage rate by N. meningitidis has 
varied from a small percentage among infants to 25-35% among teenagers 
and young adults and declines with increasing age [42, 43]. Most people 
are asymptomatic can'iers who may transfer the micro-organism to non-
calTiers. Smoking, passive exposure to cigarette smoke, viral infections, 
exposure to dust, teenagers and young adults, male sex, and changes in 
residence and vitulence of meningococcal strains are all risk factors 
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associated with high carriage rates [13, 40, 41, 43-46]. Household contacts 
of a patient with meningococcal disease are at increased risk for secondary 
disease [47]. Most secondary cases occur within the first week after 
diagnosis of the index patient. 
The first and most important line of defense against infection with N. 
meningitidis is integrity of the mucosal membrane [21]. Invasion across the 
nasopharyngeal mucosa takes place as a bacterium-directed endocytotic 
process by non-ciliated epithelial cells [19, 35] or by ciliated epithelial cells 
with decreased ciliar function [44]. This process is influenced by outer 
membrane proteins. Bacteria surviving in the bloodstream invariably resist 
antibody-independent activation of complement by several mechanisms, for 
example sialylation in serogroup B, C, Wand Y. 
8.5 SYSTEMIC HOST RESPONSE 
Low levels of bactericidal antibodies and immaturity of the T-cell 
system may play an impOltant role in the development of meningococcal 
disease in young children. The presence of bactericidal antibodies is crucial. 
The levels of "natural" bactericidal antibodies are influenced by carriage of 
meningococci or colonization by nonpathogenic bacteria such as Neisseria 
iactamica [21]. The complement system also plays a key role in host 
defense mechanisms, resulting in lysis of bacteria, enhancement of 
phagocytosis by monocytes or polymorphonuclear leukocytes or 
neutralization of endotoxin [48, 49]. 
Bacterial components, palticularly endotoxin initiate a cascade of 
events which are responsible for the clinical presentation of meningococcal 
sepsis [26, 50]. The systemic inflammatory response is aimed to neutralize 
microorganisms and their products, but may also induce harmful tissue 
damage to the host. The intravascular inflammatOlY response can be divided 
into activation of cascade systems, the release of intercellular mediators 
from cells adjacent to circulating plasma and to the altered function of 
various cells in the vascular wall. In meningococcal infection coagulation, 
fibrinolysis, complement and kallikrein-kinin systems, as well as the 
production of cytokines and the activation of neutrophils and platelets, are 
all apparently upregulated by native LPS in a dose-dependent manner [22]. 
Non-specific host defence 
Serum levels of endotoxin which is released systemically from gram-
negative bacteria, con'elate with severity of disease [51]. High density 
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lipoproteins, complement factors, antibodies, albumin and lipopoly-
saccharide binding protein (LBP) have the ability to complex with LPS. 
Several of these proteins appear to have a detoxifying affect [37, 52, 53]. A 
potent bactericidal protein produced by polymorphonuclear leukocytes is 
bactericidal/permeability-increasing protein (BPI). It is stored in the 
azurophilic granules and is also expressed on the cell surface. Bactericidal 
activity of BPI is caused by the strong affinity of BPI for LPS [54]. In 
addition to bactericidal capacity, BPI also neutralizes LPS activities in vitro 
and vivo [55]. 
Complement system activation 
Fulminant meningococcal sepsis is associated with excessive 
complement activation [49, 51]. The complement system is an essential 
element in the maintenance of homeostasis. However, overstimulation or 
inadequate inhibition may lead to an inappropriate reaction and ultimately 
to tissue injUly [56]. Complement peptides generated during activation, 
have pro-infiammatOly effects such as stimulation, aggregation and 
degranulation of neutrophils and induction of expression of selectins on the 
endothelial surface. 
The complement system can be activated through the classical and the 
altemative pathway. The classic pathway requires recognition and binding 
of bacterial antigens by specific antibodies. However, in vitro studies 
indicate that lipid A and the polysaccharide side chain may complex with 
C 1 q and factor B to initiate activation of the classical pathway without 
involvement of antibodies. The altemative complement pathway can be 
activated by a variety of substances, including polysaccharides, bacterial 
endotoxins, cytokines and immune complexes [57, 58]. Normally, 
intravascular clearance of bacteria is mediated through the deposition of 
complement components: C3b for phagocytic clearance [59]; the membrane 
attack complex or C5b-C9 for lysis [48, 49]. 
The degree of complement activation in meningococcal disease is 
related to the amount of circulating native lipopolysaccharides. Previous 
studies indicate that LPS is a potent activator of the complement system 
[60-62]. In fulminant meningococcal septic shock, the presence of C4bc, 
C4bd and Bd point to activation of both the classical and altemative 
pathways. However, Brandtzaeg et al. suggest that complement activation is 
predominantly caused by altemative pathway activation. 
Brandtzaeg and colleagues also showed that complement activation 
may persist during the first 12-24 hours of disease, when most production 
of other infiammatOlY mediators is already downregulated [51]. 
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Pro- and counterinflammatory mediators 
Lipopolysaccharides induce a release of proinflammatory mediators in 
gram-negative sepsis. These mediators are mainly synthesized and released 
by macrophages, monocytes, and endothelial cells. Experimental and 
clinical data have shown that tumor necrosis factor (TNF)-a and interleukin 
(IL)-lB are key mediators in meningococcal sepsis. TNF-a is present in the 
circulation after administration of live or heat-killed bacteria or endotoxin 
[63, 64]. Administration of TNF-a reproduces many of the clinical 
symptoms of sepsis such as rigors, fever, hypotension, and tachycardia. 
Hematologic abnormalities include leukopenia and activation of 
coagulation, fibrinolytic and complement systems [65, 66]. TNF-a and IL-
I B exett their effects by different mechanisms including the induction of 
other cytokines, activation of neutrophils, generation of prostaglandins and 
production of nitric oxide. 
Tumor necrosis factor-a and IL-I B are early mediators of inflammation 
since they appear before the release of IL-6 and IL-8. The release of the 
latter mediators is triggered by LPS, TNF-a, and IL-IB. IL-6 is a major 
pyrogen and is probably an impOltant regulator of the inflammatory 
response. The synthesis of acute-phase proteins is stimulated by IL-6 [67]. 
It is not considered to be a toxic molecule. IL-8 is a potent chemoattractant 
and activates neutrophils [68]. Futthermore, IL-8 is thought to be involved 
in neutrophil-mediated vessel-wall injury [69]. 
Leukemia inhibitOlY factor (LlF) is another proinfiammatory cytokine. 
LlF has multiple actions, many of which are shared with TNF-a, IL-I and 
IL-6 [70, 71]. LlF patticipates in the induction of the acute-phase response 
and stimulates the acute-phase protein secretion and fever. Fibroblasts, 
monocytes, macrophages, T-lymphocytes and endothelial cells may produce 
LlF. 
IL-12 is a recently described proinflammatory cytokine [72-74]. The 
precise role of IL-12 in vivo is not known, although this cytokine seems to 
play a key role in the differentiation of Thl cells [75] and in the host 
defense against bacterial, parasitic and viral infections [73]. IL-12 also 
induces the production of interferon (IFN)-y by T -cells and natural killer 
cells [76, 77]. IL-12 has been characterized as a major cytokine in the 
pathogenesis of gram-negative endotoxemia in mice [76] and in primates 
[78]. Hazelzet et al. showed that levels of IL-12 p40 and to a lesser extent 
those of IL-12 p70, are elevated in patients with meningococcal septic 
shock. Plasma levels of IL-12 p40 were related to outcome and severity of 
disease (chapter 12). 
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IFN-y may contribute to mortality as well. IFN-y activates other 
cytokines and is associated with increased selUm levels of TNF and IL-6. A 
late-acting mechanism of IFN-y is also suggested [79]. The plasma levels 
of IFN-y are increased in experimental models for sepsis [79-81] as well as 
in human sepsis [82, 83], although not consistently [24]. 
The shOit peak of pro-inflammatory cytokines is directly followed by 
an increase of IL-I receptor antagonist (IL-IRA), IL-IO and soluble TNF 
receptors (sTNFRs). These mediators are considered antiinflammatory 
because they reduce mOitality in experimental endotoxemia [84-86]. IL-IRa 
inhibits the proinflammatory actions of IL-I by competitive binding to the 
IL-I receptor. IL-I RA and also sTNFRs are present in the circulation 
during early meningococcal infection [4]. The role of sTNFR is complex. It 
is believed that sTNFR is released in the circulation after binding of TNF-a 
on the target cell. This shedding may protect the cell against ongoing 
stimulation. TNF-a induces release of sTNFR-55 and sTNFR-75 fi'om 
neutrophils in a time and dose dependent manner [87]. Soluble TNFR 
molecules are able to capture TNF-a and inhibit its biologic effects. 
Interleukin lOis released in massive amounts into the systemic circulation 
during the initial phase of fulminant meningococcal septic shock. High 
serum levels of IL-I 0 are associated with fatality in meningococcal disease 
[88]. TNF -a induces IL-IO production by human monocytes. IL-IO is a 
potent inhibitor of cytokine production [85, 89, 90]. It also suppresses the 
procoagulant activity induced by LPS at the surface of human monocytes 
[91]. IL-IO stimulates the production of IL-IRA and induces an increased 
release of sTNFRs from monocytes [92]. 
Generally, serum levels of proinflammatory cytokines are significantly 
increased at the onset of disease in patients with meningococcal sepsis and 
are associated with severity of disease [5, 22, 24, 67, 70, 93]. These 
cytokines rapidly disappear in time. A strongly negative conelation between 
the initial levels of cytokines and the duration of petechiae and serum levels 
of C-reactive protein (CRP) respectively has been repOited [67, 94]. This 
shorter duration of petechiae, as well as the lower level of CRP in non-
survivors suggests a shorter disease course and associated higher levels of 
cytokines. The earlier admission of nonsurvivors may indicate a higher 
production of LPS per time span, thus triggering mediator systems more 
intensively or may be explained by a higher responsiveness to LPS or to 
proinflammatOlY cytokines [94]. 
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Table 3. Factors involved in the pathophysiology of disseminated intravacula .. coagulation. 
-Deposition of microthrombi 
-Bleeding diathesis 
expression of procoagulant surface 
increased tumover of activated clotting factors 
consumption of regulatory proteins 
release of excess fibrinolytic inhibitors 
release of platelet activating factor 
increased fibrinolysis 
consumption of coagulation factors/platelets 
interference with platelet aggregation and fibrin polymerization by FDP's 
-Vascular injury and capillary leak 
direct toxic effect of endotoxin 
activation of kinins, complement and cytokines 
neutrophil adhesion and release of cytotoxic products 
loss of clotting factors by capillary leak 
Adapted from Manco·Johnson [170]. 
Coagulation and fibrinolysis 
Coagulation disorders and abnOlmalities of fibrinolysis are common in 
patients with meningococcal sepsis. The most severe manifestation is 
disseminated intravascular coagulation (DIC), characterized by micro-
vascular thrombosis and bleeding diathesis. Widespread microvascular 
thrombosis in various organ systems does contribute substantially to organ 
dysfunction and survival (Table 3). The production of tlu·ombin and the 
conversion of fibrinogen to fibrin, may be activated by the intrinsic 
pathway (through factor XII) or by the extrinsic pathway (through factor 
VII/tissue factor) activation. Activation of the coagulation system in sepsis 
occurs predominantly through the extrinsic route (Figure 2). The importance 
of the extrinsic route of coagulation was shown in an experimental model 
of baboons in which infusion of monoclonal antibodies against tissue-factor 
protects against lethal shock by E. coli. and attenuates coagulopathy [951. 
In contrast, inhibition of the intrinsic pathway by administration of 
monoclonal antibodies against factor XII has no effect on the coagulopathy 
in the same model [961. 
Endotoxin and TNF-a induce the expression of tissue factor by 
monocytes, macrophages and endothelial cells which activate factor VII. Of 
interest, increased levels of tissue factor are present in circulating 
monocytes isolated fi·om blood of patients with meningococcal sepsis. The 
highest values were found in nonsurvivors [971. Activated factor XII 
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Figure 2. Hemostatic mechanism. The intrinsic pathway involves the activation of coagulation 
factor XII, XI and IX. The extrinsic pathway involves the activation of factor VII by tissue 
factor. Abbreviations: ADP, adenosine diphosphate; IXa, activated coagulation factor IX; VIII, 
coagulation factor VIII; X, coagulation factor X and Xa, when activated; t-PA, tissue 
plasminogen activator; PAl, plasminogen activator inhibitor. 
Natural inhibitors (=» 1: antithrombin III; 2: activated Protein C; 3: tissue factor pathway 
inhibitor. 
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induces the kallikrein-kinine system. Hypotension is probably pa111y 
mediated by generation of kinins such as bradykinin. Factor XII levels are 
lowest in patients with septic shock [98, 99]. However, we found no 
significant difference between levels of factor XII in survivors and non-
survivors with meningococcal septic shock (manuscript in preparation). 
Levels of natural inhibitors of coagulation are markedly altered during 
meningococcal sepsis. Several studies confirmed that antithrombin III 
(ATIII) levels [100-104], protein S, and notably protein e [6, 100-102, 
104-106], are decreased in meningococcal septic shock. The decline in 
protein e levels is more pronounced than the decrease in ATIII and protein 
S levels. The decrease in A TIll, protein e and protein S levels is associated 
with the presence of DIe and poor outcome. The higher m0l1ality of infants 
with meningococcal septic shock is probably related to immaturity of the 
protein e system [6, 17]. Elevated initial levels of the extrinsic pathway 
inhibitor (EPI), another inhibitor of coagulation, were found in patients with 
fulminant meningococcemia [100]. This is in contrast to the levels of ATIII 
and protein e. The levels of EPI were significantly higher in nonsurvivors 
in comparison to survivors. FUl1hermore, levels of EPI increased during the 
course of disease [100]. 
The fibrinolytic system becomes initially activated by tissue 
plasminogen activator (t-PA) during the early course of meningococcal 
sepsis. Subsequently, fibrinolysis is inhibited by increased levels of 
plasminogen activator inhibitor (PAI)-I [17, 94, 107]. In patients with 
sepsis and septic shock t-PA levels are increased and related to outcome 
and severity of disease [108, 109]. However, we did not detect significant 
differences in the initial levels of t-PA in survivors and nonsurvivors with 
meningococcal septic shock [17, 94]. Levels of plasminogen and alfa-2-
antiplasmin are low in septic shock but not related to outcome [98, 108]. 
However, decreased alfa-2-antiplasmin levels as well as the high ratio PAI-
1It-PA were related to worse outcome in patients with meningococcal septic 
shock [17, 106, 107]. These changes in fibrinolytic parameters result in an 
ineffective fibrinolysis. Of interest, polymorphism of the PAl-I gene is 
suggested to explain higher PAl-I levels in non-survivors at a similar TNF 
stimulus [94]. 
The massive consumption coagulopathy is characterized by low lev~ls 
of coagulation factors VII, X, V, prothrombin, fibrinogen, and platelets. 
Because of the massive demand of anticoagulation factors due to 
widespread activation of the anticoagulant pathway, the host's naturally 
occurring anticoagulants are depleted to cause purpura fulminans [6]. 
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8.6 HEMODYNAMIC DERANGEMENTS 
Shock 01' circulatory collapse in patients with fulminant 
meningococcemia is caused by a combination of an inappropriate vascular 
tone, myocardial dysfunction, and capillaty leakage (Figure 3). 
A'l~" 
PMN~"Tr/c"mpl='"1 
Mediators 
ti 
Endothelial cell injury 
/. caPilla~aSOdYSregUlation 
DIC~ / 
TISSUE INJURY 
Figure 3. Pathophysiology of meningococcal sepsis. Abbreviations: LPS, lipopolysaccharides; 
PMN, polymorphonulear leukocytes; DIe, disseminated intravascular coagulation. 
Inappropriate vascular tone 
Initially, patients with meningococcal sepsis present with intense 
vasoconstriction. Subsequently, the systemic vascular resistance falls due to 
vasodilatation in the course of the treatment which requires volume 
suppletion and vasopressors. A dysbalance between forces causing 
vasodilatation and those causing vasoconstriction of the blood vessels 
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results in generalized vasodilatation and hypotension. Vasoconstrictor 
substances that are elevated in patients with shock include catecholamines, 
renin, aldosterone, thromboxane A2 and endothelin [11 0-113]. A deficiency 
of PGI, synthesis by the endothelium is also involved in vasoconstriction in 
meningococcal disease [114]. On the other hand, bradykinin and nitric 
oxide are potent vasodilator compounds leading to hypotension [115-117]. 
The complement and the contact system share the same protein as their 
inhibitor in plasma, i.e. CI-esterase inhibitor (CI-INH). CI-INH levels may 
increase up to two-fold during uncomplicated infections [118]. During 
sepsis CI-INH levels were found to be normal or even decreased especially 
in non-survivors [119]. Hack et al. hypothesized that increased degradation 
of Cl-INH in severe sepsis may result in an insufficient control of the 
complement and contact systems [118]. In meningococcal septic shock 
increased levels of complement factors C3, C4, C5, and terminal 
complement complex and decreased levels of prekallikrein are related to 
outcome [51]. 
Myocardial dysfullctioll 
Septic shock appears to have a more rapid course in children with 
severe meningococcemia than in adults. Cardiac insufficiency was 
fi'equently found in the group of non-survivors from meningococcal septic 
shock, although it was also encountered in survivors. [120]. Heatt failure 
has been attributed to the reduction of the coronary blood flow [121, 122], 
circulating myocardial depressants [123, 124], intrinsic cardiodepressant 
propetties of endotoxin [125], acidosis [126], hypoxemia [127], and acute 
pulmonary hypettension caused by capillary microthrombi [128]. The 
mechanism of the myocardial failure in sepsis remains pattly speCUlative. 
Factors such as calcium, citrate contained within fi'esh frozen plasma or 
albumin, complement, endorphins and histamine have been implied as 
possible myocardial depressant factors. Also, the diffuse capillary leakage 
may effect myocardial function. Severe myocardial edema may induce 
secondary modifications of myocardial compliance and/or contractility. 
[120] 
Endothelial damage and capillary leakage 
Endothelial cells form a selective permeability batTier between blood 
and underlying tissues. During sepsis, endotoxin and several other 
mediators activate vascular endothelial cells and initiate a rapid alteration of 
stlUcture and function of these cells. Persistent hypovolemia in spite of 
large fluid infusions results from a severe capillary leak syndrome induced 
by endothelial damage. Capillary leakage and subsequently edema are the 
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result of high molecular protein leakage, separation of tight junctions 
between endothelial cells [129], destlUctive changes of endothelium 
(especially the glycosaminoglycan component [130]. These processes are 
pattly induced by mediators (TNF-a, IL-l, IL-8, PAF, leukotrienes, 
thromboxane A" thrombin, vascular permeability factor, complement 
factors, kinins [110, 131], and the adherence of neutrophils [132-134]. 
Activated leukocytes also play a role in endothelial damage since these 
cells release of proteolytic enzymes and toxic oxygen radicals [58, 
132-134]. Ultimately, increased vascular permeability leads to profound 
interstitial edema and diffuse parenchymal cell injury and subsequent organ 
dysfunction. 
8.7 TREATMENT 
Intensive care snpport 
Patients with suspected meningococcal sepsis should be vigilantly 
observed during the first 48 hours of treatment, preferably on an intensive 
care unit. The most important complication requiring urgent intervention is 
the development of shock. Assessment of the fluid balance may be 
extremely difficult since patients with meningococcal shock invariably have 
a profound capillary leak. The aim should be to provide sufficient fluid to 
maintain the intravascular volume and electrolyte balance, while minimi-
zing the accumulation of extravascular fluid. Central venous pressure or 
pulmonary wedge pressure monitoring should therefore be used to guide 
fluid administration. Pulmonary edema is a complication requiring elective 
ventilation. When shock continues despite aggressive conection of the 
volume deficit, inotropic support with or without peripheral vasodilators 
should be given [26]. 
Antibiotic treatment and profylaxis 
Penicillin remains the treatment of choice for meningococcal disease. 
However in young children, the elderly or the immunosuppressed, 
infections with other organisms, including Haemophilus injluenzae type b, 
Streptococcus pnellllloniae and coliforms, may be indistinguishable fi'om the 
clinical picture seen with meningococcus. For this reason a third generation 
cephalosporin, either cefotaxime or ceftriaxone, is the initial antibiotic 
treatment until the organism and its sensitivity have been determined [26]. 
Some countries including Spain, South Afi'ica, Canada, the United 
States and the United Kingdom have documented an increasing number of 
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N. meningitidis isolates with a reduced susceptibility to penicillin in clinical 
isolates of N. meningitidis [135-139]. In Spain the frequency of strains with 
decreased susceptibility to penicillin increased fi'om 0,4% in 1985 to 40% 
during the first months of 1990. These strains show varying levels of cross-
resistance to other betalactam antibiotics. Multilocus enzyme electropho-
resis has established a high level of genetic diversity among these isolates 
[140]. Resistance is due, at least in part, to a decreased affinity of 
penicillin-binding protein for penicillin. Continuing surveillance is 
impOitant to detect penicillin-resistant meningococci which would cause 
serious problems in the treatment of meningococcal infections [13, 135, 
137, 141]. 
Prophylactic antibiotics are used in order to eliminate can'iage of 
virulent strains before they cause invasive disease or are spread to 
susceptible individuals. Rifampicin is most commonly used and has shown 
to be effective [37, 142]. Ten percent of the failures of eradication results 
from emergence of isolates resistant to rifampicin [143]. However cases of 
meningococcal disease due to rifampicin-resistant meningococci are rare 
[144]. When serogroup A or C strains are isolated, the close contactgroup 
should be offered meningococcal A or C vaccine in addition to rifampicin 
prophylaxis [142]. The issue if chemoprophylaxis is needed at the time of 
discharge after treatment for systemic meningococcal infection is still 
widely debated [42, 145]. 
Adjunctive treatment 
There are a number of experimental forms of therapy designed to 
reduce the inflammatory process or reverse the disordered physiology. The 
outcome in patients with septic shock can be improved by neutralization of 
circulating endotoxin or inhibition of proinflammatory cytokines as 
observed in studies with experimental animals. However efficacy was not 
shown in patients with sepsis or septic shock [146, 147]. 
Heparin, antithrombin III concentrate, fresh frozen plasma and protein 
C concentrate have been studied as agents to control disseminated 
intravascular coagulation in patients with fulminant meningococcemia [100, 
101, 148-152]. However with the exception of fi'esh frozen plasma and 
protein C, which have some fibrinolytic propelties, these drugs cannot add 
to the dissolution of fibrin clots. Recombinant tissue plasminogen activator 
(It-PA) is a new fibrinolytic drug. It specifically interferes with PAl-I and 
induces a clot-selective fibrinolysis that is associated with only a little 
decrease of fibrinogen. Preliminary experience with It-PA in two patients 
suggests that It-PA should be considered as an investigational therapeutic 
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option in patients with life threatening disease and no response to 
conventional treatment [153, 154]. 
Monoclonal antibodies against the lipid A moiety of endotoxin (HA-
IA) have been evaluated in adults [146, 155] and recently in children with 
meningococcal septic shock. The lipid A core stlUcture of LPS is well 
conserved among the diverse gram-negative pathogens and antibodies 
against epitopes on the core glycolipid have been shown to induce cross-
protection. The data of the multinational European trial in children with 
meningococcal septic shock show a 30% reduction in mortality, without 
statistical differences between the HA-IA and placebogroup. A new trial to 
evaluate the efficacy of protein C in the treatment of children with 
meningococcal septic shock is in preparation. Possible future treatment 
modalaties include r-BPI (phase I and 2 trials are initiated), CI esterase 
inhibitor, and tissue factor pathway inhibitor (Table 4). 
Table 4. Experimental therapeutic modalities. 
Anti-endotoxin agents 
monoclonal antibodies against endotoxin/lipid A 
lipopolysaccharide binding protein 
bactericidal pem1eability increasing factor 
CD 14 receptor antagonist 
Anti-cytokine response agents 
monoclonal antibodies against tumour necrosis factor 
monoclonal antibodies against interleukin-l 
tumour necrosis factor receptor antagonist 
interleukin-l receptor antagonist 
soluble TNF receptor 
Agents for the treatment of disseminated intravascular coagulation 
antithrombin III 
monoclonal antibodies against tissue factor 
protein C and S 
recombinant tissue plasminogen activator 
Adapted from Cartwright et al [36]. 
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8.8 VACCINATION 
Meningococci of serogroups A, B, C, W-135 and Y may be 
responsible for invasive infections. Vaccines are currently available against 
meningococci of serogroups A, C, W-135 and Y. However, polysaccharides 
which are the major compounds of these vaccines, are T-cell independent 
immunogens and the ability to respond to them shows an age-dependent 
maturation [156]. Group C polysaccharide vaccines are not immunogenic in 
children lesser than 18 months of age. Serogroup A, Y and W135 vaccines 
are protective in young children, but only provide short term immunity. 
Persistence of vaccine-induced antibodies is also age dependent [157]. 
Serogroup A and serogroup C polysaccharide-protein conjugate vaccines 
have recently been developed and seem to be effective also in young 
children [158]. 
A vaccine against group B meningococci, the most common cause of 
meningococcal disease, is not yet available. Group B polysaccharides do 
not induce significant increases in antibodies. The poor immunogenicity of 
these antigens is due to immunological tolerance. StlUcturally and 
immunologically related molecules, palticularly in developing brain tissue, 
have been identified on human cells [159]. Polysaccharide conjugate 
vaccines may overcome the poor antibody response. These vaccines induce 
an immune response against the normally non-immunogenic group B 
polysaccharide [158, 160]. It is conceivable that the natural tolerance to this 
polysaccharide stlUcture could cross-react in vivo with host antigens and 
thereby could initiate and autoimmune process [159]. 
A promising approach to the development of an effective serogroup B 
meningococcal vaccine is the use of OMPs. Vaccines consisting of 
membrane vesicles containing a mixture of OMPs are shown to be safe and 
immunogenic in human volunteers [161, 162]. Efficacy studies with these 
vaccines demonstrated that antibodies to these antigens do provide a 
significant protection against serogroup B meningococcal disease [163-167]. 
However, these studies showed a protective effect of limited duration and 
an age-dependent protection in the range of 50 to 80% [165-167]. Of 
interest, class I proteins appear to be more immunogenic than class 2 or 
class 3 proteins and may play a central role in the development of vaccines 
[13]. Antibodies to the class 4 outer-membrane proteins interfere with the 
protective response, and should be excluded from a protein based vaccine 
[168]. This has led to work on a new generation of vaccines in which a 
nonprotective OMP is replaced by a protective OMP from another strain. In 
this way, a multivalent vaccine has developed with the insertion of multiple 
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class 1 genes into a single strain and provide protection against many of the 
prevalent serotypes [169]. A phase II trial with this multivalent vaccine is 
cutTently ongoing in Gloucester (England) and Rotterdam (The 
Netherlands). 
8.9 CONCLUSIONS 
Several aspects of the pathophysiology of septic shock have been clarified 
in recent years. Based on this improved understanding, rational therapeutic 
approaches that supplement antibiotic treatment can now be developed. 
Therapeutic interventions may be directed against harmful bacterial 
products, against cytokines, against WBC or against some of the 
consequences of disease, such as DIe. Although some experimental 
treatment strategies have resulted in encouraging results, prevention of 
meningococcal sepsis by the development and introduction of an efficacious 
vaccine will be the major challenge of the next decade. 
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Septic shock and plllpura 
9.1 ABSTRACT 
Clinical characteristics and outcome were studied in 87 children with 
septic shock and purpura. Additionally, a new prognostic scoring system 
was developed. The median age of the patients was 3.2 years (range 3 
weeks - 17.9 years). Blood- andlor cerebrospinal fluid cultures grew 
Neisseria meningifidis in 75 children and Haemophilus influenzae in 2 
patients. Cultures remained sterile in 10 patients. The most common 
phenotype of N. meningitidis was B:4:P1.4 (27%). A mortality rate of 25% 
was observed. Ten of the 66 (15%) survivors had serious sequelae. Calcium 
levels were significantly lower in patients with seizures. Disseminated 
intravascular coagulation occul1"ed in 60% of the patients. Logistic 
regression analysis identified four laboratoty parameters independently 
associated with mottality: C-reactive protein, base excess, semm potassium, 
and platelet count. These tests were used to develop a novel scoring system 
with a predictive value for death and survival of 75% and 91% 
respectively. The outcome was predicted correctly in 87% of the patients 
which is higher than in previously repotted scoring systems. 
9.2 INTRODUCTION 
Septic shock and putpura or severe infectious putpura with shock is a 
life-tlu'eatening entity in previously healthy children. The syndrome is 
mainly caused by Neisseria meningifidis, although occasionally 
Haemophilus influenzae type b is involved. Meningococcal disease still 
remains major health problem in both developing and industrialized 
countries. Group B is the predominant serogroup among strains causing 
meningococcal disease followed by group C [1]. 
From 1970 to 1980 the annual incidence of meningococcal disease in 
the Netherlands varied between 0.7 and 2.0 cases per 100,000 popUlation. 
The incidence of meningococcal disease gradually increased during the 
1980s, and reached 3,5 per 100,000 inhabitants in 1990. The age-specific 
incidence is highest among children less than 5 years of age (- 22.8 per 
100,000) [I, 2]. In addition, the percentage of patients with meningococcal 
sepsis without clinical meningitis increased in the same period [3, 4]. 
Despite the use of antibiotics and intensive care treatment, septic shock 
and putpura is still associated with a high mottality and morbidity. 
Mortality ranges between 25% and 50% [5-7]. A relatively small 
percentage of the survivors has serious sequelae such as extensive skin 
necrosis requiring skin grafting and amputation. 
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The use of scoring systems combining data of prognostic significance 
in the assessment of patients with acute meningococcal disease or septic 
shock and purpura, has attracted much interest [6-18]. According to a 
number of studies, signs of poor prognosis on admission are the absence of 
meningeal inflammation, the presence of rapidly evolving hemorrhagic skin 
lesions, hyperpyrexia, leukocytopenia, tlu·ombocytopenia, low plasma levels 
of fibrinogen, disseminated intravascular coagulation, metabolic acidosis, 
and rapid clinical deterioration. Combinations of clinical and laboratory 
parameters have been used to develop scoring systems to predict mortality. 
However, these systems are often pattly based on subjective clinical 
criteria. 
The purpose of the present study was to evaluate the epidemiology, 
clinical features, laboratory parameters, and outcome of septic shock and 
purpura in children admitted to the Sophia Children's Hospital between 
1988 and 1995. Additionally, the prognostic significance of several clinical 
features and laboratory parameters was evaluated and a new prognostic 
score was developed. 
9.3 PATIENTS AND METHODS 
The records of all patients 18 years and younger admitted fi·om 
October 1988 through June 1995 with a clinical diagnosis of septic shock 
and purpura to the Pediatric Intensive Care Unit (PICU) of the Sophia 
Children's Hospital were prospectively evaluated. Shock was defined as a 
mean atterial blood pressure more than 2 standard deviations below the 
normal value for age [19] and/or the presence of poor end-organ perfusion 
defined by at least two of the following criteria: a.) unexplained metabolic 
acidosis (PH ~ 7.3), base excess ~ -5 mmollL or atterial plasma lactate 
levels> 2.0 mmollL; b.) atterial hypoxia defined as a Pa02 ~ 75 mm Hg, a 
Pa02 to Fi02 ratio < 250 or Tc02 ~ 96% in patients without ovett 
cardiopulmonary disease; c.) acute renal failure defined as oliguria with an 
urine output less than 0.5 mLlkg/hr for at least one hour despite acute 
volume loading or evidence of adequate intravascular volume and without 
preexistent renal disease; d.) sudden deterioration of the patient's mental 
status. 
A subset of the patients was enrolled in a randomized, double-blind 
placebo controlled trial to study the efficacy of HA-IA human monoclonal 
antibody against endotoxin (Centoxin, Centocor, Malvern, PA) in 
meningococcal septic shock. 
Medical records were analyzed for demographic parameters, clinical 
features, laboratory data, and outcome. The data were abstracted using a 
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standard form. Patients who were initially treated at other hospitals but 
were transfen'ed to this hospital for intensive care treatment were also 
included. Decisions regarding the use of antibiotics, intravenous fluids, 
inotropic and vasopressor suppmt, and the initiation of mechanical 
ventilation were made by the patients attending physician. 
Definitions 
The severity of illness on admission at the PICU was assessed using 
the pediatric risk of mmtality (PRISM) score [20]. The duration of 
symptoms and petechiae was estimated as precisely as possible. Meningitis 
was defined as the presence of a positive bacterial culture of cerebrospinal 
fluid (CSF), 01' the presence of a positive gram-stain in the CSF, or the 
presence of a positive blood culture in combination with clinical evidence 
of meningitis and a CSF white blood cell (WBC) count above 10 
cells/mm3• Respiratory distress was defined as a condition that required 
mechanical ventilation because of respiratory failure. Disseminated 
intravascular coagulation (mC) was defined by the combination of three of 
the following features: platelet count less than 150 x 1091L, fibrinogen less 
than 2 gIL, factor V less than 60%, and presence of fibrinogen degradation 
products (FOP) [21]. Patients were divided in different groups for statistical 
analyses. Survivors were compared with nonsurvivors. 
Laboratory studies 
Bacteriological methods: Specimens of CSF and/or blood were 
routinely cultured. These specimens were obtained from all patients before 
antibiotic therapy was initiated. Micro-organisms were identified according 
to standard procedures [22]. Isolates from blood and/or CSF were sent to 
the Netherlands Reference Laboratory for Bacterial Meningitis (Department 
of Medical Microbiology, University of Amsterdam, Amsterdam and 
National Institute for Public Health and the Environment, Bilthoven, the 
Netherlands). Neisseria meningitidis strains were classified into serogroups, 
serotypes and subtypes on the basis of antigenic differences in their 
capsular polysaccharides and in class 2/3 and class 1 outer membrane 
proteins (OMP's), respectively. Meningococci were serogrouped by means 
of Ouchterlony gel diffusion with the use of rabbit antisera (produced at the 
Reference Laboratory) to the capsular polysaccharides of the serogroups 
[23]. Serotyping and subtyping were performed by means of a whole cell 
ELISA [1, 24]. 
Clinical hematology and chemistlY: Laboratory studies including a 
complete blood count (hemoglobin, total and differential white blood cell 
count, and platelet count) and serum chemistry analysis were routinely 
performed on admission. Blood samples for analysis of hematologic 
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parameters were collected in a microtainer containing EDT A(K,). Blood 
samples for clinical chemistry were collected into sterilized siliconized 
vacutainer glass tubes (Becton Dickinson, Meylan Cedex, France) and 
allowed to clot at room temperature. Samples were centrifuged at 1600 g 
for 10 minutes at 4°C. 
Parameters of coagulation and fibrinolysis: All assays were performed 
with commercially available reagents and methods. Blood samples for 
analysis of coagulation and fibrinolysis assays was collected in trisodium 
citrate 0.109 M (anticoagulant to blood 1:9 vol/vol). Clotting assays were 
used for the determination of the activated pallial thromboplastin time 
(APTT). Factor V (F V) was determined with a one stage assay using factor 
V deficient plasma and fibrinogen according to the Clauss method [25] 
(Behringwerke AG, Marburg, Germany). A semi-quantification of 
fibrin/fibrinogen degradation products (FDP) in plasma was performed by 
latex agglutination (Diagnostica Stago, Asnieres-sur-Seine, France). 
Statistical analysis 
Results are expressed as means ± SD, unless stated othelwise. 
Comparison of various variables between groups of patients were tested 
with the Mann-Whitney test. Frequencies of various findings between 
groups were compared by the Fisher's Exact Test. Peason's (1') or spearman 
(r,) correlation coefficient were used to evaluate the relation between 
specific variables. Multiple regression analysis was performed to evaluate 
factors which might affect the difference in parameters between survivors 
and nonsurvivors. Logistic regression analysis with backward selection was 
performed to develop a prognostic score for mortality based on variables 
obtained on admission. Two-tailed P values ,s; .05 were considered 
statistically significant. 
9.4 RESULTS 
Patient characteristics 
Eighty-seven patients with septic shock and purpura were evaluated. 
Fifty-one were males and 36 were females. The children had a median age 
of 3.2 years (range 3 weeks - 17.9 years). Twenty-nine children (33%) were 
less than 2 years, 42 (48%) between 2 and 10 years, 16 (19%) were older 
than 10 years. Fifty-six of the children pa!licipated in the clinical trial to 
study the efficacy of the human monoclonal anti-endotoxin antibody RA-
lAo The PRISM score at admission in the PICU ranged fj'Olll 0 to 44 
(median 10). Sixteen patients were directly admitted to our hospital, and 71 
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were refel1'ed by other hospitals. None of the patients received antibiotic 
treatment before or during transpOlt to the first institution. Hospitalization 
occurred within 12 hours after the onset of petechiae in 88% of the patients. 
In II patients (13%) petechiae developed during hospitalization. The 
transferral time fi'om the first institution to the PICU of Sophia Children's 
Hospital was less than 12 hours in 50 of the 71 transferred patients. The 
duration (mean ± SD) of symptoms and the interval between the appearance 
of petechiae and admission to the Sophia Children's Hospital were 18.5 ± 
7.6 and 6.8 ± 5.5 hours respectively. 
A lumbar puncture was performed in 55 cases at the time of 
admission. Meningitis was documented in 10 cases (18%). All 87 patients 
needed inotropic and vasopressor SUppOlt. Fifty-four of the 87 patients 
(62%) needed mechanical ventilation. 
Table 1. DistJibutiOIl of serogroups, serotypcs and -subtypes in 71 patients with septic 
shock due to Neisseria menillg/tidis. 
B C 
Total no. of patients (%) 58 (82) 13 ( 18) 
serotype 
2a 2 ( 3) 7 ( 10) 
4 38 ( 54) 3 ( 4) 
Other 6 ( 8) I ( I) 
Non-typeable 12 ( 17) 2 ( 3) 
snbtype 
PI.4 24 ( 34) 3 ( 4) 
PI.15 5 ( 7) o ( 0) 
Other 16 ( 23) 7 ( 10) 
Non-typeable 13 ( 18) 3 ( 4) 
Bacteriological findings 
Cultures of blood, CSF or skin biopsies grew Neisseria meningitidis in 
75 children and Haemophilus inj/uenzae in two children. Cultures were 
sterile in 9 children (10%) and could not be obtained in one patient. A total 
of 71 strains of N. meningitidis were available for typing. Four other 
isolates were not sent to the Reference Laboratory. The distribution of the 
serogroups and serotypesfsubtypes of N. meningitidis are depicted in Table 
I. Fifty-eight of 71 strains (82%) were serogroup Band 13 (18%) were 
serogroup C. The most common phenotype of N. meningitidis in the present 
study was B:4:PIA (27%). The age distribution differed among the various 
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Table 2. Characteristics of 87 children with septic shock and purpura on admission at the 
PICU. 
survivors nonsurvivors 
charactelistic /I (/I ~ 66) (/I ~ 21) P 
Age (years) 87 5.7 ± 4.9 3.4 ± 3.4 NS 
Sex (% male) 87 39 (59) 12 (57) NS 
Transferred 87 57 (86) 14 (64) NS 
Interval (hours) from 
- onset symptoms 
to admission PIeu 83 19.3 ± 7.2 15.8 ± 8.5 .02 
- appearance of petechiae 
to admission PIeu 84 7.3 ± 5.7 5.2 ± 4.6 NS 
PRISM score 87 10.5 ± 6.9 20.4 ± 7.6 <.001 
Hematology 
Hemoglobin (mmol/L) 87 6.6 ± 0.9 6.0 ± 1.1 .05 
WBC (.IO'IL) 87 14.4 ± 9.9 8.5 ± 8.5 .005 
platelets (. I O'/L) 86 112 ± 50 66 ± 39 <.001 
Chemistry 
sodium (nunoIlL) 87 135±5 138 ± 4 .02 
potassium (mmollL) 87 3.4 ± 0.6 4.2 ± 0.8 <.001 
calcium (mmollL) 81 1.92 ± 0.23 1.88 ± 0.29 NS 
glucose (mllloIlL) 74 6.7 ± 2.8 4.2 ± 2.6 .002 
lactate (mmol IL) 81 5.0 ± 3.3 8.1 ± 4.1 <.001 
ureum (mIlloI/L) 
creatinine (l.unollL) 81 86 ± 55 116 ± 59 .03 
CRP (mglL) 77 134 ± 67 78 ± 51 <.001 
albumen (gr/L) 78 33 ± 6 32 ± 10 NS 
Acid Base balance 
pH 87 7.37 ± 0.07 7.24 ± 0.14 <.001 
BE (mmollL) 86 -6.2 ± 3.8 -12.6 ± 5.0 <.001 
bicarbonate (mmol/L) 87 17.3 ± 3.4 13.8 ± 3.0 <.001 
Microbiology 
N. meningilidis 59 (89) 16 (76) 
H inj/uenzae 0(0) 2 (10) 
No growth 7 (II) 3 (14) 
Plus-minus value are mean ± SD. Values in parentheses are percentages. Abbreviations: II, 
number of observations; PICU, Pediatric Intensive Care Unit; Hb, Hemoglobin; WBC, white 
blood cell; CRP, C-reactive protein; BE, base excess; NS, not significant. 
serogroups. The mean age of children affected with serogroup C 
meningococci was significantly higher than in those with serogroup B (4.6 
± 4.6 years versus 7.7 ± 5.3 years: P = .04). 
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Outcome 
Survivors vs. Ilonsurvivors: The mOliality was 25% (95% confidence 
interval [CI]: 15% - 34%). Eighteen children died as a consequence of 
irreversible septic shock. Three patients died as a result of central nervous 
system complications. Nearly 50% of the deaths occurred within the first 24 
hours and 90% occuned within 48 hours. The median (range) duration fi'OIn 
the onset of symptoms until death was 34 hours (11-143 hours). The 
demographic and clinical characteristics of the 67 survivors and the 21 
nonsurvivors at admission to the PICU are shown in Table 2. The mOliality 
rate was higher in children younger than 4 years of age (16 of 48 [33%] vs. 
5 of 39 [13%]; P = .03). Patients admitted primarily to the Sophia 
Children's Hospital had a higher mOliality rate in comparison with 
secondary referrals (7 of 16 [44%] vs. 14 of 71 [20%]; P = .06]. The 
PRISM score of the primary referrals was significantly worse than that of 
the secondary referrals (16.6 ± 10.0 vs. 12.1 ± 7.6; P = .05). The interval 
between the onset of symptoms and admission to the PICU was 
significantly shOlier in nonsurvivors. 
Complications and sequelae of survivors: The median hospital stay 
was 13 days (range 10 - 207) among the survivors. Thhty-three of the 66 
survivors were mechanically ventilated for a median duration of 7 days 
(range 1-24 days). Most survivors recovered without sequelae. 
Dermatologic or Olihopedic sequelae requiring skingrafts or amputations 
occul1"Cd in 9 of the 66 survivors. Two survivors had serious neurological 
sequelae (sensorineural hearing loss, spasticity). Two patients required 
hemofiltration because of renal failure, one patient developed osteomyelitis. 
Seizures occuned in 12 patients. 
Table 3. Coagulation and fibrinolysis parameters in 87 patients with septic shock and 
purpura. 
reference survivors nonsurvivors 
Characteristic range 1/ (1/ = 66) (1/ = 21) P 
Coagulation 
APIT (sec) • 28-40 77 53 (29->200) 102 (53-200) <.001 
Factor V (%) 70-140 75 41 ± 21 21 ± 12 <.001 
Fibrinogen (giL) 1.8-3.5 78 2.6 «0.4-5.8) I. I «0.4-5.4) <.001 
Fibrinolysis 
FDP (mg!L) <5 76 48 «5->300) 143 (35->300) .001 
Data are expressed as median (range) specified otherwise. ., mean ± standard deviation. 
Abbreviations: 11, number of observations; APIT, activated partial thromboplastin time; FOP, 
fibrin/fibrinogen degradation products. 
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Figure 1. Relation between initial senlln concentrations of potassium (K) and arterial pH in 87 
children with septic shock and purpura. Solid and dashed lines indicate the regression lines 
through the values of each parameter for survivors and non survivors respectively. Slopes 
between the regression lines of survivors and nonsurvivors did not significantly deviate from 
parallelism. 
Laboratory findings 
Demographic and laboratory parameters of survivors and nonsurvivors 
are depicted in Tables 2 and 3. Occasionally laboratory data were missing, 
but this never occUlTed in more than 12 patients for a given characteristic. 
Initially, 19 patients (22%) had a peripheral white blood cell (WBe) 
count lower than 5 x 109 fL. Platelet counts were below 50 x 109 fL in 15 of 
86 patients (J 7%). The acid-base status and the al1erial selUm lactate levels 
showed striking abnormalities that were more severe in nonsurvivors. 
SelUm glucose levels were significantly lower in the nonsurvivors but 
hypoglycemia « 2.5 mmollL) was observed in only 5 children. 
Hypokalemia « 3.5 mmollL) was observed in 49%. SelUm potassium 
levels were highly correlated with the arterial pH (r, = .50, P < .001). 
Analysis of covariance showed that serum potassium levels were 
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significantly higher in nonsurvivors in comparison to survivors irrespective 
of the atterial pH (Figure I). Serum calcium concentrations were measured 
in 81 cases (93%). Hypocalcemia « 2.2 mmollL) was detected in 58 
patients (72%). Ionized calcium levels were only available in a limited 
number of patients and are therefore not shown. Of interest, serum calcium 
levels were lower in patients with seizures in comparison with those 
without seizures (1.75 ± 0.29 mmollL versus 1.93 ± 0.23 mmollL; P = .05). 
The serum levels of CRP were significantly lower in nonsurvivors in 
comparison with survivors and con'elated strongly with the time interval 
between the onset of symptoms and petechiae and the moment of blood 
sampling (/' = .59, P < .001 and /' = .55, P < .001, respectively). 
Coagulation studies were performed in all patients (Table 3). 
Fibrinogen levels were less than or equal to 1.5 gIL in 22 of 78 (28%) 
patients. DIC could be determined in 77 patients. DIC occurred 
significantly more often in nonsurvivors than in survivors (18 of 19 [95%] 
vs. 28 of 58 [48%]; P = .003). 
Prognostic analysis 
Most variables listed in Tables 2 and 3 documented at the time of 
admission were associated with a poor prognosis. Factors that appeared to 
discriminate according to the univariate analysis were considered for 
inclusion in a prognostic scoring system. Logistic regression analysis 
identified four independent variables to predict the likelihood of survival. 
These were the serum level of CRP and potassium, the base-excess, and the 
platelet count. The mathematical expression of the probability of PICO 
death in this study was as follows: 
Probability (PICU death) 
in which X = 1.60 + 1,31 x Potassium (mmollL) - 0.34 x Base Excess 
(mmollL) - 0.023 x Platelets (i091L) - 4.49 x log (CRP [mgIL]). Figure 2 
gives the graphical presentation of the model. This new prognostic score 
was compared with five other scoring systems. Each scoring system was 
applied to our patients. Our score had the highest predictive value for death 
and survival (Table 4). The newly developed Rotterdam prognostic score 
was highly conelated with the PRISM-score (r = .64, P < .001). 
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Figure 2. Probability of death according to the new prognostic scoring system. 
Table 4. Outcome prediction in patients with septic shock and purpura. 
Pl'edictive value for 
Score Patients (II) 
survival death 
Niklasson [17] 55 88% 26% 
Leclerc [6] 73 92% 45% 
CRP [11] 77 90% 42% 
Giraud [7] 78 88% 55% 
PRISM [20] 87 86% 73% 
Rotterdam score 76 91% 75% 
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Accuracy 
45% 
78% 
66% 
78% 
84% 
87% 
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9.5 DISCUSSION 
The clinical picture of septic shock and purpura is induced by 
meningococci (occasionally other bacteria) and by their products 
(Jipopolysaccharides) and mediated by a multitude of inflammatory 
mediators. The inflammatory response may develop into irreversible 
circulatory collaps, renal failure, adult respiratory distress syndrome and 
death. 
In the present study we show that septic shock and purpura is 
associated with a mortality rate of 25% and serious sequelae in 15% of the 
survivors. A higher mottality was observed in patients directly admitted to 
the Sophia Children's Hospital in comparison with secondaty refet1'als. This 
was probably due to patient selection, since extremely ill patients died 
before refet1'a1 could be organized. The clinical condition of secondary 
refet1'ed patients was relatively better as can be inferred from the lower 
PRISM-score. In contrast, Tesoro et al. observed that patients transferred 
from another hospital had a higher mortality [12]. In our study, the 
mottality rate was higher among children below 4 years of age in 
comparison with older children. The lower plasma levels of the naturally 
occurring circulating anticoagulants protein C and S in children younger 
than 4 years of age may contribute to the worse outcome in this group [26]. 
Long-term morbidity was observed in 15% of the survivors and was caused 
by deforming amputation or large areas of soft tissue destmction secondary 
to the coagulopathy and by serious neurological sequelae (sensorineural 
hearing loss, spasticity or paresis). A similar percentage was obsetved by 
Madden et al. [27, 28). 
Meningococcal disease in the Netherlands has gradually increased fi'om 
1.1 cases per 100,000 in 1982 to 4.3 cases per 100,000 in 1993. Strain 
B:4:P1.4 was most fi'equently isolated in our patients. This strain was not 
found before 1980, but became the most prevalent strain in 1990 (21% of 
all isolates) [I]. 
Striking differences were observed in clinical and laboratoty 
characteristics between sUlvivors and nonsUlvivors. The significantly shorter 
interval of symptoms and the lower level of CRP in nonsUlvivors suggest a 
shotter disease course. These data indicate that nonsUlvivors deteriorate 
more quickly because they accumulate more native lipopolysaccharides 
(LPS) per time span, trigger all mediator systems more intensively or 
because they have a higher responsiveness to LPS or proinfiammatory 
cytokines [29]. 
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Complex abnormalities were observed in electrolytes and acid-base 
status. Metabolic acidosis and increased alterial selUm lactate levels are the 
inevitable consequence of poor end-organ perfusion leading to anaerobic 
glycolysis. The serum sodium level was usually normal. Interestingly, we 
found hypokalemia rather than hyperkalemia in patients with septic shock. 
Hypokalemia was more severe in survivors than in nonsurvivors even when 
adjusted for the degree of acidosis which would normally be expected to 
result in a shift of potassium fi'om the intracellular space. Hypokalemia may 
be caused by the release of catecholamines leading to an increased 
intracellular shift of potassium into skeletal muscle [30). The relatively 
higher serum potassium levels in nonsurvivors may be caused by metabolic 
derangements [30), the more severe renal impairment, 01' rhabdomyolysis. 
In addition, hypocalcaemia was also seen in a large number of patients as 
observed by others [31-33). Interestingly, patients that had seizures during 
their initial disease course had lower selUm calcium levels than the other 
children. Hypotension, acidosis and electrolyte abnormalities may play a 
major role in the deterioration of myocardial function and may predispose 
to arrhythmias and cardiac arrest. 
Scoring systems for disease severity or a prognostic score have been 
useful in the assessment of care requirement, efficacy of therapy and 
prognosis. Previously, several scoring systems were developed for patients 
with acute meningococcal infections or septic shock and purpura. Most of 
these systems include the presence or absence of meningeal irritability or an 
elevated CSF WBC count [13, 15-18, 34). The assessment of neck stiffness, 
however, is um'eliable in severely ill patients. Tesoro et al. concluded that 
absence of meningeal involvement is not an important predictor of 
mortality [12). A CSF WBC count is not always available since a lumbar 
puncture is usually not performed due to the unstable clinical condition on 
presentation. Other scoring systems require variables such as the 
erythrocyte sedimentation rate, and skin/rectal temperature difference 
determination that are not always available [10, 18). We therefore 
developed a simple score for patients with septic shock and purpura which 
only requires objective variables available at any emergency room or PICU 
soon after admission. Logistic regression analysis revealed foul' laboratory 
parameters including low potassium levels, a negative base excess, a low 
platelet count and a low CRP level which were all significantly associated 
with fatal outcome. Base excess and PQtassium levels both reflect the 
degree of metabolic abnormalities. Low platelet counts are highly predictive 
for the presence of DIC. CRP level reflect the duration of illness since this 
level correlates positively with the duration of petechiae and other 
symptoms of patients with septic shock and purpura [29). The mOltality risk 
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predictor developed by us only needs simple laboratOlY parameters which 
are routinely performed. The prognostic value was higher than in previously 
developed scoring systems. This score will enable accurate mortality risk 
prediction for individuals or provide a relative scale for severity of illness. 
This score can also be used to evaluate the effects of future therapeutic 
interventions and to assess the evolution of disease in the first 24 hours. 
The possible beneficial effects of the anti-endotoxin antibody HA-IA 
on the outcome of children in the present study with meningococcal septic 
shock are not yet known. However, a recent study did not find a reduction 
in the 14-day mOltality rate in patients with gram-negative bacteremia and 
septic shock [35]. 
We conclude that septic shock and putpura in children is associated 
with a mOltality of 25% (95% CI 15% - 34%). The mortality was even 
higher in children below 4 years of age. About 15% of the survivors had 
serious sequelae such as skin necrosis requiring skingrafts or amputation, 
and permanent neurologic sequelae. Logistic regression analysis identified 
four laboratory parameters which were used in a prognostic score to predict 
outcome. The predictive value for death and survival were 75% and 91% 
respectively. The overall outcome was predicted correctly in 87% of the 
cases. 
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Mediators in Meningococcal Septic Shock 
10.1 ABSTRACT 
Proinflammatory cytokines (tumor necrosis factor [TNFHx, interleukin 
[IL]-6 and -8), counterinflammatory compounds (IL-tO and soluble TNF 
receptors p55 and p75 [sTNFR-55 and -75]), and hemostatic parameters 
were determined in 38 patients with meningococcal septic shock. Eleven 
patients (29%) died. Serum levels of pro- and counterinflammatory 
compounds and plasma levels of plasminogen activator inhibitor (PAl)-l 
were significantly higher in nonsurvivors. The interval between appearance 
of petechiae and blood sampling was shol1er in nonsurvivors than in 
survivors (3.6 ± 2.4 vs. 6.1 ± 3.3 h; P = .04). This interval correlated 
strongly with the levels of TNF-a, lL-6, -8, -10, sTNFR-55 and -75, and 
PAl-I. However, with the exception of PAl-I, differences between 
concentrations of these mediators disappeared after adjustment for the 
interval. PAl-l levels correlated with TNF-a concentrations (r = .75; P < 
.001) and were 1.9 (P = .01) times higher in non survivors at a similar TNF-
a concentration. A polymorphism in the promotor of the PAl-l 'gene has 
been associated with differences in release of PAl-I. Thus, an increased 
PAl-l response to TNF-a may be associated with fatality, probably because 
of polymOlphism of the P Al-I gene. 
10.2 INTRODUCTION 
Septic shock with pUtpura is a serious life-threatening disease in 
otherwise healthy children and young adults. The syndrome is most 
frequently due to Neisseria meningitidis, although occasionally, 
Haemophi!us influenzae type b is involved [1-6]. 
Lipopolysaccharides (endotoxin), a component of the outer membrane 
of gram-negative bacteria, induces the release of proinflammatory cytokines 
(tumor necrosis factor [TNF]-a, and interleukin [IL]-Ill, -6, -8) in patients 
with sepsis. Subsequently, endotoxins and cytokines stimulate the 
production of a wide range of additional inflammatory mediators (Le., 
arachidonic acid metabolites, complement, platelet-activating factor), 
influence the function of leukocytes and endothelial cells, and activate 
hemostasis [7-11]. The production of pro inflammatory cytokines and the 
extent of the inflammatory response is downregulated by 
counterinflammatOlY compounds, such as lL-IO, and naturally occun'ing 
antagonists of TNF-a including the soluble extracellular domains of the 55-
and 75-kDa membrane-bound TNF receptors (sTNFR-55 and -75). 
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IL-IO is produced by activated monocytes and suppresses the 
endotoxin-induced production of TNF-ct and IL-IJ3, -6, and -8 (12]. The 
biologic activity of TNF-ct is also neutralized by sTNFR-55 and -75 (13-
17]. sTNFR is shed from the cell surface of, for example, 
polymOlphonuclear cells in response to many of the same inflammatory 
stimuli that induce TNF-ct [18]. 
Endothelial cells are among the principal targets for the action of 
endotoxin, TNF -ct and IL-1J3. These cells change to a procoagulant state 
and can modulate the fibrinolytic system by secretion of tissue-type 
plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)-I, 
which respectively activate and inhibit fibrinolysis. The activation of 
coagulation together with the inhibition of the fibrinolysis are responsible 
for the development of a hypercoagulable state, fibrin deposition, and 
microthrombi [19]. Fibrin deposition and complement activation cause 
extensive endothelial damage and are associated with multiple organ failure 
[20-22]. 
Inflammatory mediators and coagulation disorders are involved in the 
pathophysiology of septic shock and should be associated with disease 
severity. Thus, we investigated the balance between proinflammatory 
cytokines (TNF-ct, IL-6, IL-8) and counterinflammatory compounds (IL-IO, 
sTNFR-55, sTNFR-75) in admission semm samples of 38 consecutive 
children with meningococcal septic shock (MSS) and studied their 
relationship with indicators of hemostasis. 
10.3 METHODS 
Patients 
We prospectively recruited patients between ages 3 months and 18 
years with septic shock and petechiae or purpura. Primary or secondary 
refe11'als were admitted to the pediatric intensive care unit (PICD), Sophia 
Children's Hospital, between October 1991 and September 1994. Patients 
were eligible for inclusion if they met the following criteria: Presence of 
petechiae or putpura for < 12 h and presence of shock (systolic blood 
pressure < 75, < 80, < 85, or < 100 mm Hg in children ages 3 months to I 
year or 1-5, 6-12, and > 12 years old, respectively). Children were also 
included when poor end-organ perfusion was present (defined as occurrence 
of at least two of the following criteria): (I) unexplained metabolic acidosis 
(PH :s; 7.3), base excess -5 mmollL or lower, or atterial plasma lactate 
levels > 2.0 mmollL; (2) atterial hypoxia (P02 :s; 75 mm Hg, P02-to-Fi02 
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ratio < 250, or TcO, :S 96% in patients without overt cardiopulmonary 
disease); (3) acute renal failure (oliguria with urine output < 0.5 mL/kglh 
for > I h despite acute volume loading or evidence of adequate 
intravascular volume and without preexistent renal disease); or (4) sudden 
deterioration of the patient's mental status. Most of the patients were 
em-oIled in a randomized, placebo-controlled trial to study the efficacy of 
the human monoclonal anti-endotoxin antibody HA-IA (Centoxin; 
CentocOl~ Malvern, PA) in MSS. Initial blood samples were obtained before 
administration of HA-IA or placebo. There was no selection in the HA-IA 
trial to bias the present study. 
On PICU admission, the severity of illness was assessed using the 
pediatric risk for mortality (PRISM) score, a severity-of-illness index [23]. 
Parents were asked to indicate the onset of symptoms as precisely as 
possible. The time of onset of petechiae was defined as the mean time 
between observation of the child with and without petechiae. The times of 
initiation of antibiotic treatment, PICU admission, and blood sampling were 
carefully registered by the investigators. Decisions regarding the use of 
antibiotics, intravenous fluids, inotropic and vasopressor supp0l1, and 
initiation of mechanical ventilation were made by the patient's attending 
physician. 
Laboratory studies 
Cerebrospinal fluid and blood specimens were routinely cultured. 
Blood samples for the determination of biochemical parameters, TNF-a, IL-
6, -8, and -10, and sTNFR-55 and -75 were obtained from an m1erial 
catheter and collected into sterilized siliconized glass tubes (Vacutainer; 
Becton Dickinson, Meylan, France) and allowed to clot at room 
temperature. The samples were centrifuged at 1600 g for 10 min at 40 C. 
Aliquots were stored at _800 C until assayed. Blood for the platelet and 
leukocyte counts was collected in a microtainer containing EDT A(K,). 
Blood for the coagulation and fibrinolysis assays was collected in 0.109 M 
trisodium citrate (anticoagulant to blood 1:9 vol/vol) and in a 0.109 M 
trisodium citrate mixture (theophylline, adenosine, dipyridamole; Diatube 
H, Diagnostica Stago, Asnit~res-sur-Seine, France). These samples were 
immediately chilled on ice and centrifuged at 2800 g for 15 min and then at 
45,000 g for 30 min at 40 C. Platelet and white blood cell counts were 
determined by flow cytometer (HI system; Technicon Instruments, 
Tarrytown, NY); C-reactive protein (CRP) was measured by 
immunonephelometric assay [24]. 
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Cytokines and inhibitors. Levels of TNF-a, IL-6, -8, and -10, and 
sTNFR-55 and -75 in serum were determined by ELISA (Medgenix, 
Fleurus, Belgium). Mediators were determined according to the 
manufacturer's instructions with the following detection limits (lowest 
positive standard): TNF-a, 15 pg/mL; IL-6, -8, and -10, respectively, 30, 7, 
and II pg/mL; and sTNF-55 and -75, respectively, 0,4 and 1.0 ng/mL. 
Parameters of coagulation and fibrinolysis. All assays were done with 
commercially available reagents and methods. Clotting assays were used for 
the determination of the activated partial thromboplastin time (APTT). 
Factor V was determined with a one-stage assay using factor V-deficient 
plasma and fibrinogen according to the Clauss method [25) (Behringwerke, 
Marburg, Germany). Antithrombin III (A TH!) activity and protein C 
activity were determined by chromogenic substrate assays (Behringwerke). 
Total protein S was measured by ELISA (Diagnostica Stago). Plasminogen 
was determined spectrophotometrically using a chromogenic synthetic 
substrate (Behringwerke). Plasma t-PA antigen concentration was measured 
by ELISA as described [26) as was PAI-I (Diagnostica Stago). A 
semiquantification of fibrin-fibrinogen degradation products (FDP) in 
plasma was done by latex agglutination (Diagnostic a Stago). 
Disseminated intravascular coagulation (DIC) was defined by the 
combination of three of the following features: platelet count < 150 x 10'/L, 
fibrinogen < 2 gIL, factor V < 60%, and the presence of FDP [27). 
Statistical analysis 
Results are expressed as mean ± SD unless stated othelwise. 
Differences between groups of variables were tested by the Mann-Whitney 
test. Frequencies of various findings between groups were compared by 
Fisher's exact test. Pearson's con'elation coefficient was used to evaluate 
the relation between specific variables. Multiple regression analysis was 
done to evaluate factors that might affect the difference in levels of 
mediators between survivors and nonsurvivors. Two-tailed P values :0; .05 
were considered statistically significant. 
10.4 RESULTS 
During the 3-year study period, 43 patients with septic shock and 
pUipura were admitted to the PI CD. Five patients did not fulfill the entry 
criteria: 3 had pUipura > 12 h before admission, I was < 3 months old, and 
informed consent was not obtained for I child. 
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Table 1. Characteristics of patients with meningococcal septic shock. 
Survivol'S Nonsurvivors 
Characteristic (/I ~ 27) (/I ~ 11) P 
Age (yeaTs) 7.3 ± 5.7 5.1 ± 3.9 .43 
St:'x (% male) 16 (59) 7 (64) 1.0 
rransfl.'rrals* 22 (82) 7 (64) .40 
Inll.'ly<\1 (h) from 
- Onset symptoms 
to admission PIeU 18.5 ± 7.7 14.4 ± 4.8 .09 
- Appearance of petechiae 
to admission PIeU 6.1 ±3.3 3.6 ± 2.4 .04 
Duration of antibiotic treatment (h) 4.7 ± 1.8 2.8 ± 1.8 .10 
PRISM score 8.6 ± 5.4 18.6 ± 5.5 <.001 
Clinical hematology 
White blood cells (. IO'JL) IS.! ± 10.3 5.4 ± 3.2 .004 
Clinical chemistry 
Creatinine (fJ.ll1ollL) 102 ± 68 135 ± 65 .08 
C-reactive protein (mglL) 131 ± 60 81 ± 43 .02 
Microbiology 
N. menillgiticUs 25 (93) 9 (82) .56 
No growth 2 (7) 2 (18) 
Note. Date are mean ± SD or no. (%). Abbreviations: PICV, pediatric intensive care unit; 
PRISM, pediatric risk for mortality score. *Patients transferred frol11 first institution to PICU, 
Sophia Children's Hospital. 
Patient characteristics 
Thitty-eight patients (23 boys, 15 girls) entered the study. Of these, 36 
participated in the clinical trial to study the efficacy of HA-IA human 
monoclonal antibody. The median age was 4.1 years (range, 0.7-17.9 
years). Twenty-nine patients were referred from another hospital. The 
PRlSM scores at PICU admission ranged fi'om I to 25. Cultures of blood, 
cerebrospinal fluid, or skin biopsies fi'om 34 children grew N. meningitidis. 
In 4 cases with sterile cultures, the diagnosis was made on the basis of 
typical clinical findings. None of the patients received antibiotic treatment 
before or during transport to the hospital. The duration (mean ± SD) of 
symptoms and the interval between the appearance of petechiae and 
admission to Sophia Children's Hospital were 17.4 ± 7.2 and 5.4 ± 3.3 
hours respectively. All patients needed inotropic and vasopressor SUppOlt. 
Twenty-five of the 38 patients required mechanical ventilation. The overall 
fatality rate was 29%. Table I shows the demographic and clinical 
characteristics of the 27 survivors and 11 fatalities. Survivors and 
nonsurvivors were evenly distributed in regard to time of onset of petechiae 
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and time of hospitalization. The interval between onset of petechiae and 
PICU admission was significantly shorter in nonsurvivors. SelUm CRP 
levels were also significantly lower in nonsurvivors than in survivors and 
were highly correlated with the interval between the onset of symptoms and 
petechiae and the moment of blood sampling (I' = .56, P < .001 and I' = .45, 
P = .005, respectively). 
Table 2. Coagulation and fibrinolysis data in patients with meningococcal septic shock 
Reference Survivors Nonsurvivors 
Characteristic range (/I ~ 27) (/I ~ 11) P 
Coagulation 
Platelets (x 10'/L) 150-450 120 ± 45 65 ± 37 .002 
APTT* (sec) 28·40 52 (33->200) 92 (58-200) <.001 
Factor V (%) 70·140 43 ± 23 22 ± 12 .007 
A TIll act. (%) 80-120 66 ± 14 51 ± 12 .01 
Protein C activity (%) 70-140 21 ± II 17 ± 8 .08 
Protein Statal (%) 65-108 57 ± 18 41 ± 10 .006 
Fibrinogen* (gIL) 1.8-3.5 2.6 «0.4·5.3) 1.2 «0.4-2.5) .005 
Fibrinolysis 
Plasminogen (%) 75-140 62 ± 13 53 ± 14 .10 
t-PA antigen (ngimL) <10 25 ± 14 35 ± 19 .13 
PAl-I antigen (ngimL) 4-40 971 ± 848 2500 ± 1390 <.001 
FDP* (mgIL) <5 70 (20->300) 120 (100-220) .02 
Note. Data are mean ± SD unless specified otherwise. Abbreviations: APTT, activated partial 
thromboplastin time; ATIII, Antithrombin III, tMPA. tissue·type plasminogen activator; PAl, 
plasminogen activator inhibitor; FOP, fibrin/fibrinogen degradation products. 
*Mediall (range). 
The parameters of coagulation and fibrinolysis are summarized in 
Table 2. DIC was observed in all non survivors and in 13 (48%) of the 27 
survivors (P = .003). The APIT was significantly more prolonged in those 
who did not survive. The inhibitors of coagulation (ATIII, protein C, and 
protein S) were generally decreased, but more so in the nonsurvivors. 
Plasminogen levels were similar in survivors and nonsurvivors. The t-PA, 
PAI-l antigen, and FDP levels were higher in nonsurvivors than in 
survivors. 
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Table 3. Serum levels of cytokines and soluble (s) tumor necrosis factor (fNF) receptors 
(R) in patients with meningococcal septic shock. 
Survivors Nonsnrvivors P 
(/I ~ 27) (/I ~ 11) 
TNF-a (pg/mL) 144 450 .03 
(35 - 3130) (74 - 2680) 
IL-6 (pg/mL) 107,600 1,081,000 .005 
(2990 - 4,515,000) (25310 - 5,758,000) 
IL-8 (pg/mL) 746 30,760 .005 
(31 - 113,100) (599 - 118,500) 
IL-IO (pg/mL) 1479 14,780 .01 
(68 - 20,440) (636 - 28,070) 
sTNFR-55 (ng/mL) 15.5 27.2 .05 
(6.2 - 32.3) (8.5 - 36.6) 
sTNFR-75 (ng/mL) 51.2 79.6 .04 
(22.5 - 149.4) (10.0 - 119.7) 
Note. Data are median (range), IL, interleukin. 
Proinflammatory cytokines and counterinflammatory compound levels 
at admission 
At admission, selUm levels of proinflammatory cytokines and 
counterinflammatory compounds were significantly higher in the patients 
who subsequently died (Table 3). Highly significant positive correlations 
were observed between all of these mediators (Table 4). In addition, selUm 
cytokine levels were negatively correlated with the interval between the 
appearance of petechiae and blood sampling (P < .001 for all; TNF-a: r = -
.55; IL-6: r = -.57; !L-8: r = -.58; IL-IO: r = -.59; Figure I). Multiple 
regression analysis for the relation between selUm cytokine levels and 
survival and duration of skin lesions showed that the time-adjusted 
concentrations of the cytokines TNF-a and IL-6, -8, and -10 were not 
significantly higher in children who died versus survivors. sTNFR-55 and -
75 were significantly higher in nonsurvivors and also cotTelated with the 
interval between the onset of petechiae and initial selUm measurements 
(sTNFR-55: r = -.36, P = .03; sTNFR-75: r = -.61, P < .001). Both 
sTNFRs remained markedly elevated during the first 24 h after 
hospitalization (data not shown). 
SelUm cytokine levels were also associated with the duration of 
antibiotic treatment (TNF-a: r = -040, P = .02; IL-6: r = -.37, P = .03; IL-8: 
r = -.33, P = .05; IL-IO: r = -.39, P = .02). However, these associations 
were weaker than those with the duration of petechiae. The duration of 
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Figure 1. Relation between initial serum concentrations of inflammatory compounds (tumor 
necrosis factor [TNF]-a, interleukin [IL]-6, -8, -10) and interval between onset of petechiae and 
blood sampling in 38 children with meningococcal septic shock. Solid and dotted lines indicate 
regression through values for each parameter. Slopes between regression lines of survivors and 
nonsurvivors did not significantly deviate from parallelism for each parameter. 
petechiae and the duration of antibiotic treatment were significantly 
cOlTelated (r = .50, P = .002). When these time intervals were 
simultaneously related by multiple regression analysis to the levels of 
mediators, the duration of petechiae was most predictive (P < .005 for 
TNF -a., IL-6, IL-8, IL-IO) while an additional significant predictive value 
was not observed for the duration of antibiotic treatment. 
Correlation between inflammatory cytokines and clinical features 
The relationship between cytokines and certain hematologic parameters 
was assessed. The peripheral white blood cell count and the CRP level 
were negatively con'elated with levels of TNF-o. (r = .59, P < .001 and r = 
.46, P = .004), IL-6 (r = .67, P < .001 and r = .62, P < .001), and IL-8 (r = 
.68, P < .001 and r = .62, P < .001) and with the interval between the onset 
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Table 4. Correlation behreen serum levels of cytokines and soluble (s) receptors (R) for 
tumor necrosis factor (TNF) in patients with meningococcal septic shock. 
TNF-a IL-6 IL-8 IL-IO sTNFR-55 
lL-6 .90 
lL-8 .90 .92 
lL-1O .79 .85 .89 
sTNFR-55 .82 .84 .80 .82 
sTNFR-75 .87 .82 .78 .75 .77 
Note. Probabilities for all correlations were < .00 l. Abbreviation: IL, interleukin. 
of petechiae and blood sampling (r = .54, P < .001 and r = .45, P = .005). 
Initial setum TNF-a levels correlated significantly with the APTT (r = .47, 
P = .003) and the concentrations of factor V (r = -.51, P < .001), t-PA (r = 
.63, P < .001) and PAI-1 (r = .75, P < .001). PAI-I levels were 
significantly higher in nonsurvivors than in survivors (2500 ± 1390 vs. 971 
± 848 nglmL; P < .001) even when adjusted for duration of skin lesions 
before blood sampling (P = .02) (Figure 2). Of interest, PAI-I 
concentrations were 1.9 times higher in nonsurvivors (P = .0 I) than in 
survivors at similar TNF-a serum levels as shown by analysis of covariance 
(Figure 3). This relationship between the levels of PAI-1 and TNF-a was 
not affected by their association with the time interval (pmtial r = .60, P < 
.001). 
10.5 DISCUSSION 
Systemic meningococcal disease has a wide spectrum of severity, 
ranging fi'om benign meningococcemia to fulminant septic shock with 
multiple organ failure and death. TNF-a and IL-IB are thought to play a 
central role in the pathophysiology of this disease. These cytokines are 
involved in the induction of other proinflammatory cytokines, such as IL-6 
and -8, and are involved in the activation of the coagulation and 
fibrinolysis. Our study confilIDs the findings of other investigators that 
disease severity and outcome are related to concentrations of TNF -a, IL-
6, -8, and -10, and sTNFR-55 and -75 [4, 28-33]. 
A wide interindividual variability in TNF-a release after stimulation by 
endotoxin has been demonstrated in vitro in whole blood samples and 
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Figure 2. Initial plasma levels of plasminogen activator inhibitor (PAl-I; Il = 36). Left, relation 
between PAI-l levels and survival. Right, initial PAl .. I plasma levels in relation to interval 
between onset of petechiae and blood sampling. Slope between survivors and non survivors did 
not significantly deviate from parallelism. Time-adjusted PAI-! levels were 2.1 times higher in 
nonsurvivors (P = .02). 
peripheral blood mononuclear cells isolated /i'Oln healthy volunteers [34, 
35]. The high initial TNF·f.( levels in those who do not survive MSS have 
been interpreted as the result of an exaggerated response to circulating 
endotoxin [36]. This production of inappropriately large quantities of TNF· 
f.( may be due to the presence of a genetic variant in the promotor region of 
the TNF gene (TNF2 allele) as previously observed in patients with 
cerebral malaria [37]. The TNF2 allele has been associated with higher 
constitutive expression and greater secretion of TNF·f.( after induction [38]. 
The initial concentrations of TNF·f.( in this and previous studies were 
significantly higher in MSS nonsurvivors than in survivors. However, the 
magnitude of TNF·f.( semm levels and of other proinflammatory cy10kines 
(e.g., IL·6 and ·8) is also determined by the duration of disease when blood 
samples are obtained, perhaps because these cy10kines rapidly disappear 
during the acute phase of septic shock. [29, 39-41]. Accordingly, we found 
a strong negative correlation between initial cy10kine levels and the interval 
between onset of purpuric skin lesions and blood sampling. This association 
is in contrast to previous repOlis [4, 32, 39]. In addition, in the present 
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study, CRP levels, which indirectly reflect the duration of illness [42], were 
significantly correlated with the interval between the onset of petechiae and 
blood sampling. This significantly shorter interval and the lower level of 
CRP in nonsurvivors suggest a shorter disease course and may therefore 
explain the higher levels of cytokines. The earlier PICU admission of 
nonsurvivors may indicate that persons who do not survive accumulate 
more native lipopolysaccharide in a sholter time, trigger all mediator 
systems more intensively, and are recognized as more severely ill earlier in 
the course of disease. Alternatively, nonsUl'vivors may have been admitted 
earlier because of a more rapid deterioration due to greater responsiveness 
to lipopolysaccharides 01' proinflammatory cytokines. 
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Figure 3. Relation between initial levels of tumor necrosis factor (TNF)-a. and plasminogen 
activator inhibitor-l (PAl-I) in 36 patients with meningococcal septic shock. Slope between 
regression lines of survivors and nonsurvivors did not significantly deviate from parallelism (P = 
The clinical features of patients with MSS show similarities to those 
observed in experimental endotoxemia in humans. A challenge with 
endotoxin in healthy volunteers results in a transient occurrence of a sepsis-
like syndrome. The peak levels of cytokines correspond with the transient 
leukopenia that occurs shortly after the endotoxin challenge [10, 43]. In 
experiments in baboons infused continuously with Escherichia. coli, peak 
levels of TNF-a also occured very early in the course of disease [44, 45]. 
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Similarly, high levels of TNF-ex, IL-6 and -8, low white blood cell counts, 
and low CRP levels were observed in patients from whom blood was 
obtained shOltly after the onset of petechiae. We therefore assume that the 
onset of petechiae is a useful setpoint during the course of invasive 
meningococcal disease. This assumption is suppOlted by mUltiple regression 
analysis, which indicated that sel1lm levels of cytokines are dependent on 
the duration of petechiae and not on the duration of antibiotic treatment. 
Of interest, the differences in the concentrations of mediators between 
survivors and nonsurvivors disappeared after adjustment for the time 
between onset of petechiae and blood sampling. These data suggest that the 
survivors and nonsurvivors in the present study may have had similar 
releases of inflammatory cytokines (TNF -ex, IL-6, IL-8). 
The proinflammatOlY cytokines are counteracted by counter-
inflammatory compounds. We observed significantly higher concentrations 
of IL-IO in nonsurvivors with MSS. Lehmann et al. [29] recently repOlted 
that high IL-IO levels in patients with meningococcal disease are associated 
with fatality. In contrast, Derkx et al. [39] did not confilm this observation 
in patients with MSS, which may be explained by the relatively small 
number of patients evaluated. However, the time-adjusted IL-IO levels in 
the present study were similar between survivors and nonsurvivors. IL-IO 
acts as a potent inhibitor of the release of the proinflammatOlY cytokines 
TNF -ex, IL-I13, IL-6, and IL-8 from T -cells [46], polymorphonuclear 
leukocytes [47], and monocytes and macrophages [12, 48, 49]. In animal 
models of sepsis, IL-I0, given before 01' soon after challenge with gram-
negative bacterial endotoxin or staphylococcal enterotoxin B, reduced TNF-
ex production and mOltality [50-52]. Chernoff et al. [53] showed that a 
single intravenous injection of IL-l 0 in humans reduces mitogen-induced T 
cell proliferation and suppresses TNF-ex and IL-I13 production fi'om whole 
blood stimulated ex vivo with endotoxin. In the present study, the strong 
correlation between IL-I0 and the proinflammatory cytokines TNF -ex, IL-6, 
and IL-8 in survivors and nonsurvivors suggests the presence of an 
adequate IL-I0 response to down-regulate the production of 
proinflammatOlY cytokines. 
In addition, sTNFR-55 and -75 can neutralize the biologic activity of 
TNF -ex. Girardin et al. [31] found that high levels of the sTNFRs are 
associated with an increased likelihood of fatality, and Froon et al. [54] 
suggest that increased sel1lm levels of sTNFRs in patients with sepsis 
syndrome are merely the result of renal failure. Normally, the majority of 
sTNFRs is removed from the circulation by the kidneys, although the liver 
and lungs are probably also involved [55]. The higher sel1lm creatinine 
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levels of nonsurvivors (P = .08) in the present study may at least pattly 
explain the differences in sTNFR concentrations. 
Abnormalities of coagulation and fibrinolysis play an impOltant role in 
the pathophysiology of MSS. It has been known for some time that 
endotoxin, TNF -ct and IL-lfi contribute to the activation of the coagulation 
and fibrinolysis [56, 57]. Normally the endothelial cell provides a blood 
vessel lining that reduces the coagulability of blood. TNF -ct causes 
endothelial cells to have procoagulant activity by enhancing the expression 
of tissue factor and by suppressing cofactor activity for the anticoagulant 
protein C [57-61]. The prolonged APTT in patients in the present study 
indicates a massive consumption of coagulation clotting factors, leading to 
a bleeding tendency. In addition, the plasma levels of the natural inhibitor 
of coagulation, ATIII, and of protein C and protein S were markedly 
depressed, resulting in a procoagulant state. The hypercoagualability that 
occurs during DIC results in the generation and deposition of fibrin, leading 
to the formation of microvascular thrombosis in various organs and perhaps 
to mUltiple organ failure and ultimately death. In the present study, DIC 
occurred in 13 of the 27 survivors and in all of the nonsurvivors (P = .003). 
Endotoxin, TNF-ct, and IL-lfi modulate the fibrinolytic system to 
secrete both t-PA and PAl-I, which respectively activate and inhibit 
fibrinolysis [62-68]. Moreover, fibrin and thrombin formed during 
coagulation are also potent inducers for the release of t-PA and PAl-I [69, 
70]. Fibrinolysis can be initiated by the release of t-PA from vascular 
endothelium that convelis plasminogen into the active enzyme plasmin that 
degrades fibrin in the thrombi. The activity of t-PA in patients is counter-
regulated by PAI-I that binds to and thereby inhibits t-PA. Protein C can 
inhibit PAl-I activity. In the present study, the levels of PAl-I antigen were 
significantly higher in nonsUivivors. This finding together with decreased 
protein C activity result in insufficient fibrinolytic activity during a 
markedly procoagulant state that is associated with vital organ 
microembilization [19-22]. Administration of recombinant t-PA may 
therefore be considered an adjuvant therapeutic option in patients with 
fulminant meningococcemia as suggested by Zenz et al. [71]. 
In previous studies, PAl-I levels rapidly decreased after hospitalization 
[72, 73], and PAl-I and TNF-ct levels were strongly associated [74, 75]. 
Further analysis of our findings showed that PAl -I levels were significantly 
dependent on the intelval between onset of petechiae and blood sampling 
and survival. Of interest, P AI -I concentrations in this study were 
significantly higher in nonsurvivors at a similar TNF -ct concentration. We 
questioned whether interindividual differences in responsiveness to TNF-ct, 
for example, may contribute to outcome in patients with MSS. The 
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presence of a single base pair insel1ion/deletion (allele frequency 0.53/0.47) 
polymorphism in the promotor of the P AI-I gene has been associated with 
differences in release of PAI-I in postoperative patients [76] and in patients 
with an increased risk of recurrent myocardial infarction [77]. 
The promotor containing the deletion allele produced six times more 
mRNA than the inse!1ion allele in response to IL-IB [78]. The 
insertion/deletion polymorphism in the P AI-I promotor is of functional 
imp011ance in the regulation of the expression of the PAI-I gene [78]. 
These data supp011 the hypothesis that individuals homozygous for the del 
allele may respond with increased PAI-I expression in the acute phase of 
MSS. The possible presence of PAI-I gene polymorphism in patients with 
MSS is strengthened by the relatively low PAl-I response (945 ng/mL) in I 
patient with an extremely high TNF -a level (3130 pg/mL) who survived 
MSS. 
The possible beneficial effects of the HA-IA human monoclonal 
antibody against endotoxin on the outcome of children with MSS is not yet 
known. However, a recent study did not find a reduction in the 14-day 
mortality rate in patients with gram-negative bacteremia and septic shock 
[79]. 
We conclude that high levels of proinflammatory cytokines and 
counterinflammatory compounds are associated with fatality. After the 
levels of inflammatory mediators are adjusted for time after the onset of 
petechiae, the differences between survivors and nonsurvivors disappeared. 
We therefore propose that the outcome in patients with MSS is probably 
not related to TNF gene polymorphism. However, the increased PAl-I 
response to, for example, TNF-a in the fatal cases suggests the presence of 
polymorphism in the expression of the PAl -I gene that may contribute to 
the outcome of MSS. 
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PAI-I polymorphism and meningococcal sepsis 
11.1 ABSTRACT 
Meningococcal sepsis is a life-threatehing disease characterized by diffuse 
intravascular coagulation. Endotoxin and cytokine induced production of 
plasminogen activator inhibitor (P AI)-I is one of the major causes of 
deleterious thrombosis in children with meningococcal sepsis. Previously high 
plasma levels of P AI-I were associated with an increased mortality. A 4G/5G 
genetic polymorphism in the promoter of the PAI-l gene has been associated 
with differences in plasma PAl-I activity. The 4G allele is associated with 
higher basal production of PAl-I and an increased responsiveness to 
stimulation with cytokines and endotoxin. We therefore questioned whether the 
high production of PAl-I in children with meningococcal sepsis was 
associated with this polymorphism. To this purpose DNA samples of37 Dutch 
children who suffered from meningococcal sepsis were analyzed by peR and 
compared with DNA samples from control subjects. The genotype was 
determined by allele specific oligo-melting. The results of this study show that 
the 5G/5G genotype is significantly less present in children with 
meningococcal sepsis in comparison with control subjects. We propose that 
children with meningococcemia and a 4G/4G or 4G/5G genotype have a 
significantly increased production of PAl-I leading to more severe disease 
than in children with a 5G/5G genotype. 
11.2 INTRODUCTION 
Meningococcal sepsis is a life-threatening entity in which the systemic 
inflammatory response on micro-organisms or their products - in palticular 
endotoxins - results in the release of inflammatory mediators, complement 
activation, abnormalities of coagulation and fibrinolysis, endothelial cell 
damage, capillary leakage, myocardial dysfunction, and finally multiorgan 
failure fi'equently followed by death [I]. Endothelial cell secretion of tissue-
type plasminogen activator (t-PA) and plasminogen activator inhibitor (P AI)-I, 
which respectively activate and inhibit fibrinolysis, are principal determinants 
of the procoagulant state in children with meningococcal septic shock. t-PA 
is directly involved in the conversion of plasminogen to plasmin, an active 
protease which degrades and removes fibrin deposits [2]. PAI-I is a 50-kDa 
glycoprotein, which inhibits t-PA [3]. PAl-I is in vitro produced by several 
cell types including endothelial cells, hepatocytes, platelets, and smooth 
muscle cells. 
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Previously, we and others found significantly increased plasma levels of 
PAI-I antigen in children with meningococcal septic shock [4,5]. High initial 
plasma levels of PAI-I are associated with an increased mOltality [4]. Serum 
levels of tumor necrosis factor (1NF)-a, which is in vitro one of the 
stimulators of PAI-I production [6] are also significantly higher in non-
survivors versus survivors [4]. We simultaneously detected an association 
between the duration of skin lesions and serum levels of both PAl -1 and 1NF-
a. Differences in 1NF-a levels between survivors and nonsurvivors 
disappeared after adjustment for the duration of skin lesions. However, these 
differences were after adjustment still statistically significant for PAl-I. 
FUlthermore, PAI-I concentrations were significantly higher in nonsurvivors 
at a similar 1NF-a concentration [4]. This suggests that differences in the 
innate PAI-I response to 1NF-a may playa role in the outcome of disease. 
Recently, a common polymorphism in the promoter of the PAl -1 gene has 
been associated with an increased risk for myocardial infarction and coronary 
artery disease in adults with non-insulin-dependent diabetes mellitus [7-10]. 
This increased risk is probably caused by an allele-specific increase in the 
transcription of the PAI-I gene, resulting in a significantly higher production 
of PAI-I antigen especially after stimulation with cytokines such e.g. TGFB, 
IL-I, and 1NF-a [7, 11]. 
We questioned on the basis of our clinical and laboratory observations 
whether the 4G/5G polymorphism in the PAl -1 gene promoter could be 
associated with an increased risk.for meningococcal sepsis. To this pUlpose, 
DNA samples from 37 Dutch children who suffered fi'om meningococcal 
sepsis were analyzed. 
11.3 MATERIALS AND METHODS 
Patients and controls. 
A total of 37 children with meningococcal sepsis admitted to the pediatric 
intensive care unit (PICU) of the Sophia's Children Hospital were included in 
this study. The control population was a group of 137 infants between 3 
months and I year who participated in a study to evaluate the immunogenicity 
of a combined vaccine against diphtheria, peltussis, tetanus, poliomyelitis and 
Haemophilus injluenzae. Children between 3 months and 18 years with septic 
shock and petechiae or pUlpura were prospectively recruited between January 
1992 and December 1995. Meningococcal infection was documented by a 
positive culture of blood, CSF or skin biopsy specimen or by serological tests. 
Patients were eligible for inclusion if they met the following criteria: The 
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presence of shock (systolic blood pressure < 75, < 80, < 85, or < 100 mm Hg 
in children ages 3 months to I year or 1-5, 6-12, and> 12 years old, 
respectively). Children were also included when poor end-organ perfusion was 
present (defined as occurrence of at least two of the following criteria): (l) 
unexplained metabolic acidosis (pH S; 7.3), base excess -5 mmol/L or lower, 
or atterial plasma lactate levels> 2.0 mmol/L; (2) atterial hypoxia (P02 S; 75 
mm Hg, P02-to-Fi02 ratio < 250, or Tc02 S; 96% in patients without ovett 
cardiopulmonaty disease); (3) acute renal failure (oliguria with urine output 
< 0.5 mLlkg/h for> I h despite acute volume loading or evidence of adequate 
intravascular volume and without preexistent renal disease); or (4) sudden 
deterioration of the patient's mental status. 
On admission to the pediatric intensive care unit, the severity of illness 
was assessed using the pediatric risk for mortality (PRISM) score, a severity-
of-illness index [12]. 
Genetic analysis of the PAI-l promoter polymorphism. 
DNA was prepared fi'om serum or blood using a standard small-scale 
isolation technique. An 890-bp region of the PAI-l promoter from each 
subject was amplified using the polymerase chain reaction (PCR), and the 
genotype was determined by allele-specific oligo (ASO) melting, as described 
by Dawson and coworkers [II]. Controls for ASO melting consisted of DNA 
samples of known genotype determined by DNA sequence analysis. 
Statistical analysis. 
A X2 test was used to compare the observed numbers of each PAl-I 
genotype with those expected for a population in Hardy-Weinberg equilibrium. 
Allele fi'equency was estimated by gene counting and X2 analysis. 
11.4 RESULTS 
DNA samples of 37 patients with meningococcal septic shock (21 boys, 
16 girls) were analyzed. The median age of the patients was 4.1 years (range, 
0.5-17.9 years). The PRISM scores at PICU admission ranged from 1 to 25. 
The mortality rate of this group of patients was 30%. The results of the 
genetic analysis of patients and control subjects are presented in the Table. A 
section of the ASO melting autoradiograph is shown in Figure 1. The PAl-I 
4G/5G polymorphism was in Hardy-Weinberg equilibrium in the healthy 
controls. The genotype distribution was significantly different between patients 
and controls (P = .03). However, differences in genotypic distribution between 
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survivors and nonsurvivors were not found. The risk of meningococcal sepsis 
was significantly higher in patients homozygous or heterozygous for the 4G 
allele in comparison with those homozygous for the 5G allele. 
Table. Distribution of 4G/SG genotypes in children with meningococcal sepsis and controls. 
Patients 
(II ~ 37) 
No. (%) wilh 50/50 genotype 2 ( 5) 
No. (%) with 40/50 genotype 24 (65) 
No. (%) with 40/40 genotype II (30) 
Relative risk 
Frequency of 50 allele 0.38 
Frequency of 40 allele 0.62 
6.0 
(1,4 - 26.3) 
Controls 
(II ~ 137) 
35 (26) 
70 (51) 
32 (23) 
0,49 
0.51 
The relative risk of meningococcal sepsis between patients groups and controls with the 50/50 
genotype and subjects with the 40/50 and 50/50 genotype was calculated. The 95% confidence 
interval is shown in parentheses. The allele frequency was detennined by gene counting. A 
comparison between patients with meningococcal sepsis and controls revealed a difference in 
genotypic distribution (P ~ .03) and in allele frequency (P ~ .04). 
11.5 DISCUSSION 
PAI-l is a 50-kDa plasma protein involved in the inhibition of 
fibrinolysis. The production ofPAI-l is stimulated by TNF-o., IL-l, TGFJ3 and 
endotoxin [6]. These proinflammatory molecules are released at high levels in 
patients with meningococcal sepsis leading to activation of coagulation, 
inhibition of fibrinolysis, the development of a hypercoagulable state, fibrin 
deposition, and microthrombi [13]. These fonn the basis for the extensive 
endothelial damage and multiple organ failure and ultimately death in children 
and adults with meningococcal sepsis [14]. One could infer ji'om these 
findings that a higher production ofPAI-1 in patients with meningococcemia 
might contribute towards more serious disease. The results of the CutTent study 
clearly indicate that polymorphism in the promoter of the P AI -1 gene is 
associated with the development of meningococcal sepsis. We found that the 
distribution of P AI-I polymorphisms was in Hardy-Weinberg equilibrium in 
control subjects. In contrast, patients with meningococcal sepsis had a 
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significantly decreased 5G allele frequency, whereas the 5G/5G genotype was 
significantly underrepresented. Previously Dawson et al. have shown by in 
vitro experiments that the presence of a 4G/5G polymorphism is associated 
with a significantly higher mRNA production of PAl-I in response to 
interleukin (IL)-I [II]. They suggested that individuals homozygous for the 
4G allele might have a different response to acute phase proteins [II]. Several 
investigators subsequently reported that the 4G/5G genetic polymorphism in 
the promoter of the PAI-I gene is associated with differences in PAI-I activity 
in adults with non-insulin-dependent diabetes mellitus, coronary artery disease 
and myocardial infarction [7-10]. Ye et al. reported an association between 
homozygosity for the 4G allele and elevated PAI-I plasma levels and impaired 
fibrinolysis, although they did not find an increased risk for myocardial 
infarction in this study [15]. The increased PAI-I levels in patients with one 
or two 4G alleles versus those homozygous for the 5G allele are attributed to 
the absence of a DNA binding site for a repressor protein on the 4G allele [7]. 
This results in an increased basal expression of PAI-I transcription. 
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Figure. ASO melting atltoradiograph demonstrating the 40/5G polymorphism in 18 healthy controls 
(lanes I to 18). 40: the 40 allele; 50: the 50 allele. The control DNAs homozygous 40 (lane 19), 
heterozygous 40/50 (lane 20) and homozygous 50 (lane 21) are also included 
We propose that patients with meningococcemia and a 4G/4G or 4G/5G 
genotype have a significantly increased production of PAI-I leading to more 
severe disease than in children with a 5G/5G genotype. Altematively, children 
with a 5G/5G genotype may develop milder disease or acquire meningitis. We 
previously showed that P AI-I plasma levels were significantly higher in 
nonsurvivors in comparison with survivors of meningococcal sepsis [4]. This 
raises the question whether 4G/5G polymOlphisms of the P AI-I gene is also 
associated with mOl1ality. However, analysis of differences between survivors 
and nonsurvivors yielded negative results. 
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Previously Bredius et al. rep011ed that a genetic polymorphism in the Fcy 
receptor IIa on phagocytes contributes to the susceptibility for meningococcal 
sepsis (16). Westendorp et al. recently suggested that interindividual 
differences in the release of tnmor necrosis factor may also influence to the 
outcome of meningococcal disease (17]. Our data and those of previous 
investigators clearly underscore the need for fiu1her studies to unravel the 
complex genetic factors involved in the host response against and the outcome 
of patients with meningococcal disease. 
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Inilial levels of interleukin-12 
12.1 ABSTRACT 
Plasma levels of interleukin (IL)-12, a recently described cytokine 
consisting of two different polypeptide subunits (p40 and p35), were 
measured together with interferon (IFN)-y and other cytokines in 46 
children with septic shock and purpura. The median (range) plasma IL-12 
p40 level on admission was 457 (244-2677) pglmL in non-survivors versus 
189 « 40-521) pgfmL in survivors (P < .001). IL-12 p70 levels were 
elevated in only 9 patients. IL-12 p40 plasma levels were positively 
correlated with tumor necrosis factor (TNF)-a, IL-6, IL-8, IL-IO and 
PRISM-score, whereas they were negatively cOlTelated with CRP, WBC 
and serum glucose levels. Twelve (29%) of the patients had detectable 
levels of IFN-y. Thus, circulating levels of IL-12 p40 and to a lesser extent 
those of IL-12 p70, are elevated in children with septic shock and purpura, 
and cOll'elate with severity of disease and outcome. 
12.2 INTRODUCTION 
Septic shock with purpura is a clinical syndrome predominantly caused 
by N. meningitidis and characterized by a sudden onset and rapid 
progression of disease. Children younger than 10 years are most fi'equently 
affected. Lipopolysaccharides (LPS) released from gram-negative bacteria 
such as meningococci initiate the production of pro-inflammatory cytokines 
by cells of the mononuclear-macrophage lineage and endothelial cells. 
Circulating levels of these cytokines, including tumor necrosis factor 
(TNF)-a, interleukin (IL)-I [I), IL-6 [1, 2), IL-8 [3), and IL-I0 [4, 5), are 
increased in children with septic shock and purpura. Severity of disease is 
related to the initial plasma levels of LPS [6) and of these cytokines. 
Interleukin-12 is a recently described cytokine [7, 8) initially called 
natural killer cell stimulatory factor or cytotoxic lymphocyte maturation 
factor. Among cytokines, IL-12 is unique in that it is a heterodimeric 
protein composed of two different polypeptide subunits, p40 and p35 (for 
review: [8-14]). The precise role of IL-12 in vivo is not known, although 
this cytokine seems to play a key role in the differentiation of Th1 cells 
[10, 15), and in the host defense against bacterial, parasitic and viral 
infections [8). IL-12 also induces the production of interferon (IFN)-y by T-
cells and natural killer (NK)-cells [16, 17]. The plasma levels of IFN-y are 
increased in experimental models for sepsis [18-20) as well as in human 
sepsis [21, 22), although not consistently [1). Recently, IL-12 was 
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characterized as a major cytokine in the pathogenesis of gram-negative 
endotoxemia in mice [16) and in primates [23). We therefore questioned 
whether IL-12 and IFN-y play a role in the pathogenesis of septic shock 
and purpura in humans. To this purpose initial plasma levels of IL-12 and 
IFN-y were measured in children with this disease and their relation with 
outcome and severity of disease were studied. In addition, plasma levels of 
TNF -u, IL-6, IL-8, and IL-IO were determined and the possible correlation 
between these cytokines and IL-12 and IFN-y, respectively, was studied. 
12.3 PATIENTS AND METHODS 
Study protocol 
Children above 3 months and below 18 years of age with septic shock 
and petecchiae/purpura were enrolled in this study. Primary or secondary 
referrals were admitted to the pediatric intensive care unit (PICU) of the 
Sophia Children's Hospital between April 1991 and October 1994 Patients 
were eligible for inclusion when they met the following criteria: 1. presence 
of petecchiae/purpura for less than 12 hours; 2. presence of shock defined 
as sustained hypotension (systolic blood pressure < 75 mm Hg for children 
between 3-12 months, < 80 mm Hg for 1-5 years, < 85 mm Hg for 6-12 
years, < 100 mm Hg for children older than 12 years) requiring intensive 
care treatment, or evidence of poor end-organ perfusion, defined as at least 
two of the following: a. unexplained metabolic acidosis (PH S; 7.3 or base 
excess S; -5 mmollL or plasma lactate levels > 2 mmollL); b. arterial 
hypoxia (PaO, S; 75 mm Hg, a PaO,lFiO, ratio < 250, or a transcutaneous 
SaO, S; 0.96) in patients without ovett cardiopulmonary disease; c. acute 
renal failure (diuresis < 0.5 mLlkg/hr for at least one hour despite acute 
volume-loading or evidence of adequate intravascular volume) without 
preexisting renal disease; or d. sudden deterioration of the baseline mental 
status. The pediatric risk of mOitality (PRISM) score [24) was calculated 
using the most abnormal value of each variable recorded during the first 4 
hours after admission at the PICU. All patients received maximal 
supportive therapy: antibiotics, volume suppletion, inotropic SUppOlt, and 
mechanical ventilation. Informed consent was obtained from the parents or 
legal representatives. The Medical Ethics Committee of the University 
Hospital Rotterdam approved the study protocol. 
200 
Initial levels of interleukin-12 
Collection of blood 
On admission arterial blood was collected within two hours. Blood for 
cytokine analysis was collected in vials containing 3.S% trisodium citrate, 
immediately chilled on ice, and centrifuged at 2S00 g for 15 minutes and 
then at 45,000 g for 30 minutes at +4°C. Plasma was stored at -70°C until 
tests were performed. 
Assays 
White blood cell (WBC) count, as well as lactate, glucose and C-
reactive protein (CRP) levels were determined routinely. WBC counts were 
determined using a flow cytometer (Tec1micon HI-system, Technicon 
Instruments, N.Y.). Lactate was measured by enzymatic endpoint deter-
mination. CRP by a nephelometric assay [25]. 
Plasma levels of TNF-a, IL-6, IL-S, IL-IO, and IFN-y were measured 
with enzyme-linked immunosorbent assays obtained from the Depal1ment 
of Immune Reagents (Central LaboratOl), of the Bloodtransfusion service 
CLB, Amsterdam) and were performed according to manufacturers' 
instructions. Normal levels (detection limit, taking the dilution of samples 
into account) for these assays are: < 5 (1 pg/mL) for TNF-a; < 10 (I 
pg/mL) for IL-6; < 20 (4 pg/mL) for IL-S; < 30 (30 pg/mL) for IL-IO; < 10 
(2 pg/mL) for IFN-y. 
Assays of IL-12 
IL-12 p40 antigen was measured with an ELISA [26]. Briefly, 
mAbCIl.79 and biotinylated mAbCS.6, both directed against the IL-12 p40 
subunit [27], were used as coating and detecting antibodies, respectively. 
Streptavidin polymerized horseradish peroxidase (poly-HRP; CLB, 
Amsterdam, The Netherlands) was used to quantify bound antigen. 
Recombinant human p40 was used as a standard. Taking the dilution of 
tested samples into account, the lower limit of detection was 20 pg/mL. 
Normal values in 21 healthy adults were ~ 160 pg/mL. We measured the 
IL-12 p40 levels in 5 normal children age: 43 months (36-4S), the median 
value was: 2S pg/mL. As levels of IL-12 p40 were similar in children and 
adults (and healthy children of young age are difficult to obtain blood 
from), we used both groups together as control for the septic children. 
IL-12 p70 antigen was measured using a newly developed ELISA [23]. 
Sh0l11y, mAb20C2, which has relative specificity for the IL-12 p70 
heterodimer [27], and mAb CS.6 were used as a capture and detecting 
antibodies, respectively. The ELISA did not measure recombinant human 
p40 unless concentrations > 20 ng/mL were tested. In contrast, recombinant 
human p70, which was used as a standard, could be detected at 
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concentrations as low as 0.25 pg/mL. To avoid cross reaction with the p40 
chain, plasma samples were analyzed at least at a tenfold dilution. 
Therefore, the actual detection limit was 2.5 pg/mL. Normal values are 
below this detection limit. 
Statistical analysis 
Results are expressed as medians (range) unless otherwise specified. 
Differences between groups were tested with the Mann-Whitney test or 
Fisher's Exact test in case of percentages. Correlation coefficients given are 
Spearman's. Two-tailed P values <:; .05 were considered statistically 
significant. 
12.4 RESULTS 
Patients 
Forty-six patients admitted to the PICU were enrolled in the study: 29 
males (63%) and 17 females (37%). The median age was 3.4 years (range 
0.5-17.9). Cultures of blood, cerebrospinal fluid or skin biopsies revealed 
Neisseria meningitic/is in 40 patients and Haemophilus influenzae in 1 
patient. Cultures were sterile in 5 patients. Thilty-one (67%) patients 
needed mechanical ventilation. FOity-four of the children palticipated in a 
randomized, placebo controlled trial to study the efficacy of a human 
monoclonal antibody against endotoxin, HA-IA (Centoxin', Centocor, 
Malvern, PA, USA), in meningococcal septic shock. HA-IA or placebo 
were administered after blood was collected for the determination of 
cytokines and other laboratory parameters. Twenty four of these patients 
were treated with a placebo, 17 patients survived (71 %) 7 patients died 
(29%). The results of only these 24 patients were used for outcome 
analysis. 
Clinical and laboratory parameters 
Clinical and laboratory parameters obtained on admission (PRISM-
score, arterial lactate, WBC count, selUm levels of glucose and CRP) for 
the total group and separately for survivors and non-sUlvivors of the 
placebo group, are indicated in Table 1. As expected, all parameters were 
significantly associated with outcome. 
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Table 1. Clinical and laboratory parameters on admission of children with septic shock 
with purpura and their relation with outcome, 
Total group Survivors* Nonsurvivors* P 
(1/ = 46) (1/ = 17) (1/ = 7) 
Age (years) 3.8 (0.5-17.9) 4.9 (0.5-17.9) 2.2 (1.4-12.3) .259 
Male I female 29/17 918 3/4 .653 
PRISM (score) 13 (1-38) 9 (1-20) 21 (17-25) <.001 
Lactate (mmoVL) 5.0 (1.1-20.0) 4.2 (l.l-15.5) 7.2 (4.0-20.0) .047 
WEC (xlO'/L) 9.2 (1.3-44.4) 17.0 (6.1-44.4) 4.9 (1.3-8.2) <.001 
Glucose (mmollL) 5.6 (1.0-14.2) 8.4 (1.9·14.2) 2.8 (1.0-10.1) NS 
CRP (mg/L) 110 (34-250) 167 (39-250) 70 (38-162) .002 
All data shown are median (range); *data shown were obtained in patients that did not receive 
mAb; P-value for the difference between survivors and non-suvivors (?viann-Whitney test). 
Abbreviations: PRISM, pediatric risk of mortality; WBC, white blood cell; eRP, C-reactive 
protein; NS, not significant. 
IL-12 p40 and p70 levels on admission 
Levels of IL-12 p40 in surviving (and also in non-surviving) patients 
were significantly higher than in the controls (P < .001).The median (range) 
plasma IL-12 p40 level on admission (Figure I) was 457 (244-2677) 
pglmL in non-survivors versus 189 (40-521) pglmL in survivors (P < .001). 
In contrast, IL-12 p70 was elevated in only 9 patients. The median level of 
IL-12 p40 for those patients with detectable IL-12 p70 levels (n = 9) was 
significantly higher (P = .007) in comparison with those without detectable 
levels of IL-12 p70 (n = 32): 457 (76-2677) and 207 (40-1007), 
respectively. The ratio (P40/p70) in the 9 patients with detectable IL-12 p70 
levels was 117 (26-203) (Figure 2). 
Table 2. COl'relation between IL-12 p40 and TNF-a, IL-6, IL-8, 01' IL-IO on admission of 
children with septic shock and purpura. 
IL-12 p40 
(1/ = 41) 
r* p 
TNF-a .45 .003 
IL-6 .56 <.001 
IL-8 .60 <.001 
IL-lO .51 .001 
*Speannan's rank coefficient of correlation. Abbreviations: TNF, tumor necrosis factor; IL, 
interleukin. 
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Table 3. Correlation between IL-12 p40 and several clinical or laboratory parameters on 
admission of children with septic shock and purpura. 
IL-12 p40 
(/I ~ 44) 
r* p 
PRISM .42 .005 
Lactate .16 .286 
WBC -.56 <.001 
Glucose -.39 .01 
CRP -.33 .028 
*Spearman's rank coefficient of correlation. Abbreviations: PRISM, pediatric risk of mortality; 
WBC. white blood cell; eRP, C-reactive protein. 
Relation between IL-12 and other cytokines on admission 
IL-12 p40 plasma levels on admission were positively con'elated with 
TNF-a, IL-6, IL-8, and IL-IO (Table 2). The association between IL-12 p70 
and the other cytokines was different in comparison with that between IL-
12 p40 and the other cytokines. Patients with detectable IL-12 p70 levels 
had significantly higher levels of IL-8 (P = .042) and IL-12 p40 (P = .007) 
levels than patients with undetectable levels of IL-12 p70. 
Relation of IL-12 to clinical and laboratory parameters 
A negative correlation was found between CRP levels or WBC versus 
plasma IL-12 p40 levels (Table 3). Plasma IL-12 p40 levels correlated 
positively with the PRISM-score and negatively with selUm glucose levels. 
Patients with detectable levels of IL-12 p70 had significantly lower selUm 
glucose levels (P = .019). 
Interferon-'Y 
Twelve of the 41 (29%) patients had detectable levels of IFN-y. In 
those 12 patients, levels of TNF-a, IL-6, IL-8, and IL-IO, but not IL-12 
p40 were significantly (P < .005) increased in comparison with patients 
with undetectable levels of IFN-y. In addition, those 12 patients had 
significantly (P < .005) lower WBC and a significantly (P < .05) higher 
serum lactate. From the 9 patients with a detectable level of IL-12 p70, 5 
had a detectable level of IFN-y (56%), while fi'om the 30 patients without 
detectable levels of IL-12 p70, only 6 had a detectable level of IFN-y 
(20%). Due to small numbers this difference just did not reach statistical 
significance (P = .08). 
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12.5 DISCUSSION 
This is the first report showing that levels of IL-12 p40, and to a lesser 
extent those of IL-12 p70, are elevated in meningococcal sepsis. Plasma 
levels of IL-12 p40 were related to outcome and to severity of disease. 
IL-12 or NK cell stimulatory factor is a recently described [7] 
heterodimeric cytokine, which appears to play an important role as a 
functional bridge between natural resistance and adaptive immune response 
[12]. During endotoxemia in mice, IL-12, both p40 and p70, was detected 
Sh0111y after injection of LPS. Bioactive IL-12 circulated in semm before 
the appearance of IFN-y. Pretreatment with anti-IL-12 antibodies blocked 
the production of IFN-y [16], thus protecting against lethality [17]. Similar 
findings were reported in a model of a generalized Shwat1zmann reaction in 
mice [2S]. In baboons challenged with Escherichia coli [23], the systemic 
release of IL-12 p40 and p70 was also rep011ed. Our study confirms that 
circulating levels of IL-12 are also increased in human sepsis. 
IL-12 p70 was detected in only 9 of the patients and these levels were only 
slightly increased. In these 9 children IL-S, IL-12 p40 and IFN-y levels 
were significantly higher than in patients with undetectable IL-12 p70. 
Levels of p40 were approximately 100 times higher than those of p70. Such 
an excess-production of IL-12 p40 was also found in in vitro experiments 
with human peripheral mononuclear [10, 27] and polymorphonuclear cells 
[29] as well as in septic baboons [23]. The physiological significance of 
this excess-production of the free p40 subunit in comparison with the 
biologically active p70 heterodimer is not clear. It has been suggested that 
the p40 subunit has a biological activity distinct from that of p70 
heterodimer. Mattner et a!. have suggested that IL-12 bioactivity is 
inhibited by free p40 molecules [30]. Studies by Ling et a!. [31] revealed 
that human p40, as described in mice, exists in a monomeric and dimeric 
form. Again as in mice, the dimeric form was at least 20-fold more 
effective than the monomer to inhibit the activity of IL-12 or its binding to 
human IL-12 receptor (IL-12R). However, in contrast to the mouse 
homodimer, which binds to the mouse IL-12R with similar affinity as 
heterodimeric mouse IL-12 itself, the receptor binding and bioactivity of the 
human homodimer were only 10 % of the receptor binding and bioactivity 
of the human heterodimer. Perhaps the excess production of p40 in relation 
to the p70 has a regulatory role [32, 1995]. Nevertheless, in vitro an in vivo 
studies have clearly shown that the production of p40 is linked to that of 
IL-12 [S, 23], and hence elevated levels of p40 subunit in our patients 
probably reflected the production of bioactive IL-12. Consistent herewith 
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Figure 1. Plasma levels of IL-12 p40 on admission of children with septic shock with purpura 
(placebo treated, 11 = 24) and of healthy controls (11 = 26). Solid lines represent median values. 
Dotted lines indicate the range of normal values. 
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Figure 2. Scattergram of IL-12 p40 versus IL-12 p70. Data represent the levels on admission. 
Dotted lines represent the lower detection limits. 
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was the observation that patients with detectable IL-12 p70 levels had 
higher IL-12 p40 levels than those without detectable IL-12 p70 levels. 
Apparently the threshold of the IL-12 p70 assay is too high. 
The positive correlation between plasma levels of IL-12 p40 or p70, and 
other proinflammatory cytokines, was not surprising since this probably 
reflects stimulation of cells by endotoxins. However, plasma levels of IL-
10, a counter-inflammatOlY cytokine, also correlated positively with IL-12. 
In vitro, IL-IO is a potent inhibitor of LPS-dependent IL-12 production [29, 
33, 34]. Moreover, a negative correlation between IL-IO and IL-12 was 
found in baboons with sepsis suggesting that IL-IO dowmegulates the 
release of IL-12 in this sepsis model [23]. Thus, the positive correlation 
between IL-12 and IL-IO in our patients was in contrast to the findings in 
baboons. We propose that the synthesis of pro- and anti-inflammatory 
cytokines is so strongly and continuously stimulated [5, 35] in patients with 
meningococcal sepsis, that counterregulatory mechanisms are insufficient 
to suppress excessive production. 
IL-12 can induce IFN-y production by T- and NK-cells in the presence of 
cofactors as TNF-a or IL-I p [7]. The role of IFN-y during in vitro LPS-
challenge [33], in vivo endotoxemia in mice [16-20], or the generalized 
Shwartzmann reaction in mice [28, 36, 37], has well been established. 
Disseminated intravascular coagulation and shock associated with 
meningococcal sepsis are considered to be the clinical countelpalis of the 
"classical" generalized Shwatizmann reaction. However, it is not known 
whether IFN-y similarly contributes to mOliality in human sepsis. IFN-y 
levels and outcome were not cOlTelated in adult patients with septic shock 
[22] and in children with meningococcal septic shock [I]. In contrast, 
Girardin et al. repOlied high levels of IFN-y in children with severe 
meningococcal septic shock. Their plasma concentrations of IFN-y were 
related to severity of the disease and correlated with serum levels of TNF-a 
[21]. In our study only 12 patients had plasma IFN-y levels above the 
detection limit. Those children also had significantly higher levels of other 
cytokines. The propOliion of children that had elevated IL-12 p70 levels 
was higher, although just not significantly, in the group with detectable 
IFN-y, compared to the group with undetectable IFN-y. A possible 
explanation for the absence of a relation between IFN-y and IL-12 p40 is 
that these cytokines were not released simultaneously, as was observed in 
animal models for sepsis [23]. 
The clinical and laboratory parameters in this study are commonly used to 
assess the severity of disease in patients with meningococcal septic shock. 
PRISM score is a scoring system to calculate the risk of mOliality in 
pediatric intensive care patients [24]. Serum lactate is related to the degree 
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of circulatory failure [2]. WBC and CRP are negatively correlated with the 
fulminant evolution of meningococcal septic shock [38, 39]. Low serum 
glucose levels are rep011ed by some authors [40], although this finding is 
not well understood. IL-12 p40 levels in our patients, correlated with all 
these parameters reflecting severity of the disease, except for serum lactate. 
IL-12 p70 was only related to low serum glucose. IFN-y was negatively 
related to the WBC. 
In conclusion, this study is the first to rep011 a systemic release of IL-
12 and its relation with outcome, severity of disease and other cytokines, in 
children with septic shock and purpura. We suggest that new 
immunomodulatory agents in sepsis should also be studied for their effects 
on IL-12 production. 
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Age-related differences of DIe in children 
13.1 ABSTRACT 
We studied the influence of age on mortality and severity of clotting 
abnOimalities in 79 children (median age: 3.1 years) with meningococcal 
sepsis. Parameters of coagulation and fibrinolysis and plasma levels of 
cytokines were prospectively measured on admission. The mortality rate 
was 27%. The age of survivors was significantly different from that of non-
survivors (P = .013). With the exception of FVII, vWF and t-PA, 
parameters of coagulation and fibrinolysis, as well as plasma cytokine 
levels were related to outcome. Patients were divided in two groups: 
younger and older than median age. The mOitality in children :<;; 3.1 years 
was 40% versus 13% in children > 3.1 years (P = .006). In contrast to 
cytokine levels, which were not different between the two age groups, 
fibrinogen, prothrombin, factors V, VII, VIII, vWF, protein C, antithrombin, 
FDP, and the ratio PAI-llt-PA were related to age, indicating a more severe 
coagulopathy in children :<;; 3.1 years despite a similar degree of 
inflammatory response. A relative deficiency of coagulation factors due to 
an immature state of the clotting system, as well as an inadequate 
fibrinolytic response, both related to age may have caused this more severe 
coagulative response in younger children, and may have contributed to the 
higher mOitality rate. 
13.2 INTRODUCTION 
Septic shock with pUlpura is an ovelwhelming, rapidly progressive and 
often fatal syndrome. This syndrome is fi'equently diagnosed in children 
and adolescents and predominantly caused by Neisseria meningitidis and. A 
key event in the pathophysiology is disseminated intravascular coagulation 
(DIC), leading to microvascular thrombosis and end-organ damage during 
the early stage and occasionally to permanent tissue destruction and 
amputation. Septic pUlpura associated DIC is characterized by a marked 
activation of coagulation, consumption of platelets and coagulation proteins, 
and inhibition of the activated fibrinolytic system [1-5]. Natural anti-
coagulants, such as antithrombin (ATIII) and protein C and S play an 
impOitant role in this process [6-9]. Levels of protein C and S are decreased 
in septic shock and purpura, which may explain the severe procoagulant 
state [8, 10-17]. Although consumption of protein C celtainly contributes to 
the decreased levels, immaturity of the protein C system may also play a 
role. The latter could explain the rapid evolution and the high incidence of 
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purpura fulminans in young children [16]. We observed the highest 
mortality in our population in younger patients. We therefore questioned 
whether higher mOltality in young children is associated with more severe 
clotting abnormalities. To this purpose coagulation and fibrinolysis 
parameters and plasma levels of tumor necrosis factor (TNF)-a., interleukin 
(IL )-6, 8, 10 were pi'ospectively measured on admission of children with 
septic shock and purpura. The relation between these parameters and the 
ou'kome and severity of disease was studied. 
13.3 PATIENTS AND METHODS 
Study protocol 
. Childt;en above 3 months and below 18 years of age with septic shock 
and petechiae/purpura were enrolled in this study after informed consent 
was obtained fi'om their parents or legal representatives. They were 
admitted to the pediatric intensive care unit (PICU) of the Sophia Children's 
Hospital between August 1988 and December 1994. Our PICU is the only 
center for pediatric intensive care in the south-westem part of The 
Netherlands. All children younger than 14 years who need pediatric 
intensive care are referred to the PICU. Children between 14 and 18 years 
are occasionally referred to adult intensive care units itTespective of the 
severity of disease. Patients were eligible for inclusion when they met the 
following criteria: I. presence of petechiae/purpura for less than 12 hours; 
2. presence of shock defined as sustained hypotension (systolic blood 
pressure < 75 mm Hg for children between 3-12 months, < 80 mm Hg for 
1-5 years, < 85 mm Hg for 6-12 years, < 100 mm Hg for children older 
than 12 years) requiring intensive care treatment, or evidence of poor end-
organ perfusion. The latter was defined when at least two of the following 
criteria were present: a. unexplained metabolic acidosis (PH ~ 7.3 or base 
excess ~ -5 mmollL or plasma lactate levels > 2 mmollL); b. atterial 
hypoxia (Pa02 ~ 75 mm Hg, a Pa02IFi02 ratio < 250, or a transcutaneous 
Sa02 ~ 0.96) in patients without ovett cardiopulmonary disease; c. acute 
renal failure (diuresis < 0.5 mLlkg/hr for at least one hour despite acute 
volume repletion or evidence of adequate intravascular volume defined by 
the presence of a palpable liver, a cardiothoracic ratio on chest radiography 
> 0.4, and a central venous pressure> 5 mmHg) without pre-existing renal 
disease; or d. sudden deterioration of the baseline mental status. The 
pediatric risk of mortality (PRISM) score [18] was calculated using the 
most abnol'lllal value of each variable recorded during the first 4 hours after 
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admission at the PICU. All patients received maximal suppOltive therapy: 
antibiotics, volume-administration, inotropic SUppOlt, and mechanical 
ventilation. Disseminated intravascular coagulation (DlC) was defined by 
the combination of three of the following features: platelet count less than 
150x1091L, fibrinogen levels below 2 giL, factor V less than 60%, or 
increased levels of fibrin and fibrinogen degradation products (FDP). The 
study protocol was approved by the Medical Ethics Committee of the 
University Hospital Rotterdam. 
Collection of blood 
Within two hours after admission mterial blood samples were 
collected. Blood for analysis of cytokines and coagulation parameters was 
collected in vials containing 3.S% trisodium citrate and in CTAD tubes 
(containing citrate-theophylline-adenosine-dipyridamole). The vials were 
immediately chilled on ice, and centrifuged at 4000 g for 10 minutes and 
then at 20,000 g for 30 minutes at +4°C. Plasma was stored at -SO°C until 
tests were performed. 
Assays 
White blood cell and platelet counts were determined using an 
automated platelet counter (Technicon HI-system, Technicon Instmments, 
N.Y.). Lactate was measured by enzymatic end-point determination and 
CRP by nephelometric assay [19). Plasma levels of TNF-o:, IL-6, IL-8, and 
IL-IO were measured with enzyme-linked immunosorbent assays obtained 
fi'om the Depmtment of Immune Reagents (CLB, Amsterdam) and were 
performed according to manufacturers' instructions. Normal levels 
(detection limit, taking the dilution of samples in the assays into account) 
for these assays are: < 5 (1 pglmL) for TNF-o:; < 10 (I pglmL) for IL-6; 
<20 (4 pglmL) for IL-8; < 30 (30 pglmL) for IL-IO. The clotting assays as 
well as the clu'omogenic assays were performed with commercially 
available reagents and methods fi'om Behring Diagnostica (Behring-Werke 
A.G., Marburg, Germany). The enzyme-Iinked-immuno-sorbent (ELISA) 
determinations were done with reagents from Diagnostica Stago (Asnieres 
sur Seine, France). Results are expressed in % of normal adult values 
unless indicated otherwise. The activated paltial thromboplastin time or 
coagulation time, surface induced (APTT) was measured with the 
Neotromtin reagent, in which vegetable phospholipids and ellagic acid as a 
particulate activator are used. (N 28-40 seconds). Fibrinogen was 
determined with a modified Clauss method [20) (N > 2 gIL). The activities 
of coagulation prothrombin, factors VII, V and X were measured by one 
stage clotting assays, based on the coagulation time, tissue factor-induced, 
215 
Chapter 13 
Table 1. Clinical and laboratory parameters on admission in children with septic shock and 
purpura in relation with outcome and age, 
Parameter Total group Survivors Nonsurvivors ::;; 3.1 years > 3.1 years 
(/I = 79) (/I = 58) (/I = 21) (/I = 40) (/I = 39) 
Age (years) 3.1 4.4 2.1 1.3 9.0 , 
(0.3-17.9) (0.3-17.9) (0.4-12.3) (0.3-3.1) (3.2-17.9) 
Sex (male/female) 47/32 35/23 12/9 26114 21118 
Need for inotropics 74 (94%) 53 (91%) 21(100%)§ 38 (95%) 36 (92%) 
Mechanical ventilation 51 (65%) 30 (52%) 21 (l00%)§ 33 (83%) 18 (46%)§ 
PRISM 14 II 21 17 8 
(1-44) (1-38) (8-44)§ (8·44) (1-25)§ 
DIC 62177 (81%) 42/57 (74%) 20/20 (IOO%)t 33/39 (85%) 29/38 (76%) 
Lactate (mmollL) 5.0 4.2 7.3 5.1 4.4 
(l.1 -20.0) (1.1-15.5) (2.9-20.0)§ (1.8-16.7) (Ll-20.0) 
WBC (xIO'IL) 8.1 12.5 5.3 6.4 12.9 
(1.3-44.4) (1.4-44.4) (J.3-12.9)§ (1.3-26.5) (1.4-44.4)t 
Glucose (mmollL) 5.8 6.8 3.7 4.9 6.9 
(1.0-14.2) (1.0-14.2) (1.0-10.1)1 (1.0·11.4) (1.3-14.2)! 
CRP (mgIL) 98 132 65 80 128 
(14-250) (34-250) (14-162)§ (14-224) (38-258)' 
Values are medians (range) or numbers (%); significance of the difference between groups 
(Mann-Whitney U-test or Fisher's exact test): *p s .05, tp s .01, tp s .005, §p s .001. 
Abbreviations: PRISM, pediatric risk of mortality; DIe, disseminated intravascular coagulation; 
WBe, white blood cells; CRP, C-reactive protein. 
using the commercial deficient plasmas. (N 70-140% ). Factors VIII and IX 
were done with one stage assays based on the APTT. The quantitative 
determination of the Von Willebrand Factor (vWF) was performed with a 
sandwich type ELISA. (N 80-120%). The same procedure was performed 
for the amounts of protein C and S antigen. (N 70-120%). The functional 
protein-C assay was measured by a chromogenic assay with a specific 
snake venom as the particulate activator (N 70-140%). The antithrombin, 
the plasminogen as well as the plasmin inhibitor (alpha-2 antiplasmin) 
activities in plasma were determined in quantitative kinetic tests by a 
synthetic chromogenic substrate method (N 70-140%). Fibrin + fibrinogen 
degradation products (FDP) were determined in a semiquantitative assay 
using latex particles coated with antibodie.s to FDP (N <5 I1g/mL). C4BP 
amounts were measured in quantitative determinations by electro-
immunodiffusion (Laurel! rocket technique). (N 68-140%, ±250 I1g/mL). 
Plasminogen activator inhibitor (PAI)-1 antigen was determined usmg a 
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sandwich-type radioimmunoassay previously described [21] and expressed 
as ngimL. Thrombin-antithrombin complexes (TAT), plasmin-plasmin 
inhibitor complexes (plasmin-a2-antiplasmin complexes) (PAP), and 
plasminogen activator, tissue type (tissue-type plasminogen activator) (t-PA) 
were measured with ELISA's (TAT, t-PA) or radioimmunoassay (PAP) 
previously described [22]. Results were expressed as mnollL (PAP), Ilg/L 
(TAT) or nglmL (t-PA). 
Statistical analysis 
Results are expressed as medians (range) unless othelwise specified. 
Differences between groups were tested with the Mann-Whitney test or 
Fishel" s Exact test in case of percentages. Correlation coefficients given are 
Spearman's. Two-tailed P-values " .05 were considered as statistically 
significant. 
13.4 RESULTS 
Demographics. 
Seventy-nine patients fulfilling the entry criteria and admitted to the 
PICU were emolled in the study. FOity-seven were males (60%), 32 
females (40%) (Table 1). The median age was 3.1 years (range 0.3-17.9). 
The patients were divided into two groups according to the median age, i.e. 
3.1 years or younger, or above 3.1 years. Fifty-eight of the 79 patients 
(73%) survived and 21 (27%) died. The modality in children below 3.1 
years was 40 %, which was significantly (P = .006) higher than in patients 
above 3.1 years (13%). Sixteen of the 21 patients who died were younger 
than 3.1 years; five were older than 3.1 years. In each group one patient 
died due to brain edema leading to hemiation and brain death. In the other 
19 patients the principal cause of death was circulatory collapse. Cultures 
of blood, cerebrospinal fluid or skin biopsies revealed Neisseria 
lI1eningitidis in 67 (85%) patients and Haemophillis inj!lIenzae in 2 patients. 
Cultures were sterile in 10 patients. Fifty-one (65%) patients needed 
mechanical ventilation. For practical reasons, i.e lack of sufficient plasma 
sample size, coagulation parameters were not determined on admission in 3 
patients. Fifty-two of the 79 children palticipated in a randomized, placebo 
controlled trial to study the efficacy of a human monoclonal antibody, HA-
lA (Centoxin', Centocor, Malvem, PA, USA), in meningococcal septic 
shock. HA-I-A or placebo were administered after blood was collected for 
the determination of cytokines or coagulation parameters. 
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Severity parameters 
Clinical and laboratory parameters obtained on admission (PRISM-
score, presence of DIC, need for mechanical ventilation, need for inotropic 
support for more than 24 hours, atierial lactate, WBC, selUm levels of 
glucose and CRP) are indicated in Table I after stratification according to 
outcome (survivors versus non-survivors) and age (younger or older than 
3.1 years). The ages of survivors and non-survivors were significantly (P = 
.013) different: the median age was about 2 years higher for the survivors. 
All clinical and laboratory parameters, with the exception of lactate and 
need for inotropic support, were significantly associated with outcome and 
age. Inotropic suppOli longer than 24 hours was necessaty in 74 of the 79 
patients. In only two of the 40 children < 3.1 years (5%), and 3 of the 39 
children> 3.1 years (7.7%) inotropic SUppOit was not statied or could be 
discontinued within 24 hours. These five children with a relatively rapid 
recovery still needed 36 mLlkg (range: 32-50 mLlkg) plasma to normalize 
their blood pressure. Foul' of the five children had an increased atierial 
lactate level (4.2 mmollL; range: 1.1-5.5). There was no significant age 
related difference in duration of inotropic SUppOit in the survivors. 
Cytokines 
Cytokine levels were measured in 49 patients. The median plasma 
levels of TNF-a, IL-6, IL-S, and IL-IO were significantly higher in non-
survivors as compared to survivors (Table 2). These parameters did not 
significantly correlate with age. 
Table 2. Cytokines on admission in children with septic shock and purpura in relation with 
outcome and age. 
Cytokine Survivors Nonsurvivol's :s: 3.1 years > 3.1 years (II = 35) (II = 14) (II = 22) (II = 27) 
TNF-u (pg/mL) 7 32 14 8 
(2-165) (1-272)' (1-79) (2-272) 
IL-6 (pg/mL) 15,200 280,000 66,000 15,000 
(36-1.5xI0') (87-2.0xlO') t (36-2.0xI0') (87-1.5xlO') 
IL-8 (pg/mL) 1100 88,000 6500 1100 
(I 3-0.38x 10') (23-0.37xlO')1 (13-0.37xlO') (23-0.38xI0') 
IL-IO (pg/mL) 2260 19,000 7200 2260 
(41-0.1 I x 10') (30-0. IOxl 0')' (41-0.lOxlO') (30-0.lIxIO') 
Values are medians (range); significance of the difference between groups (Mann-Whitney U-
test): *p s .05, tp s: .005, tp S .001. Abbreviations: TNF, tumor necrosis factor; IL, interleukin. 
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Coagulation parameters 
The relation between coagulation parameters and outcome 01' age is 
indicated in Table 3. The median number of platelets was significantly 
decreased in non-survivors compared with survivors. The APTT was 
markedly increased in non-survivors versus survivors, and in patients below 
versus above 3.1 years. Fibrinogen, prothrombin and plasma coagulation 
factors (V, VII, VIII, IX, and X) were all decreased. Factors VII and X 
levels were not significantly different between children above and below 
3.1 years and between survivors and non-survivors, respectively. Levels of 
factor IX and TAT-complexes were only different between survivors and 
non-survivors. The plasma level of Von Willebrand factor (vWF) was 
significantly lower in patients below 3.1 years, but in both groups very high 
compares to normal values. 
The results of anti-coagulant and fibrinolytic tests are summarized in 
Table 4. Protein C was markedly decreased and serum levels were sig-
nificantly related to outcome and age. Plasma levels of antithrombin, 
plasmin inhibitor, and FDP were also related to outcome and age. In 
addition PAl-I levels tended to be higher in children below 3.1 years than 
in children above 3.1 years. The ratio between PAl-I and t-PA was 
significantly different between survivors and non-survivors, but also 
between younger and older children. When survivors were analyzed 
separately, this ratio was still significantly (P = .011) different between 
children above and below 3.1 years. 
Relationship of cytokines to coagulation parameters 
APTT, fibrinogen, FVIII, TAT, PAP, t-PA, PAl-I, as well as the PAI-
lIt-PA ratio con·elated well with the levels of most of the cytokines. A 
weak, positive correlation was found between FVII and the cytokine plasma 
levels and an inverse relation between cytokine levels and C4BP. 
Correlation coefficients were estimated separately for the patients younger 
and older than 3.1 years. Differences between the correlation patterns for 
both groups were: the strong negative correlations between fibrinogen, 
FVIII, or protein C levels and cytokine levels in the younger age groups, 
which cOlTelations were weaker or absent in the older age group; the strong 
positive con·elation in the younger age group between APTT and plasma 
cytokine levels, which was not found in the older age group; finally, PAl-I 
in both groups correlated with cytokines, yet the production of t-PA in the 
younger age group was not related to plasma cytokine levels, whereas in 
the older age group a strong, positive correlation between these parameters 
was found. 
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Table 3. Coagulation parameters in children with septic shock and purpura in relation to 
outcome and age. 
Coagulation Survivors Nonsurvivors ,. 3.1 Years > 3.1 Years Normal 
parameter (1/ = 51) (1/ = 16) (1/ = 30) (1/ = 37) values 
platelets (xlO'lL) 106 53 85 101 150-350 
(15-214) (14-141)t (15-214) (14-189) 
APIT (s) 52 103 68 51 28·40 
(29-200) (56-220)' (33-220) (29-200)' 
Fibrinogen (giL) 2.6 1.1 1.7 2.7 1.8-3.5 
(OJ-5.8) (0.2-2.5)' (0.2-5.3) (0.2-5.8)' 
Prothrombin (%) 51 41 43 55 70-120 
(24-82) (II-57)' (12-79) (11-82)' 
FV (%) 40 16 25 38 70-120 
(5-116) (2-48)' (2-116) (3-77)' 
FVlI (%) 19 21 25 18 70-120 
(3-41 ) (5-41) (5-41 ) (3-34)' 
FVlll (%) 84 22 42 87 70-150 
(3-286) (2-62)t (4-133) (2-286)' 
vWF (%) 422 394 376 454 80-120 
(200-711) (227-629) (227-570) (200-711)' 
v\VFIFVlII 5.0 17.5 8.6 5.2 I 
(1.9-147) (5.7-264)' (2.4-30.6) (1.9-264)' 
FIX (%) 50 40 48 47 70-120 
(16-118) (22-86)1 (16-86) (23-118) 
FX (%) 50 44 49 52 70-120 
(27-98) (17-60)' (21-90) (17-98) 
TAT (nglmL) 14 175 40 14 <4 
(3-455) (12-811)1 (3-467) (3-811) 
All data shown are medians (range); si!nificance of the difference between groups (ManUM 
Whitney U-test): 'P" .05, 'P'; .005, p" .001. Abbreviations: APIT, activated partial 
thromboplastin time; P, factor; vWF, Von Willcbrand Factor; TAT, thrombin-antithrombin 
complexes. 
13,5 DISCUSSION 
This study in 79 children confirms that disturbances in the coagulation 
system are associated with outcome and severity of the disease in children 
with severe septic shock and purpura. The coagulation profile in these 
children is characterized by excessive activation resulting in massive 
consumption of platelets and coagulation factors. These abnormalities in 
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Table 4. Anti-coagulation and fibrinolysis parameters in children with septic shocl{ and 
purpura in relation to outcome and age 
Anti-CoRg/Fihr Survivors Nonsurvivors ::;; 3.1 Years > 3.1 Years Normal 
parameter (II = 51) (II = 16) (II = 30) (II = 37) values 
Protein C act (%) 23 14 19 23 70-120 
(5-58) (5-32)& (5-47) (6-58)' 
Protein C ag (%) 22 13 16 22 70-120 
(3-63) (5-36)t (3-49) (12-63) 
Protein S ag (%) 63 44 48 62 70-120 
(21-112) (27-80)§ (21-[[2) (30-92) 
C4BP (%) 72 53 61 73 70-140 
(33-108) (24-89)' (24-100) (32-108) 
Antithrombin (%) 65 56 58 68 70-140 
(29-93) (25-68)§ (29-93) (25-88) , 
Plasminogen (%) 62 52 56 62 70-140 
(25-94) (27-72)' (25-94) (37-93) 
Plasmin inhibitor (%) 64 51 55 65 70-140 
(30-108) (l2-75)§ (29-103) (12-108) , 
FDP (~g/mL) 63 125 110 50 <5 
(5-325) (70-325)§ (5-325) (5-275)& 
PAP (nmoIIL) 14 23 17 14 <7 
(3-56) (4-54)t (3-52) (3-56) 
t-PA (ng/mL) 24 27 19 26 <10 
(5-79) (7-77) (5-58) (8-79) 
PAl (ng/mL) 670 2679 1409 617 <30 
(92-3268) (828-4578)§ (92-4351) (126-4578) 
PAIIt-PA 26 90 82 26 <3 
(6-206) (28-298)§ (6-298) (6-205) § 
All data shown are medians (range); significance of the difference between groups (Mann-
Whitney test): .p ~ .05, tp::;; .01, +P::;: .005, §p S .001. Abbreviations: act, activity; ag, antigen; 
PDP, fibrin/fibrinogen degradation products; PAP, plasmin-a2-antiplasmin complexes; t-PA, 
tissue-type plasminogen activator; PAl, plasminogen activator inhibitor. 
coagulation result fi'om activation of endothelial and other cells by 
endotoxins and cytokines, and are the cause for microvascular thrombosis 
with hemorrhagic necrosis. However, our observation of age-related 
differences in coagulation parameters suggests that part of the observed 
abnormalities results from age dependent relative liver insufficiency. 
Previously we and others repOlied that protein C (PC) levels in 
patients with meningococcal sepsis had decreased to a level at which they 
are at risk to develop thrombosis [10, 14, 16, 17]. There were no 
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differences between PC antigen and PC activity. Increased levels of PC 
inbibitor did, therefore, not explain the decreased PC levels [23]. We 
propose that decreased PC levels reflect massive consumption. In agreement 
herewith, administration of activated protein C to baboons with lethal septic 
shock not only prevented coagulopathy, but also improved outcome [24]. In 
addition, inbibition of PC activation using a neutralizing antibody resulted 
in a more severe response even against a sublethal dose of E. coli, implying 
that decreased PC levels in patients with meningococcal sepsis predispose 
for a more severe disease. Furthermore, PC not only regulates coagulation, 
but also enhances fibrinolysis by inhibition of PAl [25]. Together, these 
data suggest that administration of protein C concentrates may have 
beneficial effects in children with septic shock and purpura. 
Activation of coagulation is accompanied by activation of fibrinolysis. 
In animal experiments [26], studies in volunteers [4], and human septic 
shock patients [27], elevated levels of tissue plasminogen activator (t-PA) 
antigen have been demonstrated. In one study these were related to the 
severity of the disease as reflected by the APACHE score [28]. In our study 
t-PA levels, though increased, were not associated with outcome and only 
correlated weakly with sennn lactate (r = .45, P =.001) and WBC (r = .31, 
P < .05). The levels of t-PA did correlate weakly with the TAT complexes 
(r = .34, P < .05), indicating that the fibrinolytic and coagulative responses 
may have been linked either because one (fibrinolysis) occurred in response 
to the other, or because both were induced by the same stimuli. Plasmin 
inbibitor levels were significantly lower in non-survivors, as was previously 
repOlted [2, 29]. This presumably reflects consumption of this anti-
fibrinolytic protein, since nearly all patients had increased circulating P AP-
complexes. Decreased plasmin inbibitor levels facilitate enhanced 
fibrinolytic activity. Yet, we believe that overall fibrinolysis was relatively 
inhibited in our patients due to the release of high amounts of PAl -1 into 
the circulation. Increased levels of PAl -I indeed have been shown in 
experimental sepsis [26], and in human sepsis [2, 27, 29-31] and are 
associated with a decrease in levels of PAP-complexes [32]. We speculate 
that the levels of PAP complexes, though increased, presumably reflect an 
insufficient fibrinolytic response. Increased levels of PAI-l were strongly 
related to outcome and, as was previously reported by our group, an 
increased PAI-l response to TNF-a may be associated with fatality, 
probably because of polymorphism of the PAI-l gene [33]. 
Mortality of patients with septic shock and purpura is probably related to 
the severity and extent of coagulation disturbances which lead to micro-
thrombi and hemorrhagic necrosis. Mortality rates differ from 10% to 40% 
depending on patient selection criteria. Additionally 10% of all patients 
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with meningococcal disease suffer fi'Om serious sequelae like amputation, 
secondary to the coagulopathy. This study shows that mortality was three 
times higher in patients below three years. Although the maturation of the 
coagulation system is only partly umaveled, most coagulation factors do not 
reach adult levels until after the first 6 months of life [34]. Protein C is 
somewhat unusual since it does not reach adult levels until the fOUlih year 
of life [35]. Powars et al. have suggested that infants are more susceptible 
to severe depletion of protein C. These authors showed a relation between 
protein C and both age and outcome in children with meningococcal sepsis 
[16]. We studied the relation between coagulation parameters and age, and 
did not only find differences in protein C, but also in other parameters of 
coagulation and fibrinolysis. So, either both patient groups had the same 
degree of inflammatory stimulus, and the younger patients a more disturbed 
coagulation, or, the younger patients were more severely ill and for this 
reason had a more severely disturbed coagulation. Yet, cytokine levels were 
comparable in both groups indicating that younger and older children had at 
least comparable inflammatory responses. Thus, apparently a similar 
inflammatory response yields a more severe coagulative response in the 
younger children. We suggest that this more severe coagulative response 
was due to the immature state of their clotting system, in patiicular of the 
anticoagulant pathways, resulting in extensive consumption of coagulation 
factors. Striking was the increased levels of vWF caused by endothelial cell 
and platelet activation. Because of this activation factor VIII is also 
increased during sepsis just as vWF [2]. In our patients consumption and 
extravasation were probably so extreme, that factor VIII levels were much 
lower in non-suvivors, and in younger patients indicating a higher 
consumption in these patients. But since we only analyzed some of the 
cyiokine levels and no other fluid phase cascade systems, there remains 
unceliainty about the degree of intravascular inflammation in the two 
groups. Plasma levels of PAI-I of both age groups correlated strongly with 
cyiokine levels, as well as with TAT-complexes (r =.73, P < .001; r = .80, 
P < .001). FUlihermore, in contrast with the older age group, t-PA levels in 
the younger age group did not con-elate with those of cytokines. Moreover, 
the correlation between t-PA levels and TAT-complexes, was different for 
both groups: whereas no correlation was found in the younger age group 
(r = -.05, P = .81), there was a very strong cOl1"elation found in the older 
age group (r = .80, P < .001). This may indicate, that in addition to the 
relative deficiency of coagulation factors, an inadequate fibrinolyiic 
response may have contributed to the activation of coagulation. This seems 
to be contradictory to the finding that FOP's were significantly higher in 
patients ~ 3.1 years vs > 3.1 years and in non-survivors vs survivors. 
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However, FDP's are a combination of fibrinogen and fibrin degradation 
products. Fibrinogen was much lower in non-survivors than in survivors. 
So, fibrinogen consumption was more pronounced in non-survivors. 
Consistent herewith TAT complexes were much higher in non-survivors, 
making it likely that more fibrin was formed in this group. Although there 
was detectable activation of fibrinolysis as estimated by increased FDP's 
and PAP-complexes, we speculate that this was insufficient to compensate 
for coagulation activation. 
The parameters reflecting severity of disease, PRISM, lactate (higher 
in non-survivors), and WBC, glucose, and CRP (lower in non-survivors), 
were also different between the two age groups, the patients younger than 3 
years being more severely ill than the older patients. We speculate that this 
resulted from the increased tendency to develop a more severe 
coagulopathy. Additionally, lack of immune competence i.e. lack of 
bactericidal and opsonophagocytic antibodies combined with certain Fc-y 
receptor allotypes on specific cells may contribute towards the bad 
prognosis in infants and young children. 
The question remains whether coagulopathy and micro thrombosis 
contributes to circulatory collapse and mortality. The coagulopathy could be 
causally related to the circulatory collapse but could also be two separate 
manifestations of massive endotoxemia. The latter has been shown in 
baboon experiments. Blocking FXII did ameliorate the hypotensive 
response but that activation of the coagulation was not influenced [36]. 
However, the same group established that protein C treatment prevented the 
coagulopathic as well as the lethal effects [24]. The same combined effect 
was described for tissue factor pathway inhibitor [37]. Therefore one may 
argue that FXII is more related to hypotension and that blocking of this 
system possibly leads to improvement of hypotension without changing the 
coagulopathy. However, this does not prove that circulatory collapse and 
coagulopathy are separate manifestations. 
So, despite a similar degree of inflammatory response, a more severe 
coagulopathy was found in children below the age of 3.1 years, consisting 
of a relative deficiency of coagulation factors, as well as an inadequate 
fibrinolytic response, both related to age, which may have contributed to 
the higher mottality observed in younger children with meningococcal 
sepsis. 
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General Discussion and Conclusions 
14.1 INTRODUCTION 
The morbidity and mOliality in children with bacterial meningitis and 
sepsis did not decrease during the last decade despite the availability of 
excellent antibiotics, improvements in intensive care therapy, and 
application of new immunotherapeutic agents. Recently research in this 
field has been directed towards efforts to enhance our understanding of the 
host response to the major pathogens involved in bacterial meningitis and 
sepsis: Haemophilus injluenzae, Streptococcus pnellmoniae, and Neisseria 
meningitidis. These studies which were calTied out in animal experimental 
models and in humans have elucidated the major role of the host 
inflammatory response in the clinical symptomatology and outcome. 
Genetically encoded variability in the immune system also exelis major 
effects on the clinical course and outcome of infectious diseases [I]. 
Examples are the increased risk for meningococcal infections in patients 
with complement deficiency, the increased risk in celiain children for 
invasive disease by H inflllenzae or S. pnewnoniae due to an impaired 
antibody response and the association between certain Fcy receptor 
allotypes on leukocytes and insufficient phagocytosis of encapsulated 
microorganisms. The growing knowledge on the vilUlence factors of 
bacteria discussed in this thesis also points to an impOliant role of strail1, 
specific characteristics in the pathogenesis of disease. It is generally 
believed that a greater understanding of the host response against sepsis and 
meningitis and a better characterization of the molecular microbiological 
characteristics of bacteria involved in these diseases are essential elements 
for the development of new therapeutic strategies. The aims of this thesis 
were l.) to study laboratory parameters, clinical characteristics and outcome 
of patients with bacterial meningitis and sepsis and 2.) to enhance 
understanding of the host response against the major bacteria involved in 
these disease entities. 
14.2 THE OUTCOME OF CHILDHOOD BACTERIAL 
MENINGITIS AND MENINGOCOCCAL SEPSIS 
Bacterial meningitis and sepsis are clinical entities with a high 
morbidity and mortality. Baraff et al. [2] repOlied a mOliality rate of 3.8% 
in children with meningitis due to H injluenzae. The mOliality rate in 
pneumococcal meningitis in children was 15.3% [2]. Meningococcal 
meningitis, the most common cause of bacterial meningitis in the Western 
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World, especially in countries with immunization programs against H 
injluenzae type b, is associated with a m0l1ality rate of 7.5% [2]. 
Unfortunately, laymen and even health professionals sometimes do not 
clearly understand the difference between meningococcal meningitis and 
meningococcal sepsis [3]. This confusion is based on the historical idea, 
that meningococcal meningitis and sepsis are the same illness 
(cerebrospinal fever). Another issue, which has contributed to this 
misconception is that bacteremia is present in the majority of patients with 
meningitis and that cerebrospinal fluid (CSF) cultures yield positive results 
in a subset of patients with meningococcal septic shock. The real mortality 
rate for patients with meningococcal meningitis is probably less than 5%. 
Meningococcal sepsis, in contrast, is associated with a mOitality rate up to 
50% in patients with severe shock [4-6]. The outcome of these diseases also 
depends on factors such as age range of the study population, type of 
microorganism, underlying diseases, primary or secondary referral, and 
duration of the follow-up period. 
We investigated the outcome of children with pneumococcal 
meningitis and meningococcal septic shock. The overall m0l1ality rate in 
our population of patients with pneumococcal meningitis, which included a 
larger number of children than in any other previous report, was 17%. This 
rate is relatively high in comparison with that in previous studies [2, 7-9]. 
We attribute this difference to the large number of patients refened by 
other hospitals. In chapter 3, we rep0l1 the presence of significant 
differences in mortality between children with primary and secondary 
referral for pneumococcal meningitis (7% vs. 34%). The higher m0l1ality 
rate among secondary referrals could be expected since these patients were 
more severely ill. A similar observation was made by Bolu' et al. [8]. The 
mortality rate among adult patients is substantially higher than that among 
children. This is most likely due to the frequent presence of underlying 
disorders in the elderly. In a recent retrospective study of pneumococcal 
meningitis in Dutch adults a mortality rate of 33% was rep0l1ed [10]. The 
fatal outcome of pneumococcal meningitis in adults is mainly due to the 
development of cardiorespiratory failure. In contrast, children often die as a 
result of neurological complications. Clonal relatedness between the 
pneumococcal isolates was not observed (chapter 4). 
In chapter 9 the clinical outcome is described of children with 
meningococcal septic shock. We found a m0l1ality rate of 25%. In contrast 
to patients with pneumococcal meningitis, primarily refenals with 
meningococcal septic shock had a higher mortality than secondary referrals: 
44% vs. 20%. The pediatric risk of m0l1ality (PRISM) score of the primary 
refenals was significantly worse than that of the secondary referrals. The 
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mOttality rate was also higher in the group of children younger than 4 years 
(16 of 48 [33%] vs. 5 of 39 [13%]; P = .03). These findings underscore 
that epidemiologic data on mOttality rate should be interpreted with care 
since confounding factors such as age and clinical condition at referal may 
influence them. 
Survivors of these serious invasive infections do fi'equently suffer from 
sequelae. A meta-analysis of children with bacterial meningitis 
demonstrated at least one major adverse outcome (spasticity, paresis, 
deafness, seizures or severe intellectual disability) in 16.2% of these 
patients. Approximately 30% of children with pneumococcal meningitis has 
sequelae [2]. Many of these neurological abnormalities do however resolve 
within one year [11]. 
Neuropsychological evaluation is not routinely performed during 
follow-up of children with bacterial meningitis. Only few studies have 
addressed long-term consequences of bacterial meningitis and whether 
additional abnormalities of visuomotor coordination, auditory perception, 
and higher cognitive functions compromise the future learning abilities and 
development of these children [12-16]. In addition, many of these studies 
are mainly pertinent to H. injluenzae type b meningitis and the results 
cannot be generalized to meningitis due to N meningitidis and S. 
pneUlI/oniae. Because most motor or cognitive skills are immature at the 
time of meningitis, deficits may not be detected until the child is older and 
has started school. Therefore, future long-term follow-up studies on 
neuropsychological, social, and schoolfunctioning are urgently needed. 
The use of scoring systems combining prognostic parameters to assess 
patients with meningococcal disease, has attracted much interest. The 
application of a prognostic score forces clinicians to make observations in 
areas of prognostic significance and enables them to estimate the severity of 
disease. Scoring systems can be readily applied to management protocols 
thus contributing to the establishment of clinical indications for invasive 
monitoring and aggressive therapy. Scoring systems may also be used to 
stratify subsets of patients for inclusion in new therapeutic trials. We 
developed a prognostic scoring system for patients with meningococcal 
septic shock (chapter 9). This system is exclusively based on the use of 
laboratory parameters which is a major advantage above previous scoring 
systems which use subjective characteristics or laboratory parameters that 
are difficult to obtain. 
The pathophysiological effects of meningococcal sepsis and other 
related syndromes result fi'om tissue damage by the uncontrolled production 
of inflammatory mediators. Recently novel immunotherapeutic regimens 
have been developed to inhibit the induction of the inflammatory cascade 
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by endotoxin. Other experimental therapies aim to inhibit the activation of 
various mediators or to modulate this response by administration of 
antiinflammatOlY mediators such as monoclonal antibodies and other drugs 
directed against bacterial products or cytokines. 
Natural or recombinant tumor necrosis factor (TNF)-ct or interleukin 
(IL )-113 do induce in animal models clinical and laboratory features similar 
to sepsis. Inhibitors of these cytokines can reverse the features of septic 
shock in these models. In experimental gram-negative sepsis, neutralization 
of endotoxin by monoclonal antibodies also reduces mOltality [17]. 
Although beneficial effects of these new drugs have been documented in 
experimental animals, studies in man thus far did not lead to improvements 
in outcome [I 8]. A recent study even documented an increase in mOltality 
of patients treated with tumor necrosis factor:Fc fusion protein [19]. 
Inhibition of the proinflammatOlY cytokine IL-I by means of IL-l receptor 
antagonist also did not result in a reduction of mOltality [20, 21]. These 
data are in accordance with animal models of infection by salmonella 
species or by Listeria lIlonocytogenes in which inhibition of TNF -ct or 
interleukin-I production may worsen the outcome of disease [22-24]. 
Treatment with anti-TNF-ct antibody was also either ineffective or 
detrimental in mice with localized peritonitis [25, 26]. TNF-ct or IL-l may 
actually protect against endotoxin-hyporesponsiveness in C3H1HeJ mice 
during systemic infection [27]. Despite great expectations, clinical trials in 
human sepsis have not been as encouraging as animal studies. Futther 
research is necessary to elucidate the pathophysiological mechanisms in 
patients with sepsis before new therapeutic strategies can be succesfully 
applied. 
The use of vaccines against H. inj!llenzae, N. meningitidis and S. 
pnellllloniae will circumvent the problems described above. Recently, 
conjugate vaccines against H. inj!llenzae type b (Hib) have been developed 
[28-30]. Hib vaccination has been introduced in childhood vaccination 
programs in an increasing number of countries. Subsequently a 90% 
reduction in H. inj!llenzae meningitis has been observed [31]. However, a 
substantial number of children have meningitis or sepsis by N. lIIeningitidis 
or S. pnellllloniae. Meningococcal disease is caused by several serogroups 
of which N. lIIeningitidis serogroup B is the most common cause in Europe, 
North-America, and several countries in Latin America. A meningococcal 
non-conjugate tetravalent A, C, Y, and W135 polysaccharide vaccine is 
available, safe and immunogenic in adults, but not in young infants. The 
serogroup B polysaccharide, however, is poorly immunogenic in humans 
and cannot be used as a major vaccine component [32]. Therefore, vaccines 
based on outer membrane proteins are currently evaluated for their efficacy 
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[33, 34]. Recent field trials with such vaccines have demonstrated partial 
protection against group B infection [35, 36]. Our group currently performs 
a trial to study the immunogenicity of a hexavalent meningococcal vaccine 
strain developed by Dr. Jan Poolman (RIVM, Bilthoven). This vaccine uses 
class I outer membrane protein representing the serosubtypes PI.5,2; 
PI.7,16; P1.19,15; P1.12,13; PI.7h,4; P1.5c,lO. These antigens represent 
75-80% of N. meningifidis serogroup B. 
Several pneumococcal conjugate vaccines combining the most relevant 
serotypes coupled to different protein antigens are already available and are 
currently studied for their effects on prevention of otitis media and invasive 
infections by S. pnellllloniae [37]. 
14.3 MEDIATORS INVOLVED IN THE HOST DEFENCE 
Patients with bacterial meningitis and sepsis undergo profound 
pathophysiological changes induced by a variety of pro- and 
antiinflammatory mediators. Proinflammatory cytokines including TNF -a, 
IL-I, IL-6, IL-8, IL-12 and interferon (IFN)-y upregulate the host 
inflammatory response in these disease entities. Endogenous 
antiinflammatory mediators such as soluble TNF receptors (sTNFR) and IL-
10 downmodulate the host response. We and others recently showed that 
the highly reactive molecule nitric oxide is an impOliant mediator in the 
CSF compmiment of patients with bacterial meningitis. Abnormalities in 
coagulation and fibrinolysis also play an impOliant role in the 
pathophysiology of sepsis as illustrated in this thesis. 
Cytokincs 
Cytokines are impOliant molecules in the pathogenesis of bacterial 
meningitis (chapters 5 and 6) and meningococcal sepsis (chapters 10 and 
11). Proinflammatory cytokines (TNF -a, IL-IB, IL-6 and IL-8) are present 
in high concentrations in CSF specimens of patients with bacterial 
meningitis [38-40]. Higher cytokine levels have been associated with poor 
neurological outcome [38]. Proinflammatory cytokines have also been 
implicated as mediators of inflammatory changes and blood-brain barrier 
injury in the central nervous system of patients with bacterial meningitis 
[41, 42]. These compounds appear to be locally produced by the brain in 
response to bacterial cell wall components, and are thought to cause an 
influx of granulocytes fi'om cerebral capillaries to the subarachnoid space 
by upregulation of leukocyte selectins on cerebral capillary endothelium 
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[43]. We investigated in this thesis the kinetics of CSF levels of 
proinflammatory mediators (chapter 5). CSF levels of TNF -a, IL-6, and IL-
8 decreased rapidly. This observation is similar to that in consecutive serum 
samples of experimental models of bacteremia or endotoxemia and in 
patients with sepsis [44]. Production of these proinflammatory cytokines 
has been associated with the development of central nervous system injury. 
The precise mechanism has not been elucidated. It has been suggested that 
cytokines are produced by glial cells and brain capillary endothelial cells 
[45]. Intracistemal inoculation of endotoxin is followed by detection of 
TNF-a and IL-lll activity. Subsequently, leukocytosis and changes in 
protein, glucose and lactate concentrations are observed within hours. The 
inflammatory response in the CSF of experimental animals after 
intracisternal inoculation of bacterial products such as endotoxin or live H 
injluenzae may be inhibited by dexamethasone. This is only effective when 
dexamethasone is initiated before or at the same time as antibiotics [46-48]. 
Clinical trials showed an improvement in the outcome of bacterial 
meningitis when dexamethasone was used as adjuvant therapy [49, 50]. 
We measured serum levels of cytokines on admission of patients with 
meningococcal sepsis as repOlted in chapter 10. Levels of proinflammatory 
mediators were highly elevated. NonsUivivors had higher levels on 
admission than sUivivors in agreement with studies by other investigators 
[5, 51, 52]. Our data indicate that the height of serum levels of TNF-a and 
other proinflammatory cytokines (e.g., IL-6 and -8) is also determined by 
the duration of disease i.e. duration of petechiae. This conclusion is 
suppOlted by the presence of a strongly negative cOl1'elation between initial 
cytokine levels and the intelval between onset of purpuric skin lesions and 
blood sampling. In addition, C-reactive protein (CRP) levels, which 
indirectly reflect the duration of illness [53], were significantly correlated 
with the intelval between the onset of petechiae and blood sampling. The 
significantly shorter period of disease and the lower level of CRP in 
nonsurvivors suggested a shOlter disease course and may explain the 
presence of higher levels of cytokines. We speculate that serum levels of 
proinflammatOlY cytokines were already over or near their maximum when 
the patients were admitted. This is also illustrated by the rapidly 
disappearance of cytokines during the acute phase of septic shock [54-57]. 
The earlier admission on a pediatric intensive care unit of nonsUivivors 
with meningococcal septic shock may indicate that these patients 
accumulate more native lipopolysaccharide in a shOlter time, trigger all 
mediator systems more intensively, and are recognized as more severely ill 
earlier in the course of disease. Alternatively, nonsUivivors may have been 
234 
General Discussion and Conclusions 
admitted earlier because of a more rapid deterioration due to greater 
responsiveness to lipopolysaccharides or proinflammatory cytokines. 
Interestingly, differences in the concentrations of mediators between 
survivors and nonsurvivors disappeared after adjustment for the time 
intelval between the onset of petechiae and blood sampling. We speculate 
all that patients with meningococcal septic shock may have a similar 
pattern of release of proinflammatory cytokines, i1Tespective of the 
outcome. 
We also studied the role of interleukin-12, a relatively novel 
proinflammatory cytokine, in the pathophysiology of both bacterial 
meningitis (chapter 6) and meningococcal sepsis (chapter II). Interestingly, 
findings in patients with bacterial sepsis and meningitis were similar in 
many ways. The results do not allow definitive conclusions on the role in 
both clinical entities. Bioactive IL-12 is a heterodimeric protein of 70 kDa 
(P70) which consists of 40 kDa (P40) and 35 kDa (p35) subunits. IL-12 is 
produced by phagocytic cells in response to infection and stimulates the 
natural immunity. The production of IFN-y is induced and in turn enhances 
the function of macrophages and polymorphonuclear leukocytes by 
stimulation on non-specific defence mechanisms such as phagocytosis and 
reactive oxygen intermediates. Several studies have shown that IL-12 
contributes to the control of the host defence against infections with 
intracellular microorganisms such as Mycobacterium tuberculosis, Listeria 
monocytogenes, and Leishmania donovani. IL-I2 mediated protection may 
be invoked by through its ability to stimulate IFN-y, which inhibits the 
parasite. Concentrations of IFN-y are significantly increased in CSF 
samples limn children with tuberculous meningitis [58]. We propose that 
analysis of IL-12 in these children would be interesting and would probably 
reveal to a major role of this cytokine in this type of meningitis. The role 
of IL-12 in bacterial meningitis and sepsis is less clear. However, CSF 
concentrations of IL-12 p40 and IFN-y were markedly elevated in patients 
with bacterial meningitis. In addition, CSF levels of IFN-y correlated 
positively with IL-12 and the costimulator TNF-a. Interestingly, patients 
with pneumococcal meningitis had significantly higher CSF levels of IFN-y 
in comparison with those with meningitis due to H. inj/uenzae and N. 
meningitidis as was previously observed by others [17]. This observation 
can not be explained by an increased IL-12 production since CSF levels of 
IL-12 were not markedly higher in patients with pneumococcal meningitis. 
However, the high CSF ratio between the costimulator TNF -a and IL-IO, 
which inhibits IL-12 induced IFN-y production, in the patients with 
pneumococcal meningitis in comparison to those with meningitis due to 
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other pathogens, may provide an explanation for the higher CSF levels of 
IFN-y in patients with pneumococcal meningitis. 
In patients with meningococcal septic shock, plasma levels of IL-12 
p40 were elevated and related to the outcome and severity of disease. 
Bioactive IL-12 could not be detected in the large majority of children with 
meningitis and sepsis. Previously, other investigators studies already 
repOlied that levels of p40 were much higher than those of p70 [59, 60). 
The physiologic significance of the excess production of the free p40 
subunit is not clear. Mattner et al [61) suggested that IL-12 bioactivity is 
inhibited by free p40 molecules. Neveliheless, in vitro and in vivo studies 
have clearly shown that the production of p40 is linked to that of bioactive 
IL-12 p70 [60, 62). FUliher studies will be necessary to elucidate the exact 
role ofIL-12 in bacterial meningitis and sepsis. 
Countel'inflammatory mediators 
The production of proinflammatory cytokines and the extent of the 
inflammatory response is downregulated by counterinflammatory 
compounds, such as IL-lO, and naturally occurring antagonists of TNF-ex 
including the soluble extracellular domains of the 55- and 75-kDa 
membrane-bound TNF receptors (sTNFR-55 and -75). IL-IO is produced by 
monocytes and macrophages, the Th2 subset of T helper lymphocytes, and 
B lymphocytes and suppresses the synthesis of proinflammatory cytokines 
by T cells, polymorphonuclear leukocytes, and monocytes and 
macrophages. We and others found significantly elevated CSF levels of IL-
lOin patients with bacterial meningitis, suggesting a role for IL-IO in the 
control of the inflammatory response in the CSF compaliment (chapter 5). 
In vitro studies have shown that TNF -ex is cytotoxic for neuronal cells, can 
dislUpt myelin, and damage oligodendrocytes [63, 64). High levels of IL-IO 
in CSF may have a protective role in bacterial meningitis, by reduction of 
the TNF production, thus preventing the OCCUll'enCe of neurological 
sequelae. In an experimental bacterial meningitis model, intracistel'1lal or 
intravenous injection of IL-l 0, in combination with antibiotics, also led to a 
significant reduction of TNF levels in CSF [65). When dexamethasone was 
given together with IL-lO, TNF -ex levels fUliher decreased. IL-IO may also 
inhibit the inflammatory reaction in the CSF compaltment, induce a 
decrease in intracranial pressure, and water content of the brain and a 
reduction of the number of polymOlphonuclear leukocytes in the CSF, as 
demonstrated in experimental pneumococcal meningitis. 
We observed that nonsurvivors with meningococcal septic shock had 
significantly higher concentrations of IL-IO than survivors. Lelunan et al. 
recently repOited that high IL-IO levels in patients with meningococcal 
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disease were associated with fatality [54]. However, we found in our study, 
that after adjustment for the time between the onset of petechiae and blood 
sampling (as measure for the duration of the disease course) IL-I0 levels 
were similar in survivors and non-survivors. 
IL-IO protects against TNF -mediated lethality in murine models of 
endotoxemia [66]. In animal models of sepsis, IL-lO, administered before 
or soon after challenge with gram-negative bacterial endotoxin or 
staphylococcal enterotoxin B, reduced TNF-a production and m011ality [66-
68]. Chernoff et al. [69] showed that a single intravenous injection of IL-I0 
in humans reduces mitogen-induced T cell proliferation and suppresses 
TNF-a and IL-lll production from whole blood stimulated ex vivo with 
endotoxin. In the study presented in chapter 10, the strong con'elation 
between IL-I0 and the proinflammatory cytokines TNF -a, IL-6, and IL-8 in 
survivors and nonsurvivors suggests the presence of an adequate IL-I0 
response to down-regulate the production of proinfiammatory cytokines. 
The biologic activity of TNF-a is also neutralized by sTNFR-55 and -
75 [70]. sTNFR is shed from the cell surface of, for example, 
polymorphonuclear cells in response to many of the same inflammatory 
stimuli that induce TNF-a [71]. In addition, sTNFR-55 and -75 can 
neutralize the biologic activity of TNF-a. We and others measured 
significantly elevated levels of sTNFR-55 and sTNFR-75 in CSF and semm 
of patients with bacterial meningitis [51]. Of interest, levels of sTNFRs in 
our study were exclusively associated with concentrations of IL-l 0 but not 
with concentrations of TNF -a, IL-6, or IL-8. This is in agreement with the 
recent observation that IL-I0 induces an increase in the synthesis and cell-
surface tumover of sTNFRs from monocytes [72, 73]. Other studies also 
indicate that IL-I0 stimulates the release of IL-l receptor antagonist, 
another antiinflammatory compound. IL-I0 thus may suppress TNF activity 
in the CSF compartment by an inhibition of TNF -a secretion, stimulation 
of the release of sTNFRs, and down-regulation of the expression of surface 
TNFRs [72, 73]. In our study, semm and CSF levels of sTNFR-55 and 
sTNFR-75 were similar in patients with bacterial meningitis. The relatively 
low CSF levels of sTNFRs may be pat11y explained by a release of sTNFRs 
from polymorphonuclear leukocytes before entty of these cells into the CSF 
compat1ment. Alternatively, shedding of sTNFRs in the CSF compat1ment 
may be lower because of the approximately 10-fold lower white blood cell 
(WBC) count in CSF than in peripheral blood in these patients. The 
significantly higher stimulus by TNF-a and IL-IO for release of sTNFRs in 
the CSF compartment apparently does not compensate for this inequality. 
The elevated CSF levels of sTNFR-55 and sTNFR-75 in the present study 
persisted for a remarkably long time (at least 24 h), as was previously 
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observed in bacteremia [74]. This may be due to slow clearance from the 
eSF compartment or to continuing release. The elevated levels of sTNFR 
may stabilize the activity of TNF -u, and provide a reservoir of TNF -u that 
is available for gradual release [75] 
In patients with meningococcal septic shock, we and others [76] 
reported that high levels of the sTNFRs are associated with an increased 
likelihood of fatality. Froon et al. [77] suggest that increased setum levels 
of sTNFRs in patients with sepsis syndrome are merely the result of renal 
failure. Normally, the majority of sTNFRs is removed from the circulation 
by the kidneys, although the liver and lungs are probably also involved 
[78]. The higher serum creatinine levels of nonsurvivors in the present 
study may at least partly explain the differences between survivors and 
nonsurvivors in sTNFR concentrations due to a reduced renal clearance. 
Nitric oxide 
Nitric oxide (NO) is one of the most versatile molecules produced by 
mammalian cells. NO is a short-lived free radical produced by a variety of 
cell types and involved in smooth muscle relaxation, neuronal signaling, 
inhibition of platelet aggregation, and regulation of cell-mediated 
cytotoxicity [79-81]. NO production results fi'om the conversion of L-
arginine to L-citrulline by the enzyme NO synthase (NOS). Three different 
NOS isoforms have been cloned and characterized: neuronal [81, 82], 
endothelial [83, 84], and cytokine inducible. The last group includes 
macrophage [85, 86], and vascular smooth muscle NOS [87]. The role of 
NO in inflammatory processes has been the subject of intense investigation 
since its discovery in 1987. NO was shown by us to be involved in the 
pathophysiology of both bacterial meningitis and sepsis. 
The involvement of NO in the pathophysiology of bacterial meningitis 
was previously investigated in several animal studies. In experimental 
meningitis induced by intracistemalinjectionofTNF-u.anincrease of the 
NO level in eSF, a reduced oxygen uptake, a decreased eSF blood-glucose 
ratio, an increased lactate concentration in eSF, and an increased 
intracranial pressure were found [88]. In our study (chapter 7), we detected 
a strong correlation between eSF levels of TNF -u and nitrite in children 
with bacterial meningitis. In addition, eSF levels of the precursor L-
arginine were significantly decreased. These data demonstrate that TNF-u 
may be involved in the induction of arginine-dependent NO production in 
the eSF compatiment of patients with bacterial meningitis. Rats inoculated 
intracistemally with live gram-positive and gram-negative bacteria, or LPS 
showed elevated NO/nitrite levels in eSF that increased with an increased 
blood-brain barrier permeability [89]. In the study presented in chapter 7, 
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the decreased CSF levels of L-arginine (the precursor of NO), the increased 
CSF NO/nitrite levels, and the decrease of CSF NO/nitrite over time, and 
indicate the presence of enhanced NO production in the CSF compattment 
in patients during the acute phase of bacterial meningitis. 
The mechanism by which NO may contribute to the pathophysiology 
of bacterial meningitis is not yet completely understood. NO distupts 
various enzyme systems associated with mitochondrial respiration, DNA 
replication, and the citric acid cycle [90-94]. NO also initiates the 
production of other strong oxidants which may contribute to cellular 
desttuction and alterations in central nervous system homeostasis. One such 
strong oxidant is peroxynitrite, which is produced through a reaction of NO 
with superoxide anion [95-101]. Peroxynitrite may well be more damaging 
than NO itself. 
The cellular site of NO/nitrite production in children with bacterial 
meningitis is unknown. NO/nitrite can be generated by at least three 
separate mammalian cells. Experimental studies present increasing evidence 
pointing to an induction of the calcium-independent isoform of nitric oxide 
synthase (iNOS) in astrocytes and glial cells by gram-positive cell wall 
Ji'agments and endotoxin. The second source of CSF nitrite may be the 
microvascular endothelium which constitutes the blood-brain ban·iet'. 
Finally, a third source of CSF nitrite could be neutrophils that cross into the 
CSF during bacterial meningitis. Both human and rat neutrophils synthesize 
relatively high levels of nitrite when activated by various stimuli. We did 
not observe a correlation between CSF NO/nitrite levels and CSF WBC 
count or CSF protein levels in patients with bacterial meningitis. Therefore, 
we propose that WBC are probably not the major source of NO/nitrite, 
although we intend to investigate this question by applying 
immunocytochemical techniques on CSF neutrophils. 
Dtugs as well as endogenous mediators are able to reduce the NO 
production. Although the present data may suggest, that a therapeutic 
downregulation of NO production may be a useful approach one has to 
realize that NO has both beneficial and detrimental effects. Positive effects 
of elevated NO levels in CSF may be sealing of the vascular layer and 
subsequently reduced leakage of plasma proteins through postcapillaty 
venules, and inhibition of endothelial cell activation. De Caterina et al. 
showed that NO can limit the degree of activation of human endothelial 
saphenous vein endothelial cells. The ability of NO to inhibit the expression 
of endothelial-leukocyte adhesion molecules and cetiain proinflammatOlY 
cytokines may reduce the inflammatory response [102]. In contrast, Buster 
et al. demonstrated that NO contributes to the general inflammatOlY 
response during experimental bacterial meningitis, thus promoting 
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production of chemotactic factors and leukocyte-endothelial cell adhesion 
molecules which facilitate entry of leukocytes into the subarachnoid space 
[89]. 
Since high levels of NO are rep0l1ed to be cytotoxic for neuronal cells 
and thus may contribute to the development of neurological sequelae during 
bacterial meningitis, inhibition or reduction of the NO production may be 
useful [103, 104]. However, the relevance of NO as cause of neuronal 
injury in humans is not yet known. Rat astrocytes and microglia produce 
NO in neurotoxic concentrations in response to bacterial products. Human 
microglia do not seem to synthesize such concentrations of NO [105, 106]. 
Human astrocytes, however, are able to generate NO [105]. Since astrocytes 
are the most numerous cell type in the brain, their activation by bacterial 
products could play a role in the development of brain injury in bacterial 
meningitis in humans. 
NO production is suppressed by glucoc0l1icoids, transforming growth 
factor B1, IL-4, IL-10, and prostaglandin E, [107-111]. Dexamethasone may 
improve neurologic outcome in pediatric bacterial meningitis and is 
fi'equently used as adjunctive therapy [49, 50]. This beneficial effect is 
thought to result fi'om the reduction of inflammation, although the precise 
mechanism is unknown. Dexamethasone suppresses production of NO in 
astrocytes and markedly reduces the associated neurotoxicity after challenge 
with LPS [112, 113]. In the study presented in chapter 7, we did not 
observe differences in CSF nitrite levels in time between those patients with 
and without dexamethasone as adjuvant therapy. However, by the time 
meningitis is diagnosed, iNOS mRNA expression is already induced. The 
failure of dexamethasone to inhibit iNOS mRNA and NO production after 
induction may explain the ineffectiveness of glucoc0l1icoids [107]. The 
absence of a significant effect on NO/nitrite production in the CSF 
compartment may also be due to the relatively small sample of patients or 
the initiation of antibiotic therapy prior to administration of dexamethasone. 
Inhibition of NOS with N-nitro-L-arginine methyl ester (L-NAME) in 
animals with meningitis results in a reduction of CSF nitrite of CSF nitrite 
levels and a corresponding reduction in WEC counts and a decrease in 
blood-brain ban'ier permeability [89]. Administration of L-NAME was also 
accompanied by an increased mortality [114, 115]. In addition, Tauber et a!. 
showed that NO synthase inhibition during meningitis by aminoguanidine 
leads to an increase in cerebral ischemia. This increased cerebral ischemia 
is a likely cause of the worsened neuropathological outcome in animals 
with group B streptococcal meningitis treated with aminoguanidine [116]. 
NO also appears to play a role in the hemodynamic instability 
associated with septic shock. Cytokines and endotoxin stimulate synthesis 
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of inducible NOS. NO which is subsequently produced in large amounts 
over an extended period, may be the key mediator in the pathogenesis of 
septic shock. Previous investigators measured elevated levels of nitrate in 
patients with sepsis. We also found elevated serum levels of nitrate in 
patients with meningococcal septic shock (unpublished data). However, 
differences in nitrate levels between survivors and non-survivors were not 
found, althougb patients with persistent hypotension had significantly higher 
levels of nitrate. Comparison between animal studies shows a great 
variability, which may be attributable to differences in dosing regimens or 
in models of septic shock. Data obtained from human studies are more 
consistent, but are limited to a few case series. The results indicate that 
NOS inhibitors increase blood pressure and systemic vascular resistance and 
decrease cardiac output. The effects of NOS inhibitors on morbidity and 
mortality could not be assessed because of the lack of an appropriate 
sample size. Further studies are rquired to determine appropriate dosing 
regimens of NOS-inhibitors and to study the effects of these agents on 
morbidity and mortality in patients with septic shock. 
Coagulation and fibrinolysis 
Meningococcal septic shock is associated with severe disturbances of 
coagulation and fibrinolysis. Its most profound manifestation is 
disseminated intravascular coagulation (DIC) characterized by micro-
vascular thrombosis, consumption of platelets and coagulation proteins and 
by stimulation of the fibrinolytic system. Meningococcal infections may 
evolve into the most severe clinical form of DIC: purpura fuhninans with 
hemorrhagic necrosis and peripheral gangrene. We questioned whether the 
higher mmiality in young children is associated with the presence of more 
severe clotting abnormalities (chapter 12). 
The coagulation is activated through the extrinsic pathway (tissue 
factor). In vitro studies demonstrated that endotoxin, IL-I13, and TNF-o; 
enhance tissue factor expression on endothelial cells [117, 118]. Tissue 
factor binds to factor VII. The complex of activated factor VII (factor VIla) 
and tissue factor binds to factors IX and X and this sequence of proteolytic 
activation results in the formation of thrombin fi-om prothrombin. Thrombin 
cleaves fibrinogen yielding monomeric fibrin which then polymerizes to 
fmm the fibrin clot [119]. The massive consumption coagulopathy is 
characterized by low levels of coagulation factor VII, X, V, prothrombin, 
fibrinogen, and platelets. 
The natural inhibitors of coagulation, antithrombin III (ATIII) and the 
protein C-protein S system, contribute to the regulation of coagulation. The 
levels of these inhibitors are markedly altered in patients with 
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meningococcal septic shock. The ATIII levels are significantly decreased. 
The major mechanism by which ATIII activity declines in sepsis is acute 
consumption during the process of coagulation. 
Pro coagulant effects of TNF-a are also amplified by the impaired 
function of the protein C-protein S inhibitory pathway due to 
downregulation of thrombomodulin and increased serum levels of the 
protein S binding factor C4bBP. Normally, thrombomodulin binds thrombin 
and thereby reduces its coagulative potential and activate protein C [118-
122]. 
In the study presented in chapter 12 markedly decreased plasma levels 
of protein C and protein S were found, resulting in a pro coagulant state. 
Although consumption of protein C certainly contributes to the decreased 
levels, immaturity of the protein C system may also play a role. Most 
coagulation factors reach adult levels at 6 months of age [123]. Protein C, 
however, does not reach adult levels until the fOUlth year of life [124]. 
Powars et al. have suggested that infants are more susceptible to severe 
depletion of protein C. These authors showed a relation between protein C 
and both age and outcome in children with meningococcal disease [125]. 
Therefore, the lowest level of the endogenous anticoagulans protein C in 
young children may at least pattly explain the significantly lower levels of 
most coagulation factors in young children with meningococcal septic 
shock. 
Activation of coagulation is accompanied by activation of fibrinolysis. 
Endotoxin, TNF-a, and IL-IJ3 modulate the fibrinolytic system to secrete 
both tissue plasminogen activator (t-PA) and plasminogen activator 
inhibitor (P AI)-I, which activate and inhibit fibrinolysis, respectively [126-
131]. Fibrinolysis is initiated by the release of t-PA from vascular 
endothelium which convelts plasminogen into the active enzyme plasmin 
resulting in degradation of fibrin in the thrombi. Administration of low 
intravenous doses of endotoxin 01' TNF-a in healthy volunteers initially 
leads to activation of coagulation and fibrinolysis. However, a few hours 
later, an increasing inhibition of the fibrinolytic system occurs due to a 
strong elevation of PAl-I, aggravating the procoagulant state [44, 126, 129, 
135]. These data are suppOlted by in vitro studies on human endothelial 
cells showing that endotoxin enhances the release of PAl-I coinciding with 
suppression of fibrinolytic activity [128-130]. Moreover, fibrin and 
thrombin formed during coagulation are also potent inducers for the release 
of t-PA and PAl-I [133, 134]. The activity of t-PA in patients is counter-
regulated by PAl-I that binds to and thereby inhibits t-PA. 
We showed in chapter 10 by multiple regression analysis that levels of 
PAl-I correlated with the duration of petechiae and were higher in 
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nonsurvivors. The inhibition of fibrinolytic activity represented by the ratio 
PAl-I to t-PA was significantly higher in nonsurvivors compared to 
survivors. Comparison between children below and above 3 years of age 
showed a significantly lower fibrinolytic activity in the youngest age group. 
This may be indirectly caused by the higher plasma levels of thrombin and 
fibrin in the youngest age group which also stimulate the release of PAl-I. 
Of interest, the more severe coagulopathy in children below 3 years of age 
occurred in the presence of similar serum levels of proinflammatory 
cytokines in younger and older children. This indicates that the severity of 
clotting abnormalities may of greater importance than the degree of the 
inflammatOl'Y response. Therefore activation of coagulation together with 
the inhibition of the fibrinolysis are responsible for the development of a 
hypercoagulable state, fibrin deposition, microthrombi and DIC, especially 
in young children [135-138]. Fibrin deposition and complement activation 
cause extensive endothelial damage and are associated with multiple organ 
failure [136-138]. 
Heparin, antithrombin III concentrate, fresh frozen plasma, and protein 
C have been tried as therapeutic agents to control DIC in patients with 
fulminant meningococcemia [139-143]. However with exception of fresh 
fi'ozen plasma, and protein C, which have some fibrinolytic properties, 
these interventions do not contribute to the dissolution of already formed 
clots [144]. The administration of protein C may have a beneficial effect on 
patients with meningococcal septic shock and DIC, since protein C not only 
regulates coagulation, but also enhances fibrinolysis by inhibition of PAl 
[144]. A multicenter, blinded study to assess the efficacy and safety of 
protein C concentrate in the treatment of patients with septic shock and 
purpura will therefore be initiated this year. Administration of recombinant 
t-PA to enhance fibrinolysis may be an alternative adjuvans therapy, since 
preliminary data suggest an improvement in outcome in patients (n = 2) 
with severe meningococcal shock. 
14.4 GENETIC FACTORS 
Genetic factors of host and pathogen determine the susceptibility to an 
invasive infection and may be paltly responsible for the severity of disease. 
Previous investigators showed that defects in the complement system, 
i.e. in the alternative pathway, C3 and in the terminal complement 
components C5-C9, coincide with a significantly increased risk for 
meningococcal disease [145]. This is palticularly obvious in patients 
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contracting meningococcal disease by uncommon serogroups (X, Y, Z, 
Wl35) or in subjects with reClllTent meningococcal disease. Deficiencies of 
(specific) antibodies or the presence of IgA antibodies are other risk factors 
for meningococcal disease. Polymorphism of the Fc receptors (FcyR) for 
the interaction with IgG on phagocytes may also be clUcial. Genetically 
determined forms of the FcyRIla (CD32 molecule) express different 
functional activities. FcyRIla-RlRl31 neutrophils phagocytize IgG2 
opsonized microorganisms less effectively than FcyRIla-HlHl31 
neutrophiIs. IgG2 is the major subclass produced in response to bacterial 
capsular polysaccharides. Bredius et al. found that the homozygous 
FcyRIIa-RlRl31 allotype is significantly more present in survivors of 
meningococcal septic shock in comparison with a healthy Caucasian 
population [146). Thus, the Rl31 allotype of FcyRIIa, which does not bind 
IgG2, seems to be a risk factor for invasive meningococcal infections. This 
is in agreement with epidemiological observations showing a very low 
incidence of infections caused by encapsulated microorganisms in Japan, 
where the majority of individuals is FcyRIIa-HlHl31 [147, 148), and with 
observations in children with a history of reCUl1'ent infections, where a 
lower fi'equency of the FcyRIIa-HlHl31 allotype was found in comparison 
with a healthy population [149). In contrast to patients with meningococcal 
septic shock, a higher percentage of FcyRIla-RlRl31 was not found m 
children with a histoty of H. injluenzae meningitis (manuscript in 
preparation). 
Genetic polymotphisms for TNF-cx seem to be involved in the 
regulation of severity of 01' susceptibility to meningococcal disease. A wide 
interindividual variability in TNF -cx release has been demonstrated after 
stimulation by endotoxin in vitro of whole blood samples and of peripheral 
blood mononuclear cells from healthy volunteers [150, 151). The high 
initial TNF -cx levels in patients who do not survive meningococcal septic 
shock have been attributed to an exaggerated response to circulating 
endotoxin [152). The production of inappropriately large quantities of TNF-
cx may be due to the presence of a genetic variant in the promoter region of 
the TNF gene (TNF2 allele) as previously observed in patients with 
cerebral malaria [153). The TNF2 allele has been associated with higher 
constitutive expression and greater secretion of TNF -cx after induction 
[154). Genetically determined variability in the expression of other 
proinflammatory cytokines may also be associated with the outcome of 
serious infectious diseases. A similar variability in the antiinflammatoty 
response celtainly may also contribute to the outcome of disease. A reduced 
expression and release of e.g. IL-IO may enhance or prolong the 
inflammatoty response. 
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We report in this thesis, that polymorphism of the PAI-I gene is a 
determinant for the development and possibly the outcome of children with 
meningococcal septic shock. PAl-I concentrations on admission were 
significantly higher in nonsUl'vivors at a similar TNF-a. concentration, one 
of the inducers for P AI release as shown in chapter 10. The presence of a 
single base pail' SG/4G (allele fi'equency 0.S3/0.47) polymorphism in the 
promoter of the PAI-I gene has been associated with differences in release 
of PAI-I in postoperative patients [ISS] and in patients with an increased 
risk of recun'ent myocardial infarction [IS6]. The promoter containing the 
4G allele produced significantly more mRNA after stimulation by 
interleukin-I than the SG allele [IS7]. The 4G allele-specific increase in 
plasma PAl -I activity is related to a differential binding of transcription 
factors to the polymorphic site which increase the basal PAl -I transcription. 
Therefore, the 4G/SG polymorphism in the PAl-I promoter is of functional 
importance in the regulation of the expression of the PAI-I gene [IS7]. 
These data SUppOit our hypothesis proposed in chapter II that patients with 
meningococcemia and a 4G/4G or 4G/SG genotype have a significantly 
increased production of PAl-I leading to more severe disease than in 
children with a SG/SG genotype. Altematively children with a SG/SG 
genotype may develop milder disease or acquire meningitis. DNA analyses 
of children with meningococcal septic shock showed no differences in PAI-
I gene promoter allotypes between survivors and non-survivors. However, 
the study presented in chapter II in which 4G/SG polymorphism in the 
P AI-I promoter of children with meningococcal septic shock was analyzed 
and compared with a control group of healthy children clearly indicates that 
P AI-I is involved in the development of septic shock with pUlpura. The 
fi'equency of the 4G-allele, which is associated with increased plasma PAI-
I concentrations especially under conditions of stimulation by cytokines, 
was significantly higher among patients with meningococcal septic shock 
versus control subjects. The data of Bredius et al. and of our group 
underscore the impOitance of further investigations of the role of 
genetically encoded variability of the host response in the outcome of 
patients with meningococcal sepsis. 
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14.5 FINAL REMARKS 
Novel approaches to the treatment of bacterial meningitis and sepsis 
are needed to improve the outcome and reduce the mortality by these 
disease entities. Thusfar the results of studies with novel immunotherapeutic 
agents have been disappointing. Occasionally application of new dmgs has 
even been associated with increased mOltality. A better understanding of 
the complex orchestra of mediators involved in the host response against 
bacterial pathogens will celtainly contribute towards the development of 
new more effective immunotherapeutic regimens. Measurement of 
intracellular cytokine synthesis by flowcytometry 01' immunocytochemistry 
may be applied to localize specific cells responsible for the synthesis of 
celtain mediators in different compartments. A more detailed knowledge on 
the cellular synthesis of the mediators involved in the host inflammatory 
response is also needed. Determination of the kinetics of inflammatory 
mediators and other compounds may contribute towards new insights in the 
dynamics of the host response and reveal the occurrence of interactions 
between different inflammatory mediators. Finally, the development and 
application in large scale clinical studies of a new generation of conjugate 
vaccines against the major bacteria involved in bacterial meningitis will be 
the most important scientific breakthrough during the remainder of this 
century. 
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SUMMARY 
Bacterial meningitis and meningococcal sepsis are serious infectious 
diseases which are frequently encountered in previously healthy children. 
The morbidity and mortality of these clinical entities are relatively high in 
comparison to those in many other infectious diseases. In this thesis, we 
present the results of several studies in children with bacterial meningitis 
caused by Neisseria meningitidis, Haemophilus injluenzae and 
Streptococcus pneumoniae and in children with meningococcal septic 
shock. Clinical characteristics and host factors such as inflammatOlY and 
counterinflammatOlY mediators and parameters of coagulation and 
fibrinolysis were investigated to enhance the understanding of the host 
response. 
Chapter 2 reviews the current knowledge of the host inflammatory 
response in patients with and animal models of bacterial meningitis. In 
addition, the epidemiology and diagnosis of bacterial meningitis are 
discussed. Pathophysiological alterations in the CSF compaliment of 
patients with bacterial meningitis result from the combined effects of the 
microorganism, its cell wall products, and the host inflammatOlY response. 
Recent advances in understanding of the host inflammatOlY response have 
resulted in the development and application of new therapeutic strategies. 
These compounds aim to modulate the inflammatory response and reduce 
the incidence of sequelae and death. The use of steroids in children with 
bacterial meningitis has beneficial effects although the available data are 
still controversial. Additionally, studies in experimental models of bacterial 
meningitis indicate that non-steroidal anti-inflammatory dmgs and 
monoclonal antibodies against bacterial products, cytokines and CD 18 on 
leucocytes may reduce the extent of the meningeal inflammation. 
The introduction of the H. injluenzae type b vaccine in immunization 
programs has resulted in a rapid decline in the incidence of H. injluenzae 
meningitis. Effective vaccines against S. pneufIloniae and N. meningitidis 
will probably become available within a few years. 
Chapter 3 describes a retrospective study on the outcome of 
pneumococcal meningitis in 83 children admitted to the Sophia Children's 
Hospital during a 25-year period. The median age of the children was 8 
months. The most common associated infection was otitis media in 42% of 
all cases. The most tiequently isolated capsular serotypes andlor serogroups 
of S. pneullloniae were 6, 14, 18, 19 and 23. These isolates accounted for 
62% of all cases. Approximately one third of the study population consisted 
of secondary refelmls usually for intensive care treatment. A marked 
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difference in mortality was observed between primary and secondary 
refel1'als: 7% and 35% respectively. An overall mOitality rate of 17% was 
observed. Children often die of neurological sequelae. The higher mOitality 
rate (33%) in adults, mostly elderly, as observed in another Dutch 
retrospective study, is frequently due to the development of 
cardiorespiratOlY failure. The fi'equency of sequelae in the pediatric 
population was 35%: hearing loss (230 dB) in 19% and neurological 
sequelae in 25%. Coma, respiratory distress, shock, a cerebrospinal fluid 
(CSF) protein level 22.5 gIL, a peripheral white blood cell count <5xl0 91L, 
and a serum sodium level of <135 mmollL during admission were clinical 
findings with the strongest predictive value for sequelae or death m 
children. 
In Chapter 4, a study is presented on the molecular characterization of 
pneumococcal strains obtained from children with meningitis admitted to 
the Sophia Children's Hospital between 1975 and 1992. Pneumococcal 
isolates were characterized by serotyping and two genotyping methods, 
BOX-fingerprinting and restriction fi'agment end labeling, to evaluate 
whether clonal strains were present within the serotypes/-groups. 
Pneumococcal isolates from 44 of 68 patients were still available for 
analysis. All strains were susceptible to penicillin. Serotypes/-groups 6, 14, 
19, and 18 represented 56% of all isolates. The results of the molecular 
typing methods demonstrate complete absence of clonal relatedness 
between isolates fi'om children with pneumococcal meningitis. 
The following three chapters discuss the contribution of pro- and anti-
inflammatory mediators in the host response of children with bacterial 
meningitis. 
Chapter 5 describes the presence of anti-inflammatory compounds 
interleukin (IL)-IO, soluble tumor necrosis factor (TNF)-o; receptors p55 
(sTNFR-55) and sTNFR-75 in children with bacterial meningitis. These 
compounds dowl11'egulate the host inflammatory response and are therefore 
important targets for future therapeutic interventions. Pro- and anti-
inflammatory cytokines were measured in serum and CSF from 37 children 
with a bacterial meningitis. CSF concentrations of IL-I0, sTNFR-55 and 
sTNFR-75 and of the cytokines TNF-o;, IL-6, IL-8 were markedly elevated 
and were with the exception of the sTNFRs significantly higher in CSF 
than in serum. CSF concentrations of sTNFR-55 and sTNFR-75 were 
exclusively associated positively with concentrations of IL-I0. This is in 
agreement with the recent observation that IL-IO increases the synthesis and 
cell-surface tumover of sTNFRs from monocytes. IL-IO thus may suppress 
TNF -0; activity in the CSF compattment by an inhibition of TNF-o; 
secretion, stimulation of the release of sTNFRs and down-regulation of the 
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expression of surface TNFRs. Surprisingly, CSF glucose levels con'elated 
highly with IL-IO, sTNFR-55 and sTNFR-75. CSF levels of cytokines 
decreased rapidly in time while sTNFRs levels remained elevated for at 
least 24 hours. 
Chapter 6 describes the role of IL-12, a novel cytokine with 
proinflammatory effects, in the CSF compattment of patients with bacterial 
meningitis. IL-12 also stimulates the production of interferon (IFN)-y which 
in turn enhances the function of macrophages and polymorphonuclear 
leukocytes by stimulation of non-specific defence mechanisms such as 
phagocytosis and secretion of reactive oxygen intermediates. The release of 
IFN-y is costimulated by TNF-u and IL-IB, and inhibited by IL-IO. Serum 
and CSF levels of bioactive IL-12 (p70) and the inactive subunit p40 and 
IFN-y were measured in 35 patients and 10 control subjects. CSF 
concentrations of IL-12 p40 as well as those of IFN-y were markedly 
elevated whereas IL-12 p70 was hardly detectable. CSF levels of IFN-y 
correlated positively with IL-12 p40 and TNF -u but not with the other 
proinflammatory cytokines IL-6, IL-8 or IL-IO. CSF levels of IFN-y were 
significantly higher in patients with pneumococcal meningitis than in 
children with meningitis by H injluenzae and N. meningitidis. This could 
be explained by a higher TNF -u to IL-IO ratio in the CSF compaltment in 
children patients with gram-positive bacterial meningitis in comparison with 
those with gram-negative bacterial meningitis. These data suggest that IFN-
y production in the CSF compaltment is induced by IL-12 and the co-
stimulator TNF -u during the acute phase of bacterial meningitis. 
Chapter 7 discusses the role of nitric oxide (NO) in the 
pathophysiology of bacterial meningitis. NO, a shOtt-lived fi'ee radical, 
which can be produced in vitro by microglia and astrocytes after 
stimulation with cytokines (TNF -u and IL-l B) and lipopolysaccharides, has 
attracted attention as a potential neurotoxic compound. NO production 
results from the conversion of L-arginine to L-citlulline by the enzyme NO 
synthase (NOS). NO decomposes to the stable endproducts nitrate and 
nitrite. Therefore, serum and/or CSF concentrations of the precursor (L-
arginine) and degradation products of NO (nitrate, nitrite) and TNF-u were 
measured in patients and control subjects. CSF nitrate levels were 
significantly elevated in children with bacterial meningitis. This was mainly 
due to an increased blood-brain ba11'ier permeability. CSF nitrate levels are 
therefore not a good parameter for the endogenous NO production in the 
CSF compartment. CSF NO/nitrite levels were significantly elevated in 
children with meningitis. NO/nitrite levels decreased in time. CSF levels of 
NO/nitrite correlated with those of TNF-u and glucose. CSF levels of L-
arginine were significantly lower in patients in comparison to controls 
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which may be explained by the oxidation of L-arginine to NO by NO-
synthase. We conclude that enhanced NO production may be partly 
responsible for the anaerobic glycolysis and the occurrence of neurological 
damage in children with bacterial meningitis. 
Chapter 8 reviews the pathophysiological backgrounds of 
meningococcal sepsis. The ability of N. meningitidis to circumvent the 
immune system, and the rate of multiplication within the circulation leading 
to production of LPS, appear to determine the clinical symptomatology and 
outcome. The massive release of LPS induces the production of high levels 
of proinflammatory cytokines. The coagulation, fibrinolytic, complement 
and kallikrein-kinine cascade systems also become activated by these 
cytokines. Neutralization of endotoxin or inhibition of proinflammatory 
cytokines in human studies did not result in a better outcome in patients 
with septic shock. However, beneficial effects were documented in 
experimental animals. 
Current meningococcal vaccines use capsular polysaccharides of 
serogroup A, C, W-135 and Y meningococci. Since the capsular 
polysaccharide of group B meningococci lacks immunogenicity, vaccines 
based on outer membrane proteins are under investigation. An effective 
meningococcal vaccine will probably be available in the near future. 
In chapter 9 the clinical characteristics and outcome of patients with 
septic shock and pUtpura are summarized. Additionally, prognostic factors 
were examined and a new scoring system was developed. Eighty-seven 
children with septic shock and pUtpura were included in this study. The 
median age was 3.2 years (range 3 weeks - 17.9 years. Blood- andlor CSF 
cultures grew N. meningifidis in 75 children and H. influenzae in two 
patients. Cultures remained sterile in 10 patients. The most common 
phenotype of N. meningitidis was B:4:P1.4 (27%). The mortality rate was 
25% (95% confidence interval 15% - 34%). Patients admitted primarily to 
Sophia Children's Hospital died more often than those referred from other 
hospitals. However, this difference was not significant. Serious sequelae 
were observed in 15% of the survivors: skin necrosis requiring skingrafts or 
amputation (n = 9) andlor neurologic sequelae (n = 2). Serum calcium 
levels were significantly lower in patients with seizures. Disseminated 
intravascular coagulation occurred in 75% of the patients and its presence 
was associated with an increased mortality. Logistic regression analysis of 
laboratory parameters identified four independent variables for predicting 
the likelihood of survival: the semm levels of C-reactive protein (CRP), 
potassium, base excess, and platelet count. The outcome was predicted 
cOlTectly in 87% of the patients which is higher than in any of the 
previously reported scoring systems. 
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In Chapter 10, the balance between the levels of proinflammatory 
(TNF-u, IL-6, IL-8) and counterinflammatory compounds (IL-IO, sTNFR-
55, sTNFR-75) was studied. The relationship with indicators of hemostasis 
was also investigated. Blood samples were obtained fi'om 38 children who 
were consecutively admitted with meningococcal septic shock. The 
mortality rate was 29%. Serum levels of pro- and counterinflammatory 
compounds and plasma levels of plasminogen activator inhibitor (P AI)-I 
were significantly higher in nonsurvivors. The interval between appearance 
of petechiae and blood sampling was significantly shorter in nonsurvivors 
than in survivors. A strongly negative correlation was found between the 
initial levels of these mediators and the interval between the onset of 
petechiae and blood sampling. In addition, CRP levels, which indirectly 
reflect the duration of illness, were significantly correlated with this 
interval. The significantly shOtter interval and the lower level of CRP in 
nonsurvivors suggest a shorter disease course. This may explain the higher 
levels of cytokines. The earlier PICU admission of nonsurvivors points to 
an accumulation of more native lipopolysaccharide in a shOtter time which 
triggers inflammatory mediators more intensively resulting in more severely 
ill patients earlier in the course of disease. Altematively, a greater 
responsiveness to lipopolysaccharides or proinflammatory cytokines may 
have caused a more rapid deterioration leading to an earlier admission. 
However, with the exception of P AI-I levels, differences between 
concentrations of these mediators disappeared after adjustment for the 
interval mentioned above. PAl-I levels correlated with TNF-u 
concentrations and were nearly two times higher in nonsurvivors at a 
similar concentration of TNF -u. The increased PAl -I response to TNF-u 
may be associated with fatality probably because of polymorphism in the 
PAl-I promoter region. 
In chapter 11 we questioned whether the significantly increased 
production of PAl-I in nonsurvivors with meningococcal septic shock 
versus survivors could be attributed to a common 4G/5G polymorphism in 
the promoter of the PAl -I gene. The presence of the 4G allele is associated 
with higher basal production of PAl -! and an increased responsiveness to 
stimulation with cytokines and endotoxin. Other investigators previously 
showed, that 4G/5G polymorphism in the promoter of the PAl -I gene is 
associated with differences in PAl -I activity in adults with non-insulin-
dependent diabetes mellitus, coronary artery disease and myocardial 
infarction. We therefore hypothezised that higher production of PAl -I in 
patients with meningococcemia might be a contributing factor towards more 
severe disease. To this purpose, DNA samples from 37 Dutch children who 
suffered fi'om meningococcal sepsis were compared with DNA specimens 
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fi'om healthy control subjects. Genetic analysis of the PAI-l promoter 
polymorphism was documented by means of allele specific oligo-melting. 
The results of this study show that the genotype distribution was not 
different between survivors and nonsurvivors of meningococcal septic 
shock. However, the 5G/5G genotype is significantly less present in 
children with meningococcal sepsis in comparison with control subjects. 
We propose that children with meningococcemia and a 4G/4G or 4G/5G 
genotype have a significantly increased production of P AI-I leading to 
more severe disease than in children with a 5G/5G genotype. 
In chapter 12, the role of IL-12 and IFN-y in the pathophysiology of 
septic shock with purpura was investigated. IL-12 plays a role in the host 
defence against microbial infections and has been shown to induce 
production of IFN-y. Levels of IFN-y are increased in experimental as well 
as clinical sepsis. Plasma levels of IL-12, were measured together with 
IFN-y and other cytokines in 46 children with septic shock and purpura. 
The plasma IL-12 p40, TNF -a, IL-6, IL-8, IL-IO levels on admission were 
significantly higher in nonsurvivors compared to survivors. IL-12 p70 levels 
were elevated in only 9 patients and were associated with IL-12 p40. Only 
twelve (29 %) of the patients had detectable levels of IFN-y. Circulating 
levels of IL-12 p40 and to a lesser extent those of IL-12 p70, are elevated 
in children with septic shock and purpura, and correlate with severity of 
disease and outcome. 
In Chapter 13, we studied age-related differences in outcome and 
severity of clotting abnormalities in children with septic shock and purpura. 
Parameters of coagulation and fibrinolysis and plasma levels of cytokines 
were prospectively measured in 79 patients on admission. The mortality 
rate was 27%. The median age of the study population was 3.1 years and 
survivors were significantly older than nonsurvivors. The patients were 
divided in two age groups for analysis: younger and older than median age. 
The mortality in children :s; 3.1 years was 40% versus 13% in children > 
3.1 years (P = .006). With the exception of FVII, vWF and t-PA, 
parameters of coagulation and fibrinolysis, as well as plasma cytokine 
levels were related to outcome. In contrast to cytokine levels, which were 
not different between the two age groups, plasma levels of fibrinogen, 
prothrombin, factors V, VII, VIII, vWF, protein C, ATIII, FDP, and PAI-
lIt-PA were related to age, indicating a more severe coagulopathy in 
children :s; 3.1 years despite a similar degree of inflammatory response. A 
relative deficiency of coagulation factors due to an immature state of the 
clotting system, as well as an inadequate fibrinolytic response, both related 
to age may have caused this more severe coagulative response in younger 
children, and may have contributed to the higher mOltality rate. 
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In Chapter 14, the results of this thesis are critically discussed in the 
context of recent literature. Suggestions for future research are given. 
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SAMENVATTING 
Bacterie1e meningitis en meningococcensepsis zijn op de kinderleeftijd 
frequent voorkomende ernstige infectieziekten bij voorheen veelal gezonde 
kinderen. De morbiditeit en mortaliteit ten gevolge van deze ziektebeelden 
zijn hoog in vergelijking met die van andere infectieziekten. In dit 
proefschrift worden de resultaten gepresenteerd van een aantal studies bij 
kinderen met bacteriele meningitis veroorzaakt door N. meningitidis, H. 
irif/uenzae en S. pnellmoniae en bij kinderen met septische shock door N. 
meningitidis. Klinische aspecten en gastheer factoren, zoals 
ontstekingsmediatoren en parameters van coagula tie en fibrinolyse werden 
bestudeerd teneinde het inzicht in de pathofYsiologie van de 
gastheerrespons te vergroten. 
Hoofdstuk 2 geeft een overzicht van de huidige inzichten in de 
ontstekingsreactie bij patienten en proefdieren met bacteriele meningitis. 
Daarnaast wordt een beschrijving gegeven van de epidemiologie en de 
diagnostiek bij kinderen met bacteriele meningitis. De pathofYsiologische 
veranderingen in het liquor compattiment van patienten met bacteriele 
meningitis zijn het gevolg van het effect van het micro-organisme en zijn 
celwandproducten enerzijds en de ontstekingsreactie van de gastheer 
anderzijds. De toegenomen kennis op het gebied van de gastheerrespons 
heeft mede bijgedragen aan de ontwikkeling im toepassing van nieuwe 
behandelingsmodaliteiten. Nieuwe therapeutische intetventies hebben als 
doel de ontstekingsreactie te onderdrukken en de morbiditeit en mortaliteit 
te verminderen. 20 lijkt het gebruik van corticosteroYden bij kinderen met 
bacteriele meningitis gunstige effecten te hebben bij patienten met 
meningitis door H. inflllenzae, alhoewel sommige studies deze resultaten 
niet kunnen bevestigen. Onderzoek in proefdieren met bacteriele meningitis 
heeft aangetoond dat ontstekingsremmende middelen die niet tot de groep 
van corticosteroioen behoren en monoclonale antilichamen tegen 
celwandproducten van bacterien, cytokines en het CD 18 molecuul op 
leukocyten de ernst van de meningeale ontstekingsreactie verminderen. 
De introductie van het H. inflllenzae type b vaccin in het 
Rijksvaccinatieprogramma heeft geresulteerd in een snelle afhame in de 
incidentie van meningitis door H. inflllenzae. Effectieve vaccins tegen S. 
pneumoniae en N. meningitidis zijn waarschijnlijk spoedig beschikbaar. 
Hoofdstuk 3 betreft een retrospectieve studie naar de gevolgen van 
pneumococcen meningitis bij 83 patienten, die gedurende de afgelopen 25 
jaar in het Sophia Kinderziekenhuis opgenomen waren. De mediane leeftijd 
van de kinderen was 8 maanden. De meest voorkomende geassocieerde 
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infectie was otitis media (42%). De meest gei'soleerde kapsel serotypen 
en/of serogroepen van S. pneumoniae waren 6, 14, 18, 19 en 23. Tezamen 
vormen deze 62% van aIle isolaten. Ongeveer 30% van aIle kinderen waren 
velwezen vanuit een ander ziekenhuis wegens de noodzaak tot intensive 
care behandeling. Het verschil in mortaliteit tussen primaire en secondaire 
velwijzingen was respectievelijk 7 en 35%. De mortaliteit in deze groep 
was 17%. Kinderen overleden meestal ten gevolge van neurologische 
problemen. De hogere mortaliteit bij volwassenen, meestal bejaarden, was 
hoofdzakelijk het gevolg van cardiopulmonale complicaties. De morbiditeit 
ten gevolge van pneumococcen meningitis was 35%: gehoorverlies (2 
30dB) werd gevonden bij 19% en neurologische restverschijnselen bij 25% 
van de patienten. De prognose was het slechtst bij kinderen, die bij opname 
de volgende kenmerken veltoonden: coma, shock, respiratoire insufficientie, 
een liquor eiwit gehalte 2 2.5 gIL, een leukocyten getal < 5.109/L en een 
selUm natrium gehalte < 135 mmolfL. 
In hoofdstuk 4 worden de resultaten gepl'esenteerd van de moleculaire 
karakterisering van pneumococcen isolaten afkomstig van kinderen met 
meningitis opgenomen in het Sophia Kinderziekenhuis tussen 1975 en 
1992. Deze stammen werden gekarakteriseerd door middel van serotypering 
en twee genotyperingsmethoden: "BOX fingerprinting" en "restriction 
fi'agment end labeling". De aanwezigheid van clonaliteit binnen 
serotypen/groepen werd onderzocht. Pneumococcen isolaten van 44 van de 
68 patienten waren beschikbaar voor analyse. AIle stammen waren gevoelig 
voor penicilline. Serotypen/groepen 6, 14, 19 en 18 veltegenwoordigden 
56% van aIle isolaten. De moleculaire typel'ingsmethoden toonden geen 
genetische velwantschap tussen de diverse isolaten van patienten met 
pneumococcen meningitis. 
In hoofdstuk 5 wordt de aanwezigheid bestudeerd van de anti-
inflammatoire mediatoren interleukine (IL )-10, soluble tumor necrosis 
factor receptoren p55 (sTNFR-55) en sTNFR-75 bij kinderen met bacteriele 
meningitis. Deze mediatoren velminderen de omvang van de ontstekings-
reactie en zijn daarom mogelijk belangrijke kandidaten voor geblUik in 
toekomstige interventiestudies. Pro- en anti-inflammatoire mediatoren 
werden gemeten in liquor en selUm van 37 patienten met bacteriele 
meningitis. De liquor concentraties van IL-I0, sTNFR-55 en 75 en van de 
proinflammatoire cytokines TNF-a, IL-6, IL-8 waren sterk verhoogd. De 
concentraties van deze mediatoren waren, met uitzondel'ing van die van 
sTNFR-55 en 75, significant hoger in het liquorcompmtiment dan in het 
selUm. De liquor concentraties van sTNFR-55 en sTNFR-75 waren aileen 
gecorreleerd met de concentraties van IL-! O. Deze observatie is in overeen-
stemming met recente gegevens die tonen dat IL-I0 de synthese en turnover 
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van TNFRn op het celoppervlak van monocyten verhoogt. IL-IO kan dus de 
TNF -u activiteit onderdrukken door remming van de TNF -u produktie en 
stimulatie van de afgifte van sTNFRn en vermindering van de expressie van 
TNFR op het celoppervlak. De glucose concentratie in de liquor 
cerebrospinalis was positief geassocieerd met de concentraties van IL-IO, 
sTNFR-55 en sTNFR-75. De liquor concentraties van aile cytokines dalen 
snel gedurende de eerste uren na meting, terwijl de concentraties van 
sTNFR verhoogd blijven gedurende tenminste 24 uur. 
In hoofdstuk 6 wordt de functie bestudeerd van IL-12 in het liquor 
compartiment van patienten met bacteriele meningitis. IL-12 is een relatief 
nieuw cytokine met proinfiammatoire eigenschappen. IL-12 stimuleert de 
produktie van IFN-y dat op zijn beutt de functie van macrofagen en 
granulocyten verbetett door stimulatie van niet-specifieke afWeer-
mechanism en, zoals fagocytose en de secretie van zuurstofradicalen. De 
afgifte van IFN-y wordt mede gestimuleerd door TNF -u en IL-I B en 
geremd door IL-lO. Serum en liquor concentraties van bioactief IL-12 (P70) 
en de inactieve subunit p40 en van IFN-y werden gemeten bij 35 patienten 
en 10 controle personen. Zowel de liquor concentratie van IL-12 p40, als 
die van IFN-y waren verhoogd, terwijl IL-12 p70 nauwelijks meetbaar was. 
De liquor concentraties van IFN-y waren positief gecorreleerd met 
concentraties van IL-12 p40 en TNF -u maar niet met die van andere 
cytokines, zoals IL-6, IL-8 en IL-lO. De liquor concentraties van IFN-y 
waren significant hoger bij patienten met pneumococcenmeningitis dan bij 
kinderen met meningitis veroorzaakt door H. injluenzae en N. meningitidis. 
Een mogelijke verklaring hiervoor is de hogere TNF-aflL-lO ratio bij 
kinderen met een Gram-positieve bacteriele meningitis dan bij kinderen met 
een Gram-negatieve bacteriele meningitis. De resultaten van dit onderzoek 
suggereren dat de produktie van IFN-y in het liquor compattiment 
gedurende de acute fase van bacteriele meningitis wordt gei'nduceerd door 
IL-12 en TNF-u. 
In hoofdstuk 7 wordt de rol bestudeerd van stikstofoxide (NO) in de 
pathofysiologie van bacteriele meningitis. NO, een vrij radicaal, kan worden 
geproduceerd door microglia en astrocyten na stimulatie door cytokines 
(TNF -u en IL-l B) en lipopolysaccharides en heeft neurotoxische 
eigenschappen. NO produktie vindt plaats door de omzetting van L-arginine 
naar L-citrulline via het enzym NO synthase. NO wordt vervolgens 
afgebroken naar de stabiele eindprodukten nitraat en nitriet. Serum en 
liquor concentraties van het substraat (L-arginine) en de afbraakprodukten 
van NO (nitraat, nitriet) en TNF-u werden gemeten bij patienten en bij een 
controlegroep. Liquor concentraties van nitraat waren significant verhoogd 
bij kinderen met bacterieJe meningitis. Deze verhoging was hoofdzakelijk 
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het gevolg van de toegenomen doorlaatbaarheid van de bloedhersenban·ie're. 
Liquor nitraat concentraties waren derhalve geen goede maat voor endogene 
NO produktie in het liquor compartiment. Liquor NO/nitriet concentraties 
waren significant verhoogd bij kinderen met meningitis en namen af in de 
tijd. De liquor concentraties van NO/nitriet waren gecolTeleerd met die van 
TNF -(L en glucose. De liquor concentraties van L-arginine waren significant 
lager bij patienten dan bij controles, hetgeen kan worden verklaard door de 
oxydatie van L-arginine naar L-citrulline en NO via NO synthase. Wij 
concluderen dat de toename in NO produktie in het liquor compartiment 
van patienten met bacteriele meningitis tenminste gedeeltelijk 
verantwoordelijk is voor de anaerobe glycolyse en het optreden van 
neurologische schade bij patienten met bacterieie meningitis. 
Hoofdsfuk 8 geeft een overzicht van de pathorysiologische 
mechanismen, die betrokken zijn bij meningococcensepsis. Het vrijkomen 
van lipopolysacchariden induceeti de produktie van proinflammatoire 
cytokines. De coagulatie, fibrinolyse, complement en kallikreine-kinine 
systemen worden tevens geactiveerd. Studies bij de mens met 
geneesmiddelen die endotoxines en proinflammatoire cytokines 
neutraliseren leveren nauwelijks een verbetering op van de prognose bij 
patienten met een septische shock. Dierexperimentele studies tonen 
daarentegen wei gunstige effecten. De thans beschikbare meningococcen 
vaccins (serogroep A, C, W-135) zijn gericht tegen kapselpolysaccharides. 
Aangezien het kapselpolysaccharide van groep B meningococcen 
nauwelijks immunogeen is, zijn vaccins gebaseerd op membraaneiwitten in 
ontwikkeling. Een effectief meningococcen vaccin zal waarschijnlijk 
binnenkoti beschikbaar komen. 
Klinische karakteristieken en de prognose van patienten met septische 
shock en purpura worden beschreven in hoofdsfuk 9. Een nieuwe 
prognostische score werd ontwikkeld. Zevenentachtig kinderen met een 
septische shock en purpura werden geevalueerd. De mediane leeftijd was 
3.2 jaar (range 3 weken - 17.9 jaat} Bloed enlof liquor kweken toonden N. 
meningitidis bij 75 kinderen en H. injluenzae bij 2 patienten. De kweken 
bleven steriel bij 10 patienten. Het meest voorkomende fenotype van N. 
meningitidis was P:4:Pl,4 (27%). De motialiteit bedroeg 25% (95% 
betrouwbaarheidsinterval 15% - 34%). Patienten primair opgenomen in het 
Sophia Kinderziekenhuis overleden fi'equenter dan diegenen die verwezen 
waren vanuit andere ziekenhuizen. Dit verschil was echter niet significant. 
Emstige restverschijnselen werden gezien bij 15% van de overlevenden; 
huidnecrose (n = 9), enlof, neurologische restverschijnselen (n = 2). Serum 
calcium concentraties waren significant lager bij patienten met convulsies. 
Gedissemineerde intravasale stolling werd waargenomen bij 75% van de 
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patienten en was geassocieerd met het optreden van een hogere mortaliteit. 
Bij logistische regressieanalyse werden 4 onafhankelijke laboratorium 
parameters gevonden die de kans op overlijden voorspellen nl. de serum 
concentratie van "C-reactive protein" (CRP), het serum kaliumgehalte, de 
"base excess" en het aantal thrombocyten in arterieel bloed. De mortaliteit 
werd correct voorspeld bij 87% van de patH!nten, hetgeen hoger is dan bij 
andere scoringssystemen. 
De balans tussen proinflammatoire (TNF -a, IL-6, IL-8) en anti-
inflammatoire mediatoren (IL-IO, sTNFR-55, sTNFR-75) bij patienten met 
meningococcen septische shock werd bestudeerd in hoofdstuk 10. Tevens 
werd de relatie met parameters van coagulatie en fibrinolyse bestudeerd. Bij 
38 achtereenvolgende patienten opgenomen met meningococcen septische 
shock werden bij opname bloedmonsters verkregen. De mOl'taliteit bij de 
patientengroep was 29%. Serum concentraties van pro- en anti-
inflammatoire mediatoren en plasma concentraties van "plasminogeen 
activator inhibitor" (P AI)-I waren significant hoger bij patienten die 
kwamen te overIijden. Petechiae waren bij opname significant korter 
aanwezig bij patienten die overleden dan bij overlevenden. Concentraties 
van het CRP, die indirect de duur van de ziekte weerspiegelen, waren 
significant gecol1'eleerd met de duur van de aanwezigheid van petechiae. De 
significant kOltere duur van petechiae en de lagere CRP concentratie bij 
patienten die overleden suggereren de aanwezigheid van een kortere 
ziekteduur hetgeen een verklaring vormt voor de aanwezigheid van hogere 
cytokine concentraties bij opname van patienten die uiteindelijk overleden. 
Het kOltere interval tussen de ontwikkeling van ziekteverschijnselen en 
k1inische opname bij patienten die overleden, kan verklaard worden door de 
hogere produktie van Iipopolysacchariden (LPS) of door de aanwezigheid 
van een sterkere ontstekingsreactie. Anderzijds kan een grotere gevoeligheid 
voor LPS dan wei cytokines de snellere klinische achteruitgang van 
patienten die overleden zijn, verklaren. Met uitzondering van plasma P AI-I 
concentraties werden na correctie voor het bovengenoemde tijdsinterval 
geen verschillen gevonden tussen overlevende en overleden patienten in de 
concentraties van cytokines. De P AI-I concentraties waren positief 
geco11'eleerd met de serumspiegels van TNF-a. Daamaast waren de PAI-I 
concentraties bijna tweemaal hoger bij patienten die overleden dan bij de 
overlevenden bij eenzelfde serum TNF -a concentratie. De hogere P AI-I 
produktie is geassocieerd met een hogere mOltaliteit hetgeen mogelijk 
veroorzaakt wordt door een polymorfisme in de P AI -I promotor regio. 
In hoofdstuk 11 werd onderzocht of de significant hogere PAI-I 
produktie in overleden kinderen met meningococcen septische shock kan 
worden verklaard door de aanwezigheid van een 4G/5G polymorphisme in 
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de promotor van het PAI-I gen. De aanwezigheid van de 4G allel is 
geassocieerd met een hogere basale produktie van PAI-I en een 
toegenomen PAI-I respons na stimulatie met cytokines en endotoxines. In 
eerdere studies werd reeds aangetoond dat het 4G/SG polymorphisme in de 
promotor van het PAI-I gen geassocieerd is met verschillen in PAI-I 
activiteit bij volwassenen met coronair ziekte en myocard infarcten. De 
hypothese geformuleerd in hoofdstuk 10 was dat hogere PAI-I produktie 
bij patienten met een meningococcemie kan bijdragen tot emstiger beloop 
van de ziekte. DNA monsters van 37 Nederlandse kinderen met 
meningococcen sepsis werden vergeleken met DNA monsters van gezonde 
controles. Genetische analyse van het PAI-I promotor polymorfisme werd 
gedocumenteerd aan de hand van aile! specifieke oligo-melting. Er werd 
geen verschil in genotype verde ling gevonden tussen overledenen en 
overlevende patienten met meningococcen septische shock. Echter, het 
SG/SG genotype was significant mindel' frequent aanwezig bij kinderen met 
een meningococcensepsis dan bij de controle populatie. Wij veronderstellen 
dat kinderen met meningococcemie en de aanwezigheid van het 4G/SG of 
4G/4G genotype significant meer PAI-I produceren, hetgeen aanleiding 
geeft tot een emstiger ziektebeloop dan bij kinderen met het SG/SG 
genotype. 
In hoofdstuk 12 werd de rol van IL-12 en IFN-y in de pathofysiologie 
van septische shock met purpura onderzocht. IL-12 spee!t een 1'01 bij de 
afweer tegen invasieve micro-organismen en stimuleelt de produktie van 
IFN-y. De concentraties van IFN-y zijn verhoogd bij zowel experimentele 
vormen van sepsis als bij patienten met sepsis. Plasma concentraties van 
IL-12, IFN-y en andere cytokines werden gemeten bij 46 kinderen met 
septische shock en pUlpura. Plasma concentraties van IL-12 p40, TNF-a, 
IL-6, IL-8, IL-lO waren bij opname significant hoger bij kinderen die 
overleden dan bij overlevende patienten. IL-12 p70 concentraties waren 
slechts meetbaar bij 9 patienten en de serumspiegels waren positief 
geassocieerd met die van IL-12 p40. Twaalf patienten (29%) hadden 
meetbare concentraties van IFN-y. Circulerende concentraties van IL-12 
p40 en in mindere mate van IL-12 p70 waren verhoogd bij kinderen met 
septische shock en purpura. De serum concentraties waren positief 
gecorreleerd met de emst van de ziekte en met de prognose van de ziekte. 
In hoofdstuk 13 werden leeftijdsafhankelijke verschillen in de 
uitkomst en de emst van de stollingsstoomissen bij kinderen met een 
septische shock en purpura bestudeerd. Parameters van coagulatie en 
fibrinolyse en plasma concentraties van cytokines werden gemeten bij 79 
patienten. De mOltaliteit in deze studie bedroeg 27%. De mediane leeftijd 
van de patienten was 3.1 jaar. Overlevende kinderen waren significant 
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ouder dan de overleden pati(!nten. Ten behoeve van verdere analyse werden 
de patienten verdeeld in twee leeftijdsgroepen: jonger en ouder dan de 
mediane leeftijd. De mortaliteit bij kinderen :s; 3.1 jaar was 40% versus 
13% bij kinderen > 3.1 jaar (P = .006). Met uitzondering van factor (F) 
VII, van Willebrand factor (vWF) en tissue plasminogeen activator (t-PA) 
waren de parameters van coagulatie en de concentraties van cytokines 
geassocieerd met de prognose. De cytokine concentraties waren echter niet 
verschillend tussen beide leeftijdsgroepen terwijl de plasma concentraties 
van fibrinogeen, protlu'ombine, FV, VII, VIII, vWF, protein C, 
antithrombine III, fibrinogeen afbraakprodukten en de ratio P AI-llt-PA 
geassocieerd waren met de leeftijd. De stollingsstoornissen waren ernstiger 
bij kinderen :s; 3.1 jaar ondanks de aanwezigheid van gelijke cytokine 
concentraties. Een relatieve deficientie van stollingsfactoren door een nog 
onrijp stollingssysteem en een inadequate fibrinolyse waren gerelateerd aan 
de leeftijd. De sterkere stollingsstoornissen bij jongere kinderen kan 
bijdragen aan de hogere mortaliteit in deze leeftijdscategorie. 
In hoofdstuk 14 worden de resultaten van het in dit proefsclu'ift 
besclu'even onderzoek kritisch bediscussieerd. Suggesties voor verdeI' 
onderzoek worden gegeven. 
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ADH 
AIDS 
APPT 
ASO melting 
BAEP 
BBB 
bp 
BPI 
'C 
CI-INH 
CD 
CI 
CNS 
CRP 
CSF 
CTAB 
DIC 
DNA 
ELISA 
EPI 
Fc 
FcyR 
FDP 
g 
h 
H 
Hib 
IFN 
Ig 
IL 
L-NAME 
LBP 
LIF 
LPS 
mAb 
mRNA 
MSS 
n 
N 
NK-cell 
LIST OF ABBREVIATIONS 
: antidiuretic hormone 
: acquired immune deficiency syndrome 
: activated pal1ial thromboplastin time 
: allele-specific oligo melting 
: brain stem auditory evoked potentials 
: blood brain barrier 
: basepair 
: bactericidal/permeability-increasing protein 
: degree Celcius 
: C I-esterase inhibitor 
: cluster of designation/cluster of differentiation 
: confidence interval 
: central nervous system 
: C-reactive protein 
: cerebrospinal fluid 
: cetyl-trimethyl-ammoniumbromide 
: disseminated intravascular coagulation 
: deoxyribonucleic acid 
: enzyme linked immuno sorbent assay 
: extrinsic pathway inhibitor 
: crystallizable fragment 
: Fc receptor for IgG 
: fibrin/fibrinogen degradation products 
: unit of gravity 
: hour 
: Heamophilus 
: Haemophilus injluenzae type b 
: interferon 
: immunoglobulin 
: interleukin 
: N-nitro-L-arginine methyl ester 
: lipopolysaccharide binding protein 
: leukemia inhibitory factor 
: lipopolysaccharide 
: monoclonal antibody 
: mesenger mRNA 
: meningococcal septic shock 
: number in study or group 
: Neisseria 
: natural killer cell 
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NO 
NOS 
OMP 
PAF 
PAl 
PAP 
PC 
PCR 
PG 
PICU 
PMNL 
PRISM 
I' 
R 
RFEL 
RNA 
RR 
rt-PA 
S 
SD 
SIADH 
SOD 
sTNFR 
t-PA 
TAT 
TGF 
TNF 
UPGMA 
vWF 
WBC 
WHO 
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: nitric oxide 
: nitric oxide synthase 
: outer membrane protein 
: platelet activating factor 
: plasminogen activator inhibitor 
: plasmin antiplasmin complex 
: protein C 
: polymerase chain reaction 
: prostaglandin 
: pediatric intensive care unit 
: polymorphnuclear leukocytes 
: pediatric risk of mOltality 
: recombinant (e.g. It-PA) 
: receptor 
: restriction fi'agment end labeling 
: ribonucleic acid 
: relative risk 
: recombinant tissue plasminigen activator 
: Streptococclls 
: standard deviation 
: syndrome of inappropriate secretion of antidiuretic hormone 
: superoxide dismutase 
: soluble tumor necrosis factor receptor 
: tissue plasminogen activator 
: thrombin-antithrombin complex 
: transforming growth factor 
: tumor necrosis factor 
: unweighted pair group method using arithmetic averages 
: von Willebrand Factor 
: white blood cell 
: World Health Organization 
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Het afsluiten van een periode van onderzoek met een proefschrift is veelal 
het resultaat van een intense samenwerking met velen. Aan het einde van dit 
boekje wi! ik dan ook een ieder bedanken die een bijdrage heeft geleverd. Een 
aantal mensen wi! ik in het bijzonder bedanken. 
Dr. R. de Groot, co-promotor, beste Ronald. Onze samenwerking begon 
met als uiteindelijk doel een promotie. Hoewel een promotieonderzoek en de 
benodigde financien aanvankelijk nog niet beschikbaar waren, werd dit 
lUimschoots gecompenseerd door je enthousiasme en niet aflatende stroom aan 
ideeen. Mede dankzij jouw grote werkdrift werden deze idee en omgezet in 
voortreffelijke onderzoeksprojecten die hebben geleid tot dit proefschrift. 
Ondanks je dlUkke werkzaamheden was je altijd bereikbaar voor overleg. 
Eventuele hindemissen werden snel genomen. Naast wetenschappelijk 
inspanningen was er ook tijd voor ontspanning ('Even een biertje drinken'). 
De periode die achter mij ligt heb ik ervaren als uiterst plezierig en leerzaam. 
Bedankt voor alles. 
Prof. Dr. H.J. Neijens, promotor, beste Herman, ik wi! je hatielijk 
bedanken voor de gelegenheid en de vrijheid die je mij hebt geboden om 
onderzoek te doen binnen de subafdeling infectie- en immuunziekten van het 
Sophia Kinderziekenhuis te Rotterdam. Dank voor je kritisch beoordeling van 
het manuscript en voor de leerzame adviezen tijdens onze gesprekken. 
De overige leden van de k1eine commissie, Prof. Dr. J.J.M. van Dongen, 
Prof. Dr. J.W.M. van del' Meer en Prof. Dr. H.A. VerblUgh wi! ik bedanken 
voor hun bereidheid het manuscript op snelle wijze kritisch te beoordelen. 
Dr. E.D. Wolff, beste Eric. Bij jou heeft mijn interesse voor het 
wetenschappelijk onderzoek wotiel geschoten. Ik wi! je hiervoor dan ook 
hatielijk bedanken. 
Beste Henriette van Vuuren, research-verpleegkundige van het eerste uur, 
je was in de beginfase betrokken bij het beschreven onderzoek. Het 
meningitis-onderzoek en later het sepsis-onderzoek zijn mede dankzij jouw 
inspanningen geleidelijk van de grond gekomen. Nadat je de moedige stap 
hebt genomen de opleiding tot IC-verpleegkundige te beginnen, heeft Marja 
Suur je taken op uitstekende wijze overgenomen. Beste Matja, je 
organisatorische talenten en inzet zijn van ongekende hoogte. Groots is je 
prestatie om naast het "gewone werk" de graad van Master of Science te 
behalen. Ik ben jullie zeer dankbaar voor aile inspanningen en het vervullen 
van bereikbaarheidsdiensten. Mijn dank gaat ook uit naar Toos Langeveld, 
Yolanda van den Ouden, Alma van Zantwijk, Atie BlUggeling en Ester de 
K1eijn die ook deelnamen aan het patientgebonden onderzoek. 
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Beste semafoon, ik mis je niet, maar dankzij de vele keren dat je onze 
rust hebt verstoord, hebben wij vee! kostbaar materiaal kunnen verzamelen dat 
de basis vormde voor het beschreven onderzoek. Ik realiseer mij dat het 
dragen van een semafoon buitengewoon lastig kan zijn. 
Vervolgens gaat mijn dank uit naar de kinderm1sen en de al1s-assistenten 
van de ziekenhuizen die deelnamen aan het meningitis-onderzoek, te weten het 
Reinier de Graaf Gasthuis te Delft, het Zuiderziekenhuis en het Ikazia 
Ziekenhuis te Rotterdam, en het Juliana Kinderziekenhuis te Den Haag. 
Zonder jullie aanmelding van patienten zou het onderzoek zeker niet zo'n 
succes zijn geworden. 
Het sepsis-onderzoek werd uitgevoerd op de subafdeling Extra Zorg, later 
Intensive Care Pediatrie. Drs. J.A. Hazelzet en Drs. E. van der V00l1, beste 
Jan en Edwin, ik wil jullie bedanken voor de prettige wijze waarmee 
onderzoek op jullie afdeling mogelijk werd gemaakt. Jan, ik hoop dat ook jij 
binnenkort je proefschrift kan afi·onden. 
Mijn dank gaat ook uit naar ouders die toestemming gaven voor deelname 
van hun ernstig zieke kind aan het beschreven onderzoek. 
Plezierig, nuttig en efficient was de samenwerking met de afdeling 
Immunologie aan de Erasmus Universiteit te Rotterdam. Dr. Huub Save!koul, 
Dr. Hedda Koning, Astrid Vredendaal en Miranda Baert wil ik hm1elijk 
bedanken voor de prettige manier waarop jullie mij geleerd hebben cytokines 
te bepalen. De goede samenwerking maakte het mogelijk om met geringe 
hoeveelheden bloed en liquor vele cytokines tegelijkeltijd te bepalen. Bedankt. 
Dr. Peter Hermans en Marcel Sluijter wil ik bedanken voor mijn 
inwijding in het moleculaire werk. 
Dr. W.C.J. Hop, beste Wim, met genoegen denk ik terug aan onze 
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